Syros Pharmaceuticals (SYRS) S-4 18 Jul 22 Registration of securities issued in business combination transactions Financial data

Cover Page

Cover Page	12 Months Ended
	Mar. 31, 2022
Cover [Abstract]
Document Type	S-4
Amendment Flag	false
Entity Registrant Name	Syros Pharmaceuticals, Inc.
Entity Central Index Key	0001556263
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 69,575,000	$ 92,302,000		$ 173,984,000
Marketable securities	40,686,000	38,067,000
Accounts receivable				7,000
Contract assets	3,182,000	2,979,000		2,324,000
Prepaid expenses and other current assets	3,034,000	3,237,000		2,242,000
Total current assets	116,477,000	136,585,000		178,557,000
Property and equipment, net	12,554,000	12,844,000		14,213,000
Marketable securities—noncurrent	2,638,000	13,038,000
Other long-term assets	3,155,000	2,941,000		1,966,000
Restricted cash	3,086,000	3,086,000		3,086,000
Right-of-use asset—operating lease	13,900,000	14,104,000		14,831,000
Right-of-use assets—financing leases	271,000	337,000		597,000
Total assets	152,081,000	182,935,000		213,250,000
Current liabilities:
Accounts payable	2,841,000	3,692,000		3,603,000
Accrued expenses	13,249,000	15,624,000		11,084,000
Deferred revenue, current portion	7,773,000	10,181,000		12,209,000
Financing lease obligations, current portion	274,000	291,000		265,000
Operating lease obligation, current portion	1,789,000	1,720,000		1,463,000
Debt, current portion	1,667,000
Total current liabilities	27,593,000	31,508,000		28,624,000
Deferred revenue, net of current portion				9,877,000
Financing lease obligations, net of current portion	12,000	65,000		356,000
Operating lease obligation, net of current portion	22,378,000	22,858,000		24,578,000
Warrant liability	581,000	3,029,000		19,711,000
Debt, net of debt discount, long term	38,775,000	40,257,000		39,551,000
Commitments and contingencies (See Note 10)
Stockholders' equity:
Preferred stock	0	0		0
Common stock	61,000	61,000		56,000
Additional paid-in capital	551,679,000	548,815,000		467,518,000
Accumulated other comprehensive loss	(273,000)	(79,000)		0
Accumulated deficit	(488,725,000)	(463,579,000)		(377,021,000)
Total stockholders' equity	62,742,000	85,218,000	$ 149,880,000	90,553,000
Total liabilities and stockholders' equity	152,081,000	$ 182,935,000		$ 213,250,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Current assets:
Cash and cash equivalents	13,738,931		107,516,420
Marketable securities	60,611,961
Prepaid Clinical Costs	480,623		987,470
Prepaid expenses and other current assets	4,064,770		1,152,970
Total current assets	78,896,285		109,656,860
Prepaid clinical costs, net of current portion			530,989
Marketable securities—noncurrent	9,080,671
Right-of-use asset—operating lease	38,229		75,471
Total assets	88,015,185		110,263,320
Current liabilities:
Accounts payable	3,803,427		3,842,390
Severance payable	2,611,857		726,027
Accrued expenses	933,082		1,040,710
Operating lease obligation, current portion	37,332		34,658
Total current liabilities	7,385,698		5,643,785
Severance payable, net of current portion	421,575		850,709
Operating lease obligation, net of current portion			41,256
Warrant liability	124,480		1,931,921
Total liabilities	7,931,753		8,467,671
Commitments and contingencies (See Note 10)
Stockholders' equity:
Preferred stock	0		0
Common stock	17,223		17,222
Additional paid-in capital	241,030,535		238,572,442
Accumulated other comprehensive loss	(544,264)
Accumulated deficit	(160,420,062)		(136,794,015)
Total stockholders' equity	80,083,432		101,795,649
Total liabilities and stockholders' equity	$ 88,015,185		$ 110,263,320

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001		$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000		10,000,000
Preferred stock, shares issued	0	0		0
Preferred stock, shares outstanding	0	0		0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001		$ 0.001
Common stock, shares authorized	200,000,000	200,000,000		200,000,000
Common stock, shares issued	62,801,296	62,024,035		56,222,746
Common stock, shares outstanding	62,801,296	62,024,035		56,222,746
Tyme Technologies, Inc. and Subsidiaries [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Preferred stock, shares authorized	10,000,000		10,000,000
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Common stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Common stock, shares authorized	300,000,000		300,000,000
Common stock, shares issued	172,206,894		172,200,644
Common stock, shares outstanding	172,206,894		172,200,644
Related party accounts payable	$ 153,000		$ 87,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue	$ 5,467,000	$ 4,827,000		$ 23,488,000		$ 15,093,000	$ 1,982,000
Operating expenses:
Research and development	25,171,000	20,029,000		99,872,000		76,065,000	58,245,000
General and administrative	6,949,000	5,739,000		23,036,000		21,325,000	21,478,000
Total operating expenses	32,120,000	25,768,000		122,908,000		97,390,000	79,723,000
Loss from operations	(26,653,000)	(20,941,000)		(99,420,000)		(82,297,000)	(77,741,000)
Interest income	35,000	10,000		87,000		426,000	2,375,000
Interest expense	(976,000)	(967,000)		(3,907,000)		(1,792,000)	(72,000)
Change in fair value of warrant liability	2,448,000	7,670,000		16,682,000		(375,000)	0
Net loss	(25,146,000)	(14,228,000)		(86,558,000)		(84,038,000)	(75,438,000)
Net loss applicable to common stockholders	$ (25,146,000)	$ (14,228,000)		$ (86,558,000)		$ (84,038,000)	$ (75,438,000)
Net loss per share applicable to common stockholders— Basic	$ (0.4)	$ (0.23)		$ (1.38)		$ (1.82)	$ (1.88)
Net loss per share applicable to common stockholders— Diluted	$ (0.4)	$ (0.23)		$ (1.38)		$ (1.82)	$ (1.88)
Weighted-average number of common shares used in net loss per share applicable to common stockholders— Basic	63,061,423	61,379,641		62,534,978		46,051,617	40,222,182
Weighted-average number of common shares used in net loss per share applicable to common stockholders— Diluted	63,061,423	61,379,641		62,534,978		46,051,617	40,222,182
Tyme Technologies, Inc. and Subsidiaries [Member]
Operating expenses:
Research and development			$ 13,444,101		$ 16,709,649
General and administrative			9,632,103		10,185,537
Severance Costs			2,437,379		321,825
Total operating expenses			25,513,583		27,217,011
Loss from operations			(25,513,583)		(27,217,011)
Gain on warrant exchange					2,228,697
Interest income			150,339		22,077
Interest expense			(70,244)		(97,133)
Change in fair value of warrant liability			1,807,441		(3,915,393)
Total other income (expenses)			1,887,536		1,761,752
Loss before income taxes			(23,626,047)		(28,978,763)
Net loss			$ (23,626,047)		$ (28,978,763)
Net loss per share applicable to common stockholders— Basic			$ (0.14)		$ (0.22)
Net loss per share applicable to common stockholders— Diluted			$ (0.14)		$ (0.22)
Weighted-average number of common shares used in net loss per share applicable to common stockholders— Basic			172,206,534		134,250,722
Weighted-average number of common shares used in net loss per share applicable to common stockholders— Diluted			172,206,534		134,250,722

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net loss	$ (25,146,000)	$ (14,228,000)		$ (86,558,000)		$ (84,038,000)	$ (75,438,000)
Other comprehensive (loss) gain:
Unrealized holding loss on marketable securities	(194,000)			(79,000)		(24,000)	27,000
Comprehensive loss	$ (25,340,000)	$ (14,228,000)		$ (86,637,000)		$ (84,062,000)	$ (75,411,000)
Tyme Technologies, Inc. and Subsidiaries [Member]
Net loss			$ (23,626,047)		$ (28,978,763)
Other comprehensive (loss) gain:
Unrealized holding loss on marketable securities			(544,264,000)
Comprehensive loss			$ (24,170,311,000)		$ (28,978,763,000)

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY - USD ($)	Total	Warrants Related To debt arrangement	At The Market	Private Placement Pre-Funded Warrant	Follow On Offering	Follow On Offering Common Stock and Warrants	Follow On Offering Preferred Stock and Warrants	Common Stock	Common Stock At The Market	Common Stock Private Placement Pre-Funded Warrant	Common Stock Follow On Offering	Common Stock Follow On Offering Common Stock and Warrants	Series A Convertible Preferred Stock	Series A Convertible Preferred Stock Follow On Offering Preferred Stock and Warrants	Additional Paid-In Capital	Additional Paid-In Capital Warrants Related To debt arrangement	Additional Paid-In Capital At The Market	Additional Paid-In Capital Private Placement Pre-Funded Warrant	Additional Paid-In Capital Follow On Offering	Additional Paid-In Capital Follow On Offering Common Stock and Warrants	Additional Paid-In Capital Follow On Offering Preferred Stock and Warrants	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit	Tyme Technologies, Inc. and Subsidiaries [Member]	Tyme Technologies, Inc. and Subsidiaries [Member] At Market Financing Facility [Member]	Tyme Technologies, Inc. and Subsidiaries [Member] Securities Purchase Agreement [Member]	Tyme Technologies, Inc. and Subsidiaries [Member] Common Stock	Tyme Technologies, Inc. and Subsidiaries [Member] Common Stock At Market Financing Facility [Member]	Tyme Technologies, Inc. and Subsidiaries [Member] Common Stock Securities Purchase Agreement [Member]	Tyme Technologies, Inc. and Subsidiaries [Member] Additional Paid-In Capital	Tyme Technologies, Inc. and Subsidiaries [Member] Additional Paid-In Capital At Market Financing Facility [Member]	Tyme Technologies, Inc. and Subsidiaries [Member] Additional Paid-In Capital Securities Purchase Agreement [Member]	Tyme Technologies, Inc. and Subsidiaries [Member] Accumulated Other Comprehensive Gain (Loss)	Tyme Technologies, Inc. and Subsidiaries [Member] Accumulated Deficit
Balance at Dec. 31, 2018	$ 78,586,000							$ 34,000							$ 296,100,000							$ (3,000)	$ (217,545,000)
Balance (in shares) at Dec. 31, 2018								33,765,864					0
Exercise of stock options	211,000														211,000
Exercised								60,181
Issuance of common stock / preferred stock, warrants, net of issuance costs			$ 799,000			$ 60,359,000	$ 4,638,000					$ 9,000					$ 799,000			$ 60,350,000	$ 4,638,000
Issuance of common stock / preferred stock, warrants, net of issuance costs (in shares)									180,787			8,667,333		666
Conversion of preferred stock, Shares								666,000					(666)
Issuance of shares under Employee Stock Purchase Plan	161,000														161,000
Issuance of shares under Employee Stock Purchase Plan, Shares								27,386
Exercise of warrants	2,000														2,000
Exercise of warrants, Shares								250
Stock-based compensation expense	9,839,000														9,839,000
Other comprehensive gain (loss)	27,000																					27,000
Net loss	(75,438,000)																						(75,438,000)
Balance at Dec. 31, 2019	79,184,000							$ 43,000							372,100,000							24,000	(292,983,000)
Balance (in shares) at Dec. 31, 2019								43,367,801					0
Exercise of stock options	1,076,000														1,076,000
Exercised								170,723
Vesting of restricted stock units								109,362
Issuance of common stock / preferred stock, warrants, net of issuance costs		$ 302,000	11,919,000	$ 70,753,000					$ 2,000	$ 11,000						$ 302,000	11,917,000	$ 70,742,000
Issuance of common stock / preferred stock, warrants, net of issuance costs (in shares)									2,201,810	10,312,500
Issuance of shares under Employee Stock Purchase Plan	433,000														433,000
Issuance of shares under Employee Stock Purchase Plan, Shares								59,550
Exercise of warrants	9,000														9,000
Exercise of warrants, Shares								1,000
Stock-based compensation expense	10,939,000														10,939,000
Other comprehensive gain (loss)	(24,000)																					(24,000)
Net loss	(84,038,000)																						(84,038,000)
Balance at Dec. 31, 2020	$ 90,553,000							$ 56,000							467,518,000							$ 0	(377,021,000)
Balance (in shares) at Dec. 31, 2020	56,222,746							56,222,746					0									0
Balance at Mar. 31, 2020																								$ 19,025,136			$ 12,333			$ 126,828,055			$ 0	$ (107,815,252)
Balance (in shares) at Mar. 31, 2020																											123,312,252
Exercise of stock options																								$ 5,351,323			$ 203,000			5,351,120,000
Exercised																								2,028,203			2,028,203
Issuance of common stock / preferred stock, warrants, net of issuance costs																									$ 5,775,418	$ 93,771,865		$ 445	$ 4,000		$ 5,774,973	$ 93,767,865
Issuance of common stock / preferred stock, warrants, net of issuance costs (in shares)																												4,453,939	40,000,000
Warrant to share exchange																								$ 3,393,775			$ 241			3,393,534
Warrant to share exchange, Shares																											2,406,250
Stock-based compensation expense																								3,456,895						3,456,895
Net loss																								(28,978,763)										(28,978,763)
Balance at Mar. 31, 2021	$ 149,880,000							$ 61,000							541,068,000							$ 0	(391,249,000)	$ 101,795,649			$ 17,222			238,572,442			0	(136,794,015)
Balance (in shares) at Mar. 31, 2021								61,849,642																172,200,644			172,200,644
Balance at Dec. 31, 2020	$ 90,553,000							$ 56,000							467,518,000							$ 0	(377,021,000)
Balance (in shares) at Dec. 31, 2020	56,222,746							56,222,746					0									0
Exercise of stock options	$ 157,000														157,000
Exercised								20,134
Vesting of restricted stock units								206,762
Issuance of common stock / preferred stock, warrants, net of issuance costs			$ 70,468,000						$ 5,000								$ 70,463,000
Issuance of common stock / preferred stock, warrants, net of issuance costs (in shares)									5,400,000
Stock-based compensation expense	2,930,000														2,930,000
Net loss	(14,228,000)																						(14,228,000)
Balance at Mar. 31, 2021	149,880,000							$ 61,000							541,068,000							$ 0	(391,249,000)	$ 101,795,649			$ 17,222			238,572,442			0	(136,794,015)
Balance (in shares) at Mar. 31, 2021								61,849,642																172,200,644			172,200,644
Balance at Dec. 31, 2020	$ 90,553,000							$ 56,000							467,518,000							$ 0	(377,021,000)
Balance (in shares) at Dec. 31, 2020	56,222,746							56,222,746					0									0
Exercise of stock options	$ 157,000														157,000
Exercised	20,134							20,134
Vesting of restricted stock units								286,837
Issuance of common stock / preferred stock, warrants, net of issuance costs					$ 70,468,000						$ 5,000								$ 70,463,000
Issuance of common stock / preferred stock, warrants, net of issuance costs (in shares)											5,400,000
Issuance of shares under Employee Stock Purchase Plan	$ 323,000														323,000
Issuance of shares under Employee Stock Purchase Plan, Shares								94,318
Stock-based compensation expense	10,354,000														10,354,000
Other comprehensive gain (loss)	(79,000)																					$ (79,000)
Net loss	(86,558,000)																						(86,558,000)
Balance at Dec. 31, 2021	$ 85,218,000							$ 61,000							548,815,000							(79,000)	(463,579,000)
Balance (in shares) at Dec. 31, 2021	62,024,035							62,024,035					0
Balance at Mar. 31, 2021	$ 149,880,000							$ 61,000							541,068,000							0	(391,249,000)	$ 101,795,649			$ 17,222			238,572,442			0	(136,794,015)
Balance (in shares) at Mar. 31, 2021								61,849,642																172,200,644			172,200,644
Exercise of stock options																								$ 6,188			$ 1			6,187
Exercised																								6,250			6,250
Stock-based compensation expense																								$ 2,451,906						2,451,906
Other comprehensive gain (loss)																								(544,264,000)
Unrealized gain (loss) on available-for-sale securities																								(544,264)									(544,264)
Net loss																								(23,626,047)										(23,626,047)
Balance at Mar. 31, 2022	$ 62,742,000							$ 61,000							551,679,000							(273,000)	(488,725,000)	$ 80,083,432			$ 17,223			241,030,535			(544,264)	(160,420,062)
Balance (in shares) at Mar. 31, 2022	62,801,296							62,801,296																172,206,894			172,206,894
Balance at Dec. 31, 2021	$ 85,218,000							$ 61,000							548,815,000							(79,000)	(463,579,000)
Balance (in shares) at Dec. 31, 2021	62,024,035							62,024,035					0
Exercise of stock options	$ 1,000														1,000
Exercised	37,700							37,700
Vesting of restricted stock units								739,561
Stock-based compensation expense	$ 2,863,000														2,863,000
Other comprehensive gain (loss)	(194,000)																					(194,000)
Net loss	(25,146,000)																						(25,146,000)
Balance at Mar. 31, 2022	$ 62,742,000							$ 61,000							$ 551,679,000							$ (273,000)	$ (488,725,000)	$ 80,083,432			$ 17,223			$ 241,030,535			$ (544,264)	$ (160,420,062)
Balance (in shares) at Mar. 31, 2022	62,801,296							62,801,296																172,206,894			172,206,894

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (Parenthetical) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Private Placement | Pre-Funded Warrant
Issuance costs				$ 401,000
Securities Purchase Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Issuance costs		$ 6,228,135
At Market Financing Facility [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Issuance costs		$ 318,425
Common Stock | Convertible Preferred Stock
Conversion ratio of series A stock into common stock					1,000%
Common Stock | At The Market
Issuance costs	$ 5,132,000			$ 411,000
Common Stock | Follow On Offering
Issuance costs			$ 5,132,000		$ 4,600,000
Series A Convertible Preferred Stock
Issuance costs					$ 400,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss	$ (25,146,000)	$ (14,228,000)		$ (86,558,000)		$ (84,038,000)	$ (75,438,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	681,000	666,000		2,758,000		2,774,000	2,521,000
Amortization of right-of-use asset	66,000	65,000		260,000		261,000	201,000
Loss on disposal of fixed assets							(181,000)
Stock-based compensation expense	2,863,000	2,930,000		10,354,000		10,939,000	9,839,000
Change in fair value of warrant liability	(2,448,000)	(7,670,000)		(16,682,000)		375,000	0
Net amortization of premiums and discounts on marketable securities	76,000			224,000		(49,000)	(949,000)
Amortization of debt-discount and accretion of deferred debt costs	185,000	167,000		706,000		287,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	203,000	329,000		(995,000)		309,000	(783,000)
Accounts receivable		7,000		7,000		19,993,000	(20,158,000)
Contract assets	(203,000)	(298,000)		(655,000)		(2,166,000)
Other long-term assets	(338,000)	(27,000)		(1,196,000)		(1,269,000)
Accounts payable	(969,000)	63,000		48,000		(1,057,000)	1,493,000
Accrued expenses	(2,372,000)	(1,680,000)		4,830,000		593,000	(3,576,000)
Deferred revenue	(2,408,000)	(2,134,000)		(11,905,000)		(6,292,000)	18,176,000
Proceeds for tenant improvement incentive from landlord						2,035,000	7,237,000
Operating lease asset and liabilities	(207,000)	(180,000)		(736,000)		(59,000)	1,365,000
Net cash used in operating activities	(30,017,000)	(21,990,000)		(99,540,000)		(57,364,000)	(60,253,000)
Investing activities
Purchases of property and equipment	(128,000)	(262,000)		(1,245,000)		(3,336,000)	(12,638,000)
Proceeds from the disposition of property and equipment							110,000
Purchases of marketable securities				(51,408,000)			(108,206,000)
Maturities of marketable securities	7,511,000					50,000,000	109,000,000
Net cash (used in) provided by investing activities	7,383,000	(262,000)		(52,653,000)		46,664,000	(11,734,000)
Financing activities
Payments on financing lease obligations	(70,000)	(64,000)		(265,000)		(241,000)	(205,000)
Proceeds from issuance of common stock through employee benefit plans		157,000		157,000		1,076,000	211,000
Proceeds from the issuance of common stock through exercise of option	1,000			200,000		1,100,000	200,000
Proceeds from the issuance of common stock through employee stock purchase plan				323,000		433,000	161,000
Proceeds from the issuance of common stock through exercise of warrants				0		0	2,000
Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs						11,896,000	824,000
Proceeds from term loan, net of issuance costs						39,619,000
Proceeds from issuance of common stock and accompanying warrants and pre-funded warrants in private placement, net of issuance costs						90,377,000
Proceeds from issuance of common stock and warrants in public offerings, net of issuance costs		70,353,000		70,337,000			60,359,000
Proceeds from issuance of convertible preferred stock and accompanying warrants in public offering, net of issuance costs							4,638,000
Payment of issuance costs related to out of period offering	(24,000)	(36,000)		(41,000)		(207,000)
Net cash (used in) provided by financing activities	(93,000)	70,410,000		70,511,000		142,953,000	65,990,000
Net (decrease) increase in cash, cash equivalents and restricted cash	(22,727,000)	48,158,000		(81,682,000)		132,253,000	(5,997,000)
Cash and cash equivalents, Beginning of period	95,388,000	177,070,000	$ 225,228,000	177,070,000		44,817,000	50,814,000
Cash and cash equivalents, End of period	72,661,000	225,228,000	72,661,000	95,388,000	$ 225,228,000	177,070,000	44,817,000
Supplemental disclosure of cash flow information:
Cash paid for interest	783,000	789,000		3,191,000		1,505,000	72,000
Cash paid for tax						7,000	29,000
Non-cash investing and financing activities:
Property and equipment received but unpaid as of period end	165,000			26,000		6,000	1,565,000
Asset acquired under operating lease				0		0	16,240,000
Assets acquired under financing lease				0		0	1,059,000
Deferred debt financing costs incurred but unpaid as of period end				24,000		5,000	58,000
Offering costs incurred but unpaid as of period end	10,000	26,000		$ 10,000		$ 298,000	$ 23,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Operating activities
Net loss			(23,626,047)		(28,978,763)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation					5,181
Stock-based compensation expense			2,451,906		3,456,895
Change in fair value of warrant liability			(1,807,441)		3,915,393
Gain on warrant exchange					(2,228,697)
Net amortization of premiums and discounts on marketable securities			1,615,332
Loss on call redemption of marketable securities			1,416
Changes in operating assets and liabilities:
Prepaid clinical costs			1,037,836		144,528
Prepaid expenses and other assets			(2,224,512)		(171,021)
Operating lease right-of-use asset			37,242		150,269
Accounts payable and other current liabilities			(38,963)		1,015,088
Severance payable			1,456,696		(58,896)
Accrued bonuses			(107,628)		(760,269)
Operating lease liability			(38,582)		(54,186)
Net cash used in operating activities			(21,242,745)		(23,564,478)
Investing activities
Maturities of marketable securities			22,703,798
Purchases of marketable securities			(95,244,730)
Net cash (used in) provided by investing activities			(72,540,932)
Financing activities
Proceeds from the issuance of common stock through exercise of option			6,188		5,351,323
Insurance note payments					(518,124)
Proceeds from registered offerings, net of issuance costs					99,547,283
Net cash (used in) provided by financing activities			6,188		104,380,482
Net (decrease) increase in cash, cash equivalents and restricted cash			(93,777,489)		80,816,004
Cash and cash equivalents — beginning of year			107,516,420		26,700,416
Cash and cash equivalents — end of year	$ 13,738,931	$ 107,516,420	13,738,931		107,516,420
Supplemental disclosure of cash flow information:
Cash paid for interest			$ 70,244		97,133
Non-cash investing and financing activities:
Operating lease right-of-use asset obtained in exchange for lease liabilities					$ 75,439

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - Tyme Technologies, Inc. and Subsidiaries [Member]	12 Months Ended
	Mar. 31, 2022 shares
Share Exchange Agreements [Member]
Cashless exchange of warrants to purchase	5,833,333
Cashless exchange of shares of common stock	2,166,667
Warrant Exchange Agreements [Member]
Cashless exchange of warrants to purchase	2,406,250

Nature of Business

Nature of Business	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Nature Of Business [Line Items]
Nature of Business	1. Nature of Business Syros Pharmaceuticals, Inc. (the “Company”), a Delaware corporation formed in November 2011, is a biopharmaceutical company seeking to redefine the power of small molecules to control the expression of genes. The Company is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals; risks inherent in the development and commercialization of medicines to treat human disease; competition from other companies, many of which are larger and better capitalized; risks relating to obtaining and maintaining necessary intellectual property protection; and the need to obtain adequate additional financing to fund the development of its product candidates and discovery activities. If the Company is unable to raise capital when needed or on favorable terms, it would be forced to delay, reduce, eliminate or out-license The Company has incurred significant net operating losses in every year since its inception. It expects to continue to incur significant and increasing net operating losses for at least the next several years. The Company’s net losses were $86.6 million, $84.0 million and $75.4 million for the years ended December 31, 2021, 2020 and 2019, respectively. As of March 31, 2022, the Company had an accumulated deficit of $488.7 million. The Company has not generated any revenues from product sales, has not completed the development of any product candidate and may never have a product candidate approved for commercialization. The Company has financed its operations to date primarily through a credit facility, the sale of equity securities and through license and collaboration agreements. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative activities to support such research and development. The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company’s stockholders’ equity and working capital. Under ASC Topic 205-40, Presentation of Financial Statements—Going Concern Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company’s cost structure and operating plan. Management’s plans to alleviate its financing requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company’s control: • raise funding through the sale of the Company’s common or preferred stock; • raise funding through debt financing; and • establish collaborations with potential partners to advance the Company’s product pipeline. Based on its current operating plan, the Company’s management believes that its cash, cash equivalents and marketable securities of $112.9 million as of March 31, 2022 will allow the Company to meet its liquidity requirements into the second quarter of 2023. The Company’s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management’s assessment that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful.		1. Nature of Business Syros Pharmaceuticals, Inc. (the “Company”), a Delaware corporation formed in November 2011, is a biopharmaceutical company seeking to redefine the power of small molecules to control the expression of genes. The Company is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals; risks inherent in the development and commercialization of medicines to treat human disease; competition from other companies, many of which are larger and better capitalized; risks relating to obtaining and maintaining necessary intellectual property protection; and the need to obtain adequate additional financing to fund the development of its product candidates and discovery activities. If the Company is unable to raise capital when needed or on favorable terms, it would be forced to delay, reduce, eliminate or out-license In January 2021, the Company issued and sold an aggregate of 5,400,000 shares of the Company’s common stock in an underwritten public offering at a public offering price of $14.00 per share, resulting in gross proceeds of $75.6 million before deducting underwriting discounts and commissions and other transaction expenses of approximately $5.1 million. On December 8, 2020, through a private placement, the Company issued 10,312,500 shares of the Company’s common stock, par value $0.001 per share, and, in lieu of such shares of common stock, pre-funded “Pre-Funded Pre-Funded Pre-Funded On December 4, 2020, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Orsenix, LLC (“Orsenix”), pursuant to which the Company acquired all of Orsenix’s assets related to a novel oral form of arsenic trioxide, which the Company refers to as SY-2101 In April 2019, the Company completed two concurrent underwritten public offerings of the Company’s equity securities, which together resulted in gross proceeds to the Company of $70.0 million, before underwriting discounts and commissions and offering expenses of approximately $5.0 million. In one of the public offerings, the Company sold 8,667,333 shares of its common stock and accompanying Class A warrants (the “2019 Warrants”) to purchase 1,951,844 shares of the Company’s common stock, at a combined price to the public of $7.50 per common share and accompanying 2019 Warrant. In the other public offering, the Company sold 666 shares of its Series A convertible preferred stock (the “Series A Stock”), and accompanying 2019 Warrants to purchase 166,500 shares of the Company’s common stock, at a combined public offering price of $7,500 per share and accompanying 2019 Warrant. Each 2019 Warrant is immediately exercisable at an exercise price of $8.625 per share, subject to adjustment in certain circumstances, and will expire on October 10, 2022. During November 2019, the Company issued and sold an aggregate of 180,787 shares of its common stock to the public pursuant to its at-the-market The Company has incurred significant annual net operating losses in every year since its inception. It expects to continue to incur significant and increasing net operating losses for at least the next several years. The Company’s net losses were $86.6 million, $84.0 million and $75.4 million for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of $463.6 million. The Company has not generated any revenues from product sales, has not completed the development of any product candidate and may never have a product candidate approved for commercialization. The Company has financed its operations to date primarily through a credit facility, the sale of equity securities and through license and collaboration agreements. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company’s stockholders’ equity and working capital. Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company’s cost structure and operating plan. Management’s plans to alleviate its financing requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company’s control: • raise funding through the sale of the Company’s common or preferred stock; • raise funding through debt financing; and • establish collaborations with potential partners to advance the Company’s product pipeline. Based on the Company’s current operating plan, its cash, cash equivalents and marketable securities of $143.4 million as of December 31, 2021 will allow the Company to meet its liquidity requirements into the first quarter of 2023. The Company’s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management’s assessment that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issuance date of this Annual Report on Form 10-K. If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful.
Tyme Technologies, Inc. and Subsidiaries [Member]
Nature Of Business [Line Items]
Nature of Business		Note 1. Nature of Business Tyme Technologies, Inc. is a Delaware corporation headquartered in Bedminster, New Jersey, with a wholly owned subsidiary, Tyme Inc. (together, “TYME” or the “Company”). The majority of the Company’s research, development and other business activities are conducted by Tyme Inc., which was incorporated in Delaware in 2013. TYME is an emerging biotechnology company developing CMBTs that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to cause cancer cell death. The Company is currently focused on developing its novel compound, SM-88, TM TYME-19 CoV-2 SM-88 TM Ongoing Studies OASIS Trial in metastatic HR+/HER2- breast cancer The Company is collaborating with Georgetown University to support a Phase II trial, OASIS, for SM-88 SM-88 two-stage SM-88 HoPES Trial in sarcoma In early 2020, the open-label Phase 2 investigator-sponsored trial of SM-88 SM-88 SM-88 Preclinical Pipeline Programs The Company has begun a comprehensive translational preclinical program focused on SM-88 SM-88 SM-88, TYME-18 TM TYME-18 TYME-18, difficult-to-treat TYME-19 TYME-18. TYME-19 The Company has retained virology experts at Evotec to assess the MOAs of TYME-19 TYME-19 COVID-19 TYME-19 SARS-CoV-2 Tumor Targeting Technology TYME has developed a technology (“Tumor Targeting Technology”) by which the tyrosine isomer L metyrosine (L-α-methylparatyrosine) Discontinuing Programs Precision Promise Trial- SM-88 In October 2018 the Company partnered with PanCAN to study SM-88 SM SM-88 On January 26, 2022, the Company announced the discontinuation of SM-88 SM-88 TYME-88-PANC In fiscal year 2020, we launched our pivotal study for SM-88 TYME-88-Panc quarter of the fiscal year. As described previously, the COVID-19 Following the strategic review, considering, in part, the timeline and regulatory utility for this trial compared to the parallel Precision Promise trial and concentration of investment in this specific cancer, management concluded that it would be best to focus on the second-line Precision Promise trial which offers treatment options to patients earlier in their disease and includes tumor biopsy and biomarker analyses that align with the Company’s overall strategic focus on identifying targeted therapies. Therefore, the Company decided to stop enrollment and begin the process of closing down the trial. Patients currently on therapy are allowed to continue treatment until progression or unacceptable toxicity. The closing of this trial is expected to require several months to complete. During the year ended March 31, 2022, the Company expensed $723,000 of estimated close out costs. The trial’s remaining ongoing expense to the Company is approximately $400,000 and is expected to be incurred over the five months following March 31, 2022. Liquidity The consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. In February 2021, the Company raised $100 million in gross proceeds through a registered direct offering of 40,000,000 shares of its common stock, at a purchase price of $2.50 per share. The Company incurred $6.2 million of related costs which offset such proceeds. On January 7, 2020, the Company entered into a Securities Purchase Agreement with Eagle Pharmaceuticals, (“Eagle”), pursuant to which the Company raised $20,000,000 through the issuance and sale to Eagle of 10,000,000 shares of common stock, at a price of $2.00 per share. On October 18, 2019, TYME entered into an Open Market Sale Agreement SM not The proceeds of the aforementioned offerings are being used by the Company for continued clinical studies, drug commercialization and development activities and other general corporate and operating expenses. For the year ended March 31, 2022, the Company had negative cash flow from operations of $21.2 million and net loss of $23.6 million, which included $2.5 million non-cash Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements. This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Summary Of Significant Accounting Policies [Line Items]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of March 31, 2022, the results of its operations, statements of cash flows and statements of stockholders’ equity for the three months ended March 31, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three months ended March 31, 2022 are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Syros Pharmaceuticals, Inc. and its wholly owned subsidiaries, Syros Securities Corporation, a Massachusetts corporation formed by the Company in December 2014 to exclusively engage in buying, selling and holding securities on its own behalf, and Syros Pharmaceuticals (Ireland) Limited, an Irish limited liability company formed by the Company in January 2019. All intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, which include, but are not limited to, expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. Management’s estimation process may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, warrant liability, stock-based compensation expense, accrued expenses, income taxes and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results may differ from those estimates or assumptions. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is its chief executive officer. The Company and the chief operating decision maker view the Company’s operations and manage its business in one operating segment. The Company operates only in the United States. Cash and Cash Equivalents The Company considers all highly liquid instruments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents, which consist of money market funds that invest in U.S. Treasury obligations, as well as overnight repurchase agreements and corporate debt securities, are stated at fair value. The Company maintains its bank accounts at one major financial institution. Off-Balance The Company has no financial instruments with off-balance Fair Value of Financial Instruments ASC 820, Fair Value Measurement ASC 820 identified fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 established a three-tier fair value hierarchy that distinguishes between the following: Level 1—Quoted market prices (unadjusted) in active markets for identical assets or liabilities. Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3—Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying amounts reflected in the condensed consolidated balance sheets for cash and cash equivalents, prepaid expenses, other current assets, restricted cash, accounts payable, accrued expenses and deferred revenue approximate their respective fair values due to their short-term nature. Property and Equipment Property and equipment consists of laboratory equipment, computer equipment, furniture and fixtures and leasehold improvements, all of which are stated at cost, less accumulated depreciation. Expenditures for maintenance and repairs that do not improve or extend the lives of the respective assets are recorded to expense as incurred. Major betterments are capitalized as additions to property and equipment. Depreciation and amortization are recognized over the estimated useful lives of the assets using the straight-line method. Construction-in-progress construction-in-progress Impairment of Long-Lived Assets The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses from inception through March 31, 2022. Other Long-Term Assets Other long-term assets primarily consisted of advance payments made to the contract research organizations responsible for conducting the Company’s tamibarotene and SY-5609 Revenue Recognition To date the Company’s only revenue has consisted of collaboration and license revenue. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers reflects the consideration the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. If the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, the Company records a contract asset, excluding any amounts presented as accounts receivable. The Company includes unbilled accounts receivable as contract assets on its consolidated balance sheets. The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses contract assets and accounts receivable for impairment and, to date, no impairment losses have been recorded. From time to time, the Company may enter into agreements that are within the scope of ASC 606. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements Research and Development Expenditures relating to research and development are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with the development of the Company’s gene control platform and product candidates. Research and development costs include salaries and benefits, materials and supplies, external research, preclinical and clinical development expenses, stock-based compensation expense and facilities costs. Facilities costs primarily include the allocation of rent, utilities, depreciation and amortization. In certain circumstances, the Company is required to make non-refundable non-refundable The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the work being performed, including the phase or completion of the event, invoices received and costs. Significant judgements and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company may in-license in-license up-front Warrants The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock 815-40”). 480-10, 480-10, 815-40 ASC 815-40, 815-40, 815-40 Stock-Based Compensation Expense The Company accounts for its stock-based compensation awards in accordance with ASC 718, Compensation—Stock Compensation non-employees, options. The expected term of stock options to non-employees The Company expenses the fair value of its stock-based awards to employees and non-employees Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period. For stock-based awards that contain performance-based milestones, the Company records stock-based compensation expense in accordance with the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. Income Taxes The Company accounts for uncertain tax positions using a more-likely-than-not Net Loss per Share Basic net earnings per share applicable to common stockholders is calculated by dividing net earnings applicable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net earnings per share applicable to common stockholders is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method and the if-converted As of March 31, 2022, 1,000,000 Pre-Funded The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2022 2021 Stock options 7,527,152 6,504,401 Unvested restricted stock units 4,539,729 2,070,150 Warrants* 4,990,156 4,990,156 Total 17,057,037 13,564,707 * As of March 31, 2022 and 2021, this is comprised of 2,117,094 warrants to purchase common stock issued in connection with the Company’s April 2019 financing (refer to Note 10), 27,548 warrants to purchase common stock issued in connection with the execution of the Company’s loan agreement in February 2020 (refer to Note 7), 17,389 warrants to purchase common stock issued in connection with the second draw on this loan agreement in December 2020 (refer to Note 7), and 2,828,125 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 10). Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016-13”), 2016-13 available-for-sale 2016-13 Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): 2020-06”). 2020-06		2. Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Principles of Consolidation The accompanying consolidated financial statements include the accounts of Syros Pharmaceuticals, Inc. and its wholly owned subsidiaries, Syros Securities Corporation, a Massachusetts corporation formed by the Company in December 2014 to exclusively engage in buying, selling and holding securities on its own behalf, and Syros Pharmaceuticals (Ireland) Limited, an Irish limited liability company formed by the Company in January 2019. All intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, which include, but are not limited to, expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, warrant liability, stock-based compensation expense, accrued expenses, income taxes and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results may differ from those estimates or assumptions. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business in one operating segment. The Company operates only in the United States. Cash and Cash Equivalents The Company considers all highly liquid instruments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents, which consist of money market funds that invest in U.S. Treasury obligations, as well as overnight repurchase agreements, are stated at fair value. The Company maintains its bank accounts at one major financial institution. Off-Balance The Company has no financial instruments with off-balance Fair Value of Financial Instruments ASC 820, Fair Value Measurement ASC 820 identified fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 established a three-tier Level 1—Quoted market prices (unadjusted) in active markets for identical assets or liabilities. Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3—Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, prepaid expenses, other current assets, restricted cash, accounts payable, accrued expenses, deferred revenue, and financing and operating lease liabilities approximate their respective fair values due to their short-term nature. Property and Equipment Property and equipment consists of laboratory equipment, computer equipment, furniture and fixtures and leasehold improvements, all of which are stated at cost, less accumulated depreciation. Expenditures for maintenance and repairs that do not improve or extend the lives of the respective assets are recorded to expense as incurred. Major betterments are capitalized as additions to property and equipment. Depreciation and amortization are recognized over the estimated useful lives of the assets using the straight-line method. Construction-in-progress construction-in-progress Impairment of Long-Lived Assets The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses from inception through December 31, 2021. Other Long-Term Assets As of December 31, 2021 and 2020, other long-term assets primarily consisted of advance payments made to the contract research organizations responsible for conducting the Company’s tamibarotene and SY-5609 Revenue Recognition To date the Company’s only revenue has consisted of collaboration and license revenue. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future. For the year ended December 31, 2021, the Company recognized approximately $23.5 million of revenue, $19.4 million of which was related to the Company’s collaboration with Global Blood Therapeutics, Inc. (“GBT”), and $4.1 million of which was related to the Company’s target discovery collaboration with Incyte Corporation (“Incyte”). For the year ended December 31, 2020 the Company recognized $15.1 million of revenue, $11.7 million of which was related to the Company’s collaboration with GBT, and $3.4 million of which was related to the Company’s target discovery collaboration with Incyte. For the year ended December 31, 2019, the Company recognized $2.0 million of revenue, all of which was attributable to the target discovery collaboration with Incyte. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. If the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, the Company records a contract asset, excluding any amounts presented as accounts receivable. The Company includes contract assets as unbilled accounts receivable on its consolidated balance sheets. The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses contract assets and accounts receivable for impairment and, to date, no impairment losses have been recorded. From time to time, the Company may enter into agreements that are within the scope of ASC 606. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements Research and Development Expenditures relating to research and development are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with the development of the Company’s gene control platform and product candidates. Research and development costs include salaries and benefits, materials and supplies, external research, preclinical and clinical development expenses, stock-based compensation expense and facilities costs. Facilities costs primarily include the allocation of rent, utilities, depreciation and amortization. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, even when there is no alternative future use for the research and development, until related goods or services are provided. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the work being performed, including the phase or completion of the event, invoices received and costs. Significant judgements and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company may in-license in-license up-front Warrants The Company accounts for issued warrants as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity 480-10”) 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock 815-40”). 480-10, 480-10, 815-40 815-40, 815-40, 815-40 Stock-Based Compensation Expense The Company accounts for its stock-based compensation awards in accordance with ASC 718, Compensation—Stock Compensation non-employees, non-employees non-employees non-employees The Company expenses the fair value of its stock-based awards to employees and non-employees Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period. For stock-based awards that contain performance-based milestones, the Company records stock-based compensation expense in accordance with the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. For certain of the performance-based awards, notwithstanding any vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth anniversary of the vesting commencement date. Compensation expense for such awards is recognized over the six-year Income Taxes The Company accounts for uncertain tax positions using a more-likely-than-not Net Loss per Share Basic net earnings per share applicable to common stockholders is calculated by dividing net earnings applicable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net earnings per share applicable to common stockholders is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method and the if-converted As of December 31, 2021 and 2020, 1,000,000 Pre-Funded The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of December 31, 2021 2020 2019 Stock options 6,657,268 5,468,605 4,618,421 Unvested restricted stock units 2,687,487 1,734,383 1,116,358 Warrants* 4,990,156 4,990,156 2,118,094 Total 14,334,911 12,193,144 7,852,873 * As of December 31, 2021 and 2020, this is comprised of 2,117,094 2019 Warrants to purchase common stock issued in connection with the Company’s April 2019 financing (refer to Note 11), 27,548 warrants to purchase common stock issued in connection with the execution and first draw of the Loan Agreement in February 2020 (refer to Note 7), 17,389 warrants to purchase common stock issued in connection with the second draw on the Loan Agreement in December 2020 (refer to Note 7), and 2,828,125 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 11). As of December 31, 2019, this was comprised solely of 2,118,094 2019 Warrants to purchase common stock issued in connection with the Company’s April 2019 financing. The weighted average number of common shares used in net loss per share applicable to common stockholders on a basic and diluted basis were 62,534,978, 46,051,617 and 40,222,182 shares for the years ended December 31, 2021, 2020 and 2019, respectively. Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): Instruments and Contracts in an Entity’s Own Equity 2020-06”). 2020-06 In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016-13”), 2016-13 available-for-sale 2016-13 early adoption is permitted. The Company is currently evaluating this new standard and does not anticipate that it will have a material impact on its consolidated financial statements and related disclosures. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) 2019-12”), 2019-12
Tyme Technologies, Inc. and Subsidiaries [Member]
Summary Of Significant Accounting Policies [Line Items]
Summary of Significant Accounting Policies		Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and ASU of the FASB. Significant Accounting Policies Principles of Consolidation The Company’s consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiary, Tyme, Inc. All intercompany transactions and balances have been eliminated in consolidation. Reclassifications Certain prior year amounts, primarily severance expense which was broken out to a separate line item on the Consolidated Statements of Operations and Comprehensive Loss, have been reclassified to conform to the current year presentation. These reclassifications have no effect on the previously reported net loss or cash flows. Risks and Uncertainties The Company is subject to those risks associated with any biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Current Economic Conditions The novel COVID-19 day-to-day COVID-19 COVID-19 Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant items subject to such estimation include the calculation of the stock-based compensation and warrant valuation. Actual results could differ from such estimates. Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents are stated at fair value. The Company’s cash and cash equivalents consisted of $13.7 million at March 31, 2022 and $107.5 million at March 31, 2021. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and marketable securities. Cash is deposited with major banks and, at times, such balances with any one financial institution may be in excess of FDIC insurance limits. The Company exceeded the FDIC limit of $250,000 by $10.1 million at March 31, 2022 and $107.3 million at March 31, 2021. Although the Company has exceeded the federally insured limit, it has not incurred losses related to these deposits. Management monitors the Company’s accounts with these institutions to minimize credit risk. Marketable Securities In the first quarter of fiscal year 2022, the Company established an investment policy and invested in a portfolio of highly liquid investments and marketable securities. The primary objectives of the Company’s policy are to preserve capital and diversify risk, while maintaining sufficient liquidity to meet cash flow requirements. All of the Company’s marketable securities are debt securities and are classified as available-for-sale available-for-sale For individual debt securities classified as available-for-sale Fair Value of Financial Instruments The Company records certain financial assets and liabilities at fair value in accordance with the provisions of ASC Topic 820, Fair Value Measurements and Disclosures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value should be based on the assumptions that market participants would use when pricing an asset or liability and is based on a fair value hierarchy that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to the Company’s assumptions (unobservable inputs). Fair value measurements should be disclosed separately by level within the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with established fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. Additionally, from time to time, the Company may be required to record at fair value other assets on a nonrecurring basis, such as assets held for sale and certain other assets. These nonrecurring fair value adjustments typically involve application of lower-of-cost-or-market Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The carrying amounts of the Company’s financial instruments, including cash, accounts payable and other current liabilities approximates fair value given their short-term nature. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. Cash equivalents, marketable securities and the derivative warrant liability are recorded at fair value. See Note 7. Prepaid Expenses and Other Current Assets Prepaid expenses represent expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time. As of March 31, 2022, prepaid expenses and other current assets includes $1.1 million of prepaid insurance, $0.6 million accrued interest receivable on marketable securities and a $2.1 million deposit with our payroll vendor to satisfy the Chief Science Officer severance payment. As of March 31, 2021, prepaid expenses and other current assets includes $1.0 million of prepaid insurance. Property and Equipment, Net Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives. The Company estimates a life of three years for equipment and furniture and fixtures. Upon sale or retirement, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in results of operations. Repairs and maintenance costs are expensed as incurred. Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets, which include fixed assets and operating lease right of use assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended March 31, 2022 and 2021, the Company determined that there were no triggering events requiring an impairment analysis. Research and Development Research and development costs are expensed as incurred and are primarily comprised of, but not limited to, external research and development expenses incurred under arrangements with third parties, such as CROs, CMOs and consultants that conduct clinical and preclinical studies, costs associated with preclinical and development activities, costs associated with regulatory operations, depreciation expense for assets used in research and development activities and employee related expenses, including salaries and benefits for research and development personnel. Costs for certain development activities, such as clinical studies, are accrued, over the service period specified in the contract and recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense. Income Taxes Income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management’s best estimate of current and future taxes to be paid. The Company is subject to income taxes in the United States, for federal and various state jurisdictions. Significant judgments and estimates are required in the determination of the income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when, after consideration of available positive and negative evidence that it is not more likely than not that the benefit from deferred tax assets will be realizable. In recognition of this risk, we have provided a full valuation allowance against the net deferred tax assets. The assumptions about future taxable income require the use of significant judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various jurisdictions. ASC 740 “Income Taxes” states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. When and if the Company were to recognize interest and penalties related to unrecognized tax benefits, they would be reported in tax expense. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise and certain price protection provisions. Warrants of this type are subject to re-measurement As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features or requires issuance of registered common shares upon exercise which cause the warrants to be treated as derivatives. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model or the Black-Sholes model and is subsequently re-measured Basic and Diluted Loss Per Share The Company calculates net loss per share in accordance with Earning per Share (Topic 260) Stock-based Compensation The Company follows the authoritative guidance for accounting for stock-based compensation in ASC 718, Compensation-Stock Compensation. The guidance requires that stock-based payment transactions be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over the vesting period as services are being provided. (See Note 12, Equity Incentive Plan.) The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend yield of the common stock. For awards subject to time-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. The Company accounts for forfeitures as they occur. The Company adopted ASU 2018-07 non-employees Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”), Income Taxes 2019-12 In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016-13”) available-for-sale In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) ’ s Own Equity (Subtopic 815-40) No. 2020-06 No. 2020-06

Collaboration and Research Arra

Collaboration and Research Arrangements	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Collaborative Arrangement Disclosure [Abstract]
Collaboration and Research Arrangements	3. Collaboration and Research Arrangements Collaboration with Global Blood Therapeutics On December 17, 2019, the Company entered into a license and collaboration agreement (the “GBT Collaboration Agreement”) with Global Blood Therapeutics, Inc. (“GBT”), pursuant to which the parties agreed to a research collaboration to discover novel targets that induce fetal hemoglobin in order to develop new small molecule treatments for sickle cell disease and beta thalassemia. The research term (the “Research Term”) is for an initial period of three years and can be extended for up to two additional one-year Pursuant to the terms of the GBT Collaboration Agreement, GBT paid the Company an upfront payment of $20.0 million. GBT also agreed to reimburse the Company for full-time employee and out-of-pocket costs The Company granted to GBT an option (the “Option”) to obtain an exclusive, worldwide license, with the right to sublicense, under relevant intellectual property rights and know-how of th Should GBT exercise its Option, the Company could receive up to $315.0 million in option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting from the collaboration. The Company will also be entitled to receive, subject to certain reductions, tiered mid-to-high single Either party may terminate the GBT Collaboration Agreement for the other party’s uncured material breach or insolvency, and in certain other specified circumstances, subject to specified notice and cure periods. GBT may unilaterally terminate the GBT Collaboration Agreement in its entirety, for any or no reason, upon nine-months’ GBT Collaboration Revenue The Company analyzed the GBT Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606. The Company identified a single performance obligation, which includes a (i) non-exclusive non-exclusive non-exclusive non-exclusive non-exclusive At inception, the total transaction price was determined to be approximately $60.0 million, which consisted of a $20.0 million upfront non-refundable non-creditable Collaboration Agreement also provides for development and regulatory milestones which are only payable subsequent to the exercise of the Option, and therefore are excluded from the transaction price at inception. The Company will re-evaluate During the three months ended March 31, 2022, there was no change in the total transaction price, which remained at approximately $54.2 million. ASC 606 requires an entity to recognize revenue only when it satisfies a performance obligation by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer obtains control. As the non-exclusive During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $5.1 million and $4.0 million, respectively, under the GBT Collaboration Agreement. As of March 31, 2022, the Company had deferred revenue outstanding under the GBT Collaboration Agreement of approximately $6.9 million, all of which is classified as deferred revenue, current portion on the Company’s condensed consolidated balance sheets. Agreements with Incyte Corporation In January 2018, the Company and Incyte entered into a Target Discovery, Research Collaboration and Option Agreement (the “Incyte Collaboration Agreement”). The Incyte Collaboration Agreement was amended in November 2019. Under the Incyte Collaboration Agreement, the Company is using its proprietary gene control platform to identify novel therapeutic targets with a focus on myeloproliferative neoplasms, and Incyte has received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for the development and commercialization of therapeutic products directed to up to seven validated targets. For each option exercised by Incyte, Incyte will have the exclusive worldwide right to use the licensed intellectual property to develop and commercialize therapeutic products that modulate the target as to which the option was exercised. Under the terms of the Incyte Collaboration Agreement, Incyte paid the Company $10.0 million in up-front pre-paid In January 2018, the Company also entered into a Stock Purchase Agreement with Incyte (the “Stock Purchase Agreement”) whereby, for an aggregate purchase price of $10.0 million, Incyte purchased 793,021 shares of the Company’s common stock at $12.61 per share. Under the terms of the Stock Purchase Agreement, the shares were purchased at a 30% premium over the volume-weighted sale price of the shares of the Company’s common stock over the 15-trading Incyte Collaboration Revenue The Company analyzed the Incyte Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606. The Company identified a single performance obligation which includes (i) a research license that Incyte retains as long as there remains an unexercised option (the “Research License”), and (ii) research and development services provided during the research term. The Incyte Collaboration Agreement includes options to (x) obtain additional time to exercise the license options for certain targets designated as definitive validation targets, and (y) obtain license rights to each validated target, both of which were not considered by the Company’s management to be material rights, and therefore not performance obligations, at inception. At inception, the total transaction price was determined to be $12.3 million and was subsequently increased to $12.8 million following a November 2019 amendment. As of March 31, 2022, the total transaction price is $12.8 million, consisting of a $2.5 million upfront non-refundable non-creditable The Incyte Collaboration Agreement also provides for development and regulatory milestones that are only payable subsequent to the exercise of an option and were therefore excluded from the transaction price at inception. The Company re-evaluates The Company recognizes revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred as related to the research and development activities and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs during this time and is the best measure of progress towards satisfying the performance obligation. During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.4 million and $0.8 million, respectively, under the Incyte Collaboration Agreement. As of March 31, 2022, the Company had deferred revenue outstanding under the Incyte Collaboration Agreement of approximately $0.8 million, all of which is classified as deferred revenue, current portion on the Company’s condensed consolidated balance sheets. The following table presents the changes in accounts receivable, contract assets and liabilities for the three months ended March 31, 2022 (in thousands): Balance at December 31, Additions Deductions Balance at Accounts receivable and contract assets: Billed receivables from collaboration partners $ — $ 2,857 $ (2,857 ) $ — Unbilled receivables from collaboration partners 2,979 3,181 (2,978 ) 3,182 Total accounts receivable and contract assets $ 2,979 $ 6,038 $ (5,835 ) $ 3,182 Contract liabilities: Deferred revenue—Incyte $ 1,268 $ — $ (421 ) $ 847 Deferred revenue—GBT 8,913 — (1,987 ) 6,926 Total contract liabilities $ 10,181 $ — $ (2,408 ) $ 7,773	3. Collaboration and Research Arrangements Collaboration with Global Blood Therapeutics On December 17, 2019, the Company entered into a license and collaboration agreement (the “GBT Collaboration Agreement”) with Global Blood Therapeutics, Inc. (“GBT”), pursuant to which the parties agreed to a research collaboration to discover novel targets that induce fetal hemoglobin in order to develop new small molecule treatments for sickle cell disease and beta thalassemia. The research term (the “Research Term”) is for an initial period of three years and can be extended for up to two (2) additional one-year Pursuant to the terms of the GBT Collaboration Agreement, GBT agreed to pay the Company an upfront payment of $20.0 million, which was collected in January 2020. GBT also agreed to reimburse the Company for full-time employee and out-of-pocket costs The Company granted to GBT an option (the “Option”) to obtain an exclusive, worldwide license, with the right to sublicense, under relevant intellectual property rights and know-how of th Should GBT exercise its Option, the Company could receive up to $315.0 million in option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting from the collaboration. The Company will also be entitled to receive, subject to certain reductions, tiered mid-to-high single Either party may terminate the GBT Collaboration Agreement for the other party’s uncured material breach or insolvency, and in certain other specified circumstances, subject to specified notice and cure periods. GBT may unilaterally terminate the GBT Collaboration Agreement in its entirety, for any or no reason, upon nine-months’ prior written notice to the Company if such notice is delivered during the Research Term, or 90 days’ prior written notice to the Company if such notice is delivered after the expiration or termination of the Research Term. GBT Collaboration Revenue The Company analyzed the GBT Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606. The Company has identified a single performance obligation, which includes a (i) non-exclusive non-exclusive non-exclusive non-exclusive non-exclusive At inception, the total transaction price was determined to be approximately $60.0 million, which consisted of a $20.0 million upfront non-refundable non-creditable re-evaluate ASC 606 requires an entity to recognize revenue only when it satisfies a performance obligation by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer obtains control. As the non-exclusive The Company had no account receivable balance as of December 31, 2021 and 2020. The Company had contract asset balances of $3.0 million and $2.3 million as of December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company had deferred revenue related to the GBT Collaboration Agreement of $9.0 million, all of which was classified as deferred revenue, current portion on the Company’s consolidated balance sheet. As of December 31, 2020, the Company had deferred revenue of $16.7 million, of which $8.4 million and $8.3 million was classified as deferred revenue, current portion and deferred revenue, net of current portion, respectively, on the Company’s consolidated balance sheet. The Company recognized revenue under the GBT Collaboration Agreement of $19.4 million and $11.7 million, respectively, during the years ended December 31, 2021 and 2020. Agreements with Incyte Corporation In January 2018, the Company and Incyte entered into a Target Discovery, Research Collaboration and Option Agreement (the “Incyte Collaboration Agreement”). The Incyte Collaboration Agreement was amended in November 2019. Under the Incyte Collaboration Agreement, the Company is using its proprietary gene control platform to identify novel therapeutic targets with a focus on myeloproliferative neoplasms, and Incyte has received options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for the development and commercialization of therapeutic products directed to up to seven validated targets. For each option exercised by Incyte, Incyte will have the exclusive worldwide right to use the licensed intellectual property to develop and commercialize therapeutic products that modulate the target as to which the option was exercised. Under the terms of the Collaboration Agreement, Incyte paid the Company $10.0 million in up-front pre-paid In January 2018, the Company also entered into a Stock Purchase Agreement with Incyte (the “Stock Purchase Agreement”) whereby, for an aggregate purchase price of $10.0 million, Incyte purchased 793,021 shares of the Company’s common stock at $12.61 per share. Under the terms of the Stock Purchase Agreement, the shares were purchased at a 30% premium over the volume-weighted sale price of the shares of the Company’s common stock over the 15-trading Incyte Collaboration Revenue The Company analyzed the Incyte Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC 606. The Company identified a single performance obligation which includes (i) a research license that Incyte retains as long as there remains an unexercised option (the “Research License”) and (ii) research and development services provided during the research term. The Incyte Collaboration Agreement includes options to (x) obtain additional time to exercise the license options for certain targets designated as definitive validation targets and (y) obtain license rights to each validated target, both of which were not considered by the Company’s management to be material rights, and therefore not performance obligations, at inception. At inception, the total transaction price was determined to be $12.3 million. Following a November 2019 amendment, the total transaction price is now $12.8 million, consisting of a $2.5 million upfront non-refundable non-creditable The Incyte Collaboration Agreement also provides for development and regulatory milestones that are only payable subsequent to the exercise of an option and were therefore excluded from transaction price at inception. The Company re-evaluates The Company recognizes revenue associated with the performance obligation as the research and development services are provided using an input method, according to the costs incurred as related to the research and development activities and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs during this time and is the best measure of progress towards satisfying the performance obligation. During the years ended December 31, 2021, 2020 and 2019, the Company recognized $4.1 million, $3.4 million and $2.0 million of revenue, respectively, under the Incyte Collaboration Agreement. As of December 31, 2021, the Company has deferred revenue outstanding under the Incyte Collaboration Agreement of approximately $1.3 million, all of which was classified as deferred revenue, current portion on the Company’s consolidated balance sheets. The following table presents the changes in contract assets and liabilities for the year ended December 31, 2021 (in thousands): Balance at December 31, 2020 Additions Deductions Balance at 2021 Accounts receivable and contract assets: Billed receivables from collaboration partners $ 7 $ 10,931 $ (10,938 ) $ — Unbilled receivables from collaboration partners 2,324 11,410 (10,755 ) 2,979 Total accounts receivable and contract assets $ 2,331 $ 22,341 $ (21,693 ) $ 2,979 Contract liabilities: Deferred revenue – Incyte $ 5,365 $ — $ (4,097 ) $ 1,268 Deferred revenue – GBT 16,721 174 (7,982 ) 8,913 Total contract liabilities $ 22,086 $ 174 $ (12,079 ) $ 10,181 The change in deferred revenue is due to the timing of the payments and the recognition of revenue related to the Company’s collaboration agreements during the period.

Net Loss Per Common Share

Net Loss Per Common Share	12 Months Ended
	Mar. 31, 2022
Tyme Technologies, Inc. and Subsidiaries [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net Loss Per Common Share	Note 3. Net Loss Per Common Share. The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Year Ended March 31, 2022 2021 Basic and diluted net loss per common share calculation Net loss $ (23,626,047 ) $ (28,978,763 ) Weighted average common shares outstanding — basic and diluted 172,206,534 134,250,722 Net loss per share of common stock — basic and diluted $ (0.14 ) $ (0.22 ) The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Warrants issued in April 2019, discussed further in Note 8, participated on a one-for-one two-class two-class The following outstanding securities at March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive: Year Ended March 31, 2022 2021 Stock options 14,504,271 12,588,068 Warrants 3,104,318 3,104,318 Total 17,608,589 15,692,386

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Cash, Cash Equivalents and Marketable Securities	4. Cash, Cash Equivalents and Marketable Securities Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. Marketable securities consist of securities with original maturities greater than 90 days when purchased. The Company classifies these marketable securities as available-for-sale Cash, cash equivalents and marketable securities consisted of the following at March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 69,575 $ — $ — $ 69,575 Marketable securities: Corporate debt securities—due in one year or less 28,915 — (111 ) 28,804 US Treasury obligation—due in one year or less 12,000 — (118 ) 11,882 Corporate debt securities—due in more than one year to five years 2,682 — (44 ) 2,638 Total $ 113,172 $ — $ (273 ) $ 112,899 December 31, 2021 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 92,302 $ — $ — $ 92,302 Marketable securities: Corporate debt securities—due in one year or less 30,100 — (12 ) 30,088 US Treasury obligation—due in one year or less 8,000 — (21 ) 7,979 Corporate debt securities—due in more than one year to five years 9,085 — (33 ) 9,052 US Treasury obligation—due in more than one year to five years 3,999 — (13 ) 3,986 Total $ 143,486 $ — $ (79 ) $ 143,407 Although available to be sold to meet operating needs or otherwise, securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. During the three months ended March 31, 2022 and 2021, there were no realized gains or losses on sales of investments, and no investments were adjusted for other-than-temporary declines in fair value. As of March 31, 2022, marketable securities with maturities of one year or less when purchased are presented in current assets and those with maturities of more than one year are presented in the noncurrent assets in the accompanying condensed consolidated balance sheet. At March 31, 2022, the Company held ten securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position for less than twelve months as of March 31, 2022 was $27.4 million. There were no securities held by the Company in an unrealized loss position for more than twelve months as of March 31, 2022. The Company has the intent and ability to hold such securities until recovery. The Company determined that there was no material change in the credit risk of the above marketable securities. As a result, the Company determined it did not hold any marketable securities with an other-than temporary impairment as of March 31, 2022.	4. Cash, Cash Equivalents and Marketable Securities Cash equivalents are highly liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. Marketable securities consist of securities with original maturities greater than 90 days when purchased. The Company classifies these marketable securities as available-for-sale Cash, cash equivalents and marketable securities, available-for-sale, December 31, 2021 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 92,302 $ — $ — $ 92,302 Marketable securities: Corporate debt securities – due in one year or less 30,100 — (12 ) 30,088 US Treasury obligation – due in one year or less 8,000 — (21 ) 7,979 Corporate debt securities – due in more than one year to five years 9,085 — (33 ) 9,052 US Treasury obligation – due in more than one year to five years 3,999 — (13 ) 3,986 Total $ 143,486 $ — $ (79 ) $ 143,407 December 31, 2020 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 173,984 $ — $ — $ 173,984 Total $ 173,984 $ — $ — $ 173,984 Although available to be sold to meet operating needs or otherwise, securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. During the years ended December 31, 2021, 2020 and 2019, there were no realized gains or losses on sales of investments, and no investments were adjusted for other than temporary declines in fair value. As of December 31, 2021, marketable securities with maturities of one year or less when purchased are presented in current assets and those with maturities of more than one year are presented in the noncurrent assets in the accompanying condensed consolidated balance sheet. There were no marketable securities held as of December 31, 2020. As of December 31, 2021, the Company held eleven securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position for less than twelve months as of December 31, 2021 was $30.1 million. There were no securities held by the Company in an unrealized loss position for more than twelve months as of December 31, 2021. The Company has the intent and ability to hold such securities until recovery. The Company determined that there was no material change in the credit risk of the above marketable securities during the year ended December 31, 2021. As a result, the Company determined it did not hold any marketable securities with an other than temporary impairment as of December 31, 2021.

Available-for-Sale-Securities

Available-for-Sale-Securities	12 Months Ended
	Mar. 31, 2022
Tyme Technologies, Inc. and Subsidiaries [Member]
Marketable Securities [Line Items]
Available-for-Sale-Securities	Note 4. Available-for-Sale-Securities. The following table summarizes available-for-sale March 31, 2022 Amortized Gross Gross Fair Value Money market funds $ 3,409,178 $ — $ — $ 3,409,178 Corporate debt securities 32,831,174 — (343,134 ) 32,488,040 Municipal debt securities 37,405,722 — (201,130 ) 37,204,592 Total $ 73,646,074 $ $ (544,264 ) $ 73,101,810 The following table summarizes the classification of available-for-sale March 31, March 31, Cash and cash equivalents $ 3,409,178 $ — Marketable securities 69,692,632 — Total $ 73,101,810 $ — The following table summarizes our portfolio of available-for-sale Less than 12 months 12 months or Longer Total Fair Value Net Fair Value Net Fair Value Net Money market funds $ 3,409,178 $ — $ — $ — $ 3,409,178 $ — Corporate debt securities 26,195,025 (227,300 ) 6,293,015 (115,834 ) 32,488,040 (343,134 ) Municipal debt securities 34,416,936 (153,855 ) 2,787,656 (47,275 ) 37,204,592 (201,130 ) Total $ 64,021,139 $ (381,155 ) $ 9,080,671 $ (163,109 ) $ 73,101,810 $ (544,264 )

Accounts Payable and Other Curr

Accounts Payable and Other Current Liabilities	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Line Items]
Accounts Payable and Other Current Liabilities	8. Accrued Expenses Accrued expenses consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 External research and preclinical development 8,521 $ 8,274 Employee compensation and benefits 3,180 6,344 Professional fees 1,495 953 Facilities and other 53 53 Accrued expenses $ 13,249 $ 15,624		9. Accrued Expenses Accrued expenses consist of the following as of December 31, 2021 and 2020 (in thousands): December 31, 2021 December 31, 2020 External research and preclinical development $ 8,274 $ 4,702 Employee compensation and benefits 6,344 5,715 Professional fees 953 602 Facilities and other 53 65 Accrued expenses $ 15,624 $ 11,084
Tyme Technologies, Inc. and Subsidiaries [Member]
Payables and Accruals [Line Items]
Accounts Payable and Other Current Liabilities		Note 5. Accounts Payable and Other Current Liabilities. Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following: March 31, March 31, Legal $ 263,111 $ 454,139 Consultant and professional services 300,051 176,957 Accounting and auditing 14,410 55,349 Research and development 2,776,594 2,657,202 Board of Directors and Scientific Advisory Board Compensation 418,389 435,594 Other 30,872 63,149 $ 3,803,427 $ 3,842,390

Severance Payable

Severance Payable	12 Months Ended
	Mar. 31, 2022
Tyme Technologies, Inc. and Subsidiaries [Member]
Severance Payable [Line Items]
Severance Payable	Note 6. Severance Payable. The Company entered into a Release Agreement, dated March 24, 2022, pursuant to which the Chief Science Officer resigned and will receive severance that would be payable under his employment agreement in a lump sum payment of $2.1 million. The Company also entered into Separation and General Release Agreement with three other employees. The agreements provide separation benefits which the Company recorded as severance expense. In April 2021, the Company entered into a Separation and General Release Agreement related to the separation of employment of its Chief Medical Officer as of March 31, 2021. The agreement provides for separation benefits which the Company recorded as severance expense for the year ended March 31, 2021. On March 15, 2019 the Company entered into a Release Agreement related to the separation of employment of their Chief Operating Officer, which provides for salary continuance for five years, reimbursement of health benefits for three years and a modification to his outstanding stock options to extend the post-termination exercise period for his vested options from three months to five years. The Company recorded severance expense at its present value of $2.5 million, (using a discount rate of 6%) for the year ended March 31, 2019, including $0.4 million relating to the stock option modification. The aggregate severance liability payable was $3.0 million and $1.6 million as of March 31, 2022 and March 31, 2021.

Fair Value Measurements

Fair Value Measurements	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Fair value Disclosure [Line Items]
Fair Value Measurements	5. Fair Value Measurements Assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 were as follows (in thousands): Description March 31, 2022 Active Observable Unobservable Assets: Cash $ 59,769 $ 59,769 — $ — Money market funds 9,806 9,806 — — Corporate debt securities—due in one year or less 28,804 — 28,804 — US Treasury obligation—due in one year or less 11,882 11,882 — — Corporate debt securities—due in more than one year to five years 2,638 — 2,638 — Total $ 112,899 $ 81,457 $ 31,442 $ — Liabilities: Warrant liability $ 581 $ — $ — $ 581 Total $ 581 $ — $ — $ 581 Description December 31, 2021 Active Observable Unobservable Assets: Cash $ 57,213 $ 57,213 $ — $ — Money market funds 35,089 35,089 — — Corporate debt securities—due in one year or less 30,088 — 30,088 — US Treasury obligation—due in one year or less 7,979 7,979 — — US Treasury obligation—due in more than one year to five years 3,986 3,986 — — Corporate debt securities—due in more than one year to five years 9,052 — 9,052 — Total $ 143,407 $ 104,267 $ 39,140 $ — Liabilities: Warrant liability $ 3,029 $ — $ — $ 3,029 Total $ 3,029 $ — $ — $ 3,029 Assumptions Used in Determining Fair Value of Warrants The Company issued warrants to purchase an aggregate of up to 2,828,125 shares of common stock in connection with a private placement on December 8, 2020 (see Note 10) (the “Warrants”). In the event of certain fundamental transactions involving the Company, the Warrant holders may require the Company to make a payment based on a Black-Scholes valuation, using specified inputs; therefore, the Warrants were accounted for as liabilities. The Company recorded the fair value of the Warrants upon issuance using the Black-Scholes valuation model and is required to revalue the Warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the Warrants is considered under Level 3 of the fair value hierarchy and influenced by the fair value of the underlying common stock of the Company. A summary of the Black Scholes pricing model assumptions used to record the fair value of the Warrants is as follows: March 31, 2022 December 31, 2021 Stock price $ 1.19 $ 3.26 Risk-free interest rate 2.44 % 1.11 % Dividend yield — — Expected life (in years) 3.69 3.94 Expected volatility 85.49 % 81.14 % Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis The following table reflects the change in the Company’s Level 3 Warrant liability for the three months ended March 31, 2022 and the year ended December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 Fair value of warrant liability as of beginning of the period $ 3,029 $ 19,711 Change in fair value (2,448 ) (16,682 ) Fair value of warrant liability as of end of the period $ 581 $ 3,029		5. Fair Value Measurements Assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020 were as follows (in thousands): Description December 31, 2021 Active Observable Unobservable Assets: Cash $ 57,213 $ 57,213 $ — $ — Money market funds 35,089 35,089 — — Corporate debt securities – due in one year or less 30,088 — 30,088 — US Treasury obligation – due in one year or less 7,979 7,979 — — US Treasury obligation – due in more than one year to five years 3,986 3,986 — — Corporate debt securities – due in more than one year to five years 9,052 — 9,052 — Total $ 143,407 $ 104,267 $ 39,140 $ — Liabilities: Warrant liability $ 3,029 $ — $ — $ 3,029 Total $ 3,029 $ — $ — $ 3,029 Description December 31, 2020 Active Observable Unobservable Assets: Cash $ 47,579 $ 47,579 $ — $ — Money market funds 126,405 126,405 — — Total $ 173,984 $ 173,984 $ — $ — Liabilities: Warrant liability $ 19,711 $ — $ — $ 19,711 Total $ 19,711 $ — $ — $ 19,711 Assumptions Used in Determining Fair Value of Warrants The Company issued Warrants in connection with private placement on December 8, 2020 (see Note 11). In the event of certain fundamental transactions involving the Company, the Warrant holders may require the Company to make a payment based on a Black-Scholes valuation, using specified inputs; therefore, these Warrants were accounted as liabilities. The Company recorded the fair value of the Warrants upon issuance using the Black-Scholes valuation model and is required to revalue the Warrants at each reporting date with any changes in fair value recorded on our statement of operations. The valuation of the Warrants is considered under Level 3 of the fair value hierarchy and influenced by the fair value of the underlying common stock of the Company. A summary of the Black Scholes pricing model assumptions used to record the fair value of the warrants is as follows: December 31, 2021 December 31, 2020 Stock price $ 3.26 $ 10.85 Risk-free interest rate 1.11 % 0.35 % Dividend yield — — Expected life (in years) 3.94 4.94 Expected volatility 81.14 % 82.66 % Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis The following table reflects the change in the Company’s Level 3 Warrant liability for the years ended December 31, 2021 and December 31, 2020 (in thousands): December 31, 2021 December 31, 2020 Fair value of warrant liability as of beginning of year $ 19,711 $ 19,336 Change in fair value (16,682 ) 375 Fair value of warrant liability as of end of year $ 3,029 $ 19,711
Tyme Technologies, Inc. and Subsidiaries [Member]
Fair value Disclosure [Line Items]
Fair Value Measurements		Note 7. Fair Value Measurements. The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. Transfers are calculated on values as of the transfer date. There were no transfers between Levels 1, 2 and 3 during the years ended March 31, 2022 and March 31, 2021. The Company’s financial instruments measured at fair value on a recurring basis are as follows: March 31, 2022 Total Quoted prices in active markets Significant other observable inputs Significant unobservable inputs Financial assets Cash equivalents Money market funds $ 3,409,178 $ 3,409,178 $ — $ — Marketable Securities Short-term Corporate debt securities 26,195,025 — 26,195,025 — Municipal debt securities 34,416,936 — 34,416,936 — Long-term Corporate debt securities 6,293,015 — 6,293,015 — Municipal debt securities 2,787,656 — 2,787,656 — $ 73,101,810 $ 3,409,178 $ 69,692,632 $ — Financial liability Warrant liability $ 124,480 $ — $ — $ 124,480 March 31, 2021 Warrant liability $ 1,931,921 — — $ 1,931,921 Fair values of available-for-sale municipal debt securities. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The fair value measurement for the warrant issued in conjunction with the Exchange Agreements (see Note 8 for transaction details) (the “May 2020 Warrant”) is based on significant inputs not observable in the market and is classified as Level 3 liability as of March 31, 2022 and March 31, 2021.The fair value of the May 2020 Warrant was determined using a Black Scholes model and included significant unobservable inputs such as volatility. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk free interest rate over the term. The following table details key inputs and assumptions used to estimate the fair value of the May 2020 Warrant as of March 31, 2022 and March 31, 2021 using a Black Scholes model: May 2020 Warrant May 2020 Warrant March 31, 2022 March 31, 2021 Stock price $ 0.35 $ 1.78 Volatility 98 % 78 % Remaining term (years) 2.01 3.01 Expected dividend yield — — Risk-free rate 2.28 % 0.35 % The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: Warrant liability Beginning balance, March 31, 2021 $ 1,931,921 Change in fair value of May 2020 Warrant liability (1,807,441 ) Ending balance, March 31, 2022 $ 124,480

Restricted Cash

Restricted Cash	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Restricted Cash [Abstract]
Restricted Cash	6. Restricted Cash At March 31, 2022 and December 31, 2021, the Company had $3.1 million in restricted cash, which was classified as long-term on the Company’s condensed consolidated balance sheets, and all of which was attributable to the HQ Lease (See Note 9). In connection with the execution of the HQ Lease, the Company was required to provide the landlord with a letter of credit in the amount of $3.1 million that will expire 95 days after expiration or early termination of the HQ Lease. The Company will have the right, under certain conditions, to reduce the amount of the letter of credit to $2.1 million in October 2023. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the amounts shown in the Company’s condensed consolidated statement of cash flows as of March 31, 2022, and December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 Cash and cash equivalents $ 69,575 $ 92,302 Restricted cash, net of current portion 3,086 3,086 Total cash, cash equivalents and restricted cash $ 72,661 $ 95,388	6. Restricted Cash As of December 31, 2021, the Company had $3.1 million in restricted cash, which was classified as long-term on the Company’s consolidated balance sheets. The restricted cash pertained to the $3.1 million letter of credit issued by the Company in connection with the 2019 Lease (See Note 10). The letter of credit will expire 95 days after expiration or early termination of the 2019 Lease. The Company will have the right, under certain conditions, to reduce the amount of the letter of credit to $2.1 million in October 2023. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the amounts shown in the consolidated statement of cash flows as of December 31, 2021, 2020, 2019 and 2018 (in thousands): December 31, 2021 2020 2019 2018 Cash and cash equivalents $ 92,302 $ 173,984 $ 41,441 $ 49,886 Restricted cash, current portion — — 290 638 Restricted cash, net of current portion 3,086 3,086 3,086 290 Total cash, cash equivalents and restricted cash $ 95,388 $ 177,070 $ 44,817 $ 50,814

Oxford Finance Loan Agreement

Oxford Finance Loan Agreement	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Oxford Finance Loan Agreement	7. Oxford Finance Loan Agreement On February 12, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (the “Lender”). Pursuant to the Loan Agreement, a term loan of up to an aggregate principal amount of $60.0 million is available to the Company. A first tranche term loan for $20.0 million was funded on February 12, 2020, and a second tranche term loan for $20.0 million was funded on December 23, 2020. The remaining $20.0 million is still available under the Loan Agreement, at the sole discretion of the Lender. The term loan bears interest at an annual rate equal to the greater of (i) 7.75% and (ii) the sum of 5.98% and the greater of (A) one-month In connection with the Loan Agreement, the Company granted the Lender a security interest in all of the Company’s personal property now owned or hereafter acquired, excluding intellectual property (but including the right to payments and proceeds of intellectual property), and a negative pledge on intellectual property. The Loan Agreement also contains certain events of default, representations, warranties and non-financial In connection with the funding of the first tranche in February 2020, the Company issued the Lender warrants to purchase 27,548 shares of the Company’s common stock at an exercise price per share of $7.26. In connection with the funding of the second tranche in December 2020, the Company issued the Lender warrants to purchase 17,389 shares of the Company’s common stock at an exercise price of $11.50 per share (collectively, the “Oxford Warrants”). The Oxford Warrants are exercisable within five years from their respective dates of issuance. The Oxford Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Oxford Warrants do not provide any guarantee of value or return. The Company valued the Oxford Warrants at issuance using the Black-Scholes option pricing model and determined the fair value of the Oxford Warrants to be $0.1 million for the first tranche and $0.2 million for the second tranche. The key inputs to the valuation model included an average volatility of 75.43% for the first tranche and 82.41% for the second tranche, and an expected term of 5.0 years for both tranches. The Company has the following minimum aggregate future loan payments as of March 31, 2022 (in thousands): Nine months ending December 31, 2022 $ — Year ending December 31, 2023 16,666 Year ending December 31, 2024 20,000 Year ending December 31, 2025 3,334 Total minimum payments $ 40,000 Less unamortized debt discount (410 ) Plus accumulated accretion of final fees 852 Total carrying value of debt 40,442 Less current portion (1,667 ) Long-term debt, net of current portion $ 38,775 For the three months ended March 31, 2022 and 2021, interest expense related to the Loan Agreement was approximately $1.0 million and $0.9 million, respectively. For the three months ended March 31, 2022, the current portion of debt is $1.7 million and the long-term portion of debt is $38.8 million as classified on the Co m	7. Oxford Finance Loan Agreement On February 12, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (the The term loan bears interest at an annual rate equal to the greater of (i) 7.75% and (ii) the sum of 5.98% and the greater of (A) one-month In connection with the Loan Agreement, the Company granted the Lender a security interest in all of the Company’s personal property now owned or hereafter acquired, excluding intellectual property (but including the right to payments and proceeds of intellectual property), and a negative pledge on intellectual property. The Loan Agreement also contains certain events of default, representations, warranties and non-financial In connection with the issuance of the first tranche, the Company issued the Lender warrants to purchase 27,548 shares of the Company’s common stock at an exercise price per share of $7.26 in February 2020. In connection with the issuance of the second tranche, the Company issued the Lender warrants to purchase 17,389 shares of the Company’s common stock at an exercise price of $11.50 per share in December 2020 (collectively, the “Oxford Warrants”). The Oxford Warrants are exercisable within five years from the respective dates of issuance. The Oxford Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Oxford Warrants do not provide any guarantee of value or return. The Company valued the Oxford Warrants at issuance using the Black-Scholes option pricing model and determined the fair value of the Oxford Warrants to be $0.1 million for the first tranche and $0.2 million for the second tranche. The key inputs to the valuation model included an average volatility of 75.43% for the first tranche and 82.41% for the second tranche, and an expected term of 5.0 years for both tranches. The Company has the following minimum aggregate future loan payments as of December 31, 2021 (in thousands): Year ending December 31, 2022 $ — Year ending December 31, 2023 16,666 Year ending December 31, 2024 20,000 Year ending December 31, 2025 3,334 Total minimum payments $ 40,000 Less unamortized debt discount (459 ) Plus accumulated accretion of final fees 716 Less current portion — Long-term debt, net of current portion $ 40,257 For the year ended December 31, 2021, interest expense related to the Loan Agreement was approximately $3.9 million. The total carrying value of debt is classified as long-term on the Company’s consolidated balance sheets as of December 31, 2021. The carrying value of the outstanding debt facility approximates its f a

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	8. Property and Equipment Property and Equipment consist of the following as of December 31, 2021 and 2020 (in thousands): Estimated useful life December 31, 2021 December 31, 2020 Construction-in-process — $ — $ 6 Laboratory equipment 5 7,989 7,028 Computer equipment 3 1,979 1,841 Furniture and fixtures 4 1,075 897 Leasehold improvements * 11,657 11,657 $ 22,700 $ 21,429 Less: Accumulated depreciation (9,856 ) (7,216 ) Total property and equipment, net $ 12,844 $ 14,213 * Leasehold improvements are depreciated over the shorter of the life of the asset and the term of the lease at 8.2 years and 9.3 years as of December 31, 2021 and 2020, respectively. The Company moved into its corporate headquarters in November 2019 and the 2019 Lease term ends in February 2030. Depreciation expense, including depreciation expense for two immaterial capital leases, for the years ended December 31, 2021, 2020 and 2019 was $2.8 million, $2.8 million and $2.5 million, respectively.

Accrued Expenses

Accrued Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued Expenses	8. Accrued Expenses Accrued expenses consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 External research and preclinical development 8,521 $ 8,274 Employee compensation and benefits 3,180 6,344 Professional fees 1,495 953 Facilities and other 53 53 Accrued expenses $ 13,249 $ 15,624	9. Accrued Expenses Accrued expenses consist of the following as of December 31, 2021 and 2020 (in thousands): December 31, 2021 December 31, 2020 External research and preclinical development $ 8,274 $ 4,702 Employee compensation and benefits 6,344 5,715 Professional fees 953 602 Facilities and other 53 65 Accrued expenses $ 15,624 $ 11,084

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Other Commitments [Line Items]
Commitments and Contingencies	9. Commitments and Contingencies Operating Lease On January 8, 2019, the Company entered into a lease (the “HQ Lease”) with respect to approximately 52,859 square feet of space in Cambridge, Massachusetts for a lease term commencing in January 2019 and ending in February 2030. The Company has the option to extend the lease term for one additional ten-year In connection with the execution of the HQ Lease, the Company was required to provide the landlord with a letter of credit in the amount of $3.1 million (See Note 6).The Company determined that, for purposes of applying the lease accounting guidance codified in ASU No. 2016-02, Leases (Topic 842) (“ right-of-use The Company elected the practical expedient provided under ASC 842 and therefore combined all lease and non-lease right-of-use Financing Lease In March 2019, the Company entered into an equipment lease agreement (the “Equipment Lease”) that has a 48-month right-of-use The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating and financing lease liabilities as of March 31, 2022 (in thousands): Operating Financing Nine months ending December 31, 2022 $ 2,956 $ 234 Year ending December 31, 2023 4,049 66 Year ending December 31, 2024 4,166 — Year ending December 31, 2025 4,287 — Year ending December 31, 2026 and beyond 19,256 — Total minimum lease payments 34,714 300 Less imputed interest (10,547 ) (14 ) Total lease liability $ 24,167 $ 286 The following table outlines the total lease cost for the Company’s operating and financing leases as well as weighted average information for these leases as of March 31, 2022 (in thousands): Three Months Ended Lease cost: Operating lease cost $ 772 Financing lease cost: Amortization of right-of-use $ 66 Interest on lease liabilities 7 Total financing lease cost $ 73 Cash paid for amounts included in the measurement of liabilities: Operating cash flows from operating lease $ 979 Operating cash flows from financing lease $ 78 Three Months Ended Other information: Weighted-average remaining lease term (in years)—operating lease 7.92 Weighted-average discount rate—operating lease 9.30 % Weighted-average remaining lease term (in years)—financing lease 1.07 Weighted-average discount rate—financing lease 9.47 % Following the adoption of ASC 842, the Company has a right-of-use right-of-use Asset Purchase Agreement Orsenix, LLC On December 4, 2020, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Orsenix, LLC (“Orsenix”), pursuant to which the Company acquired Orsenix’s assets related to a novel oral form of arsenic trioxide, which the Company refers to as SY-2101. • an upfront fee of $12.0 million, which was paid with cash on hand upon the closing of the transaction; • single-digit million milestone payments related to the development of SY-2101 • $6.0 million following the achievement of a regulatory milestone related to the development of SY-2101 • up to $10.0 million upon the achievement of certain commercial milestones with respect to SY-2101. The Company’s obligation to pay the commercial milestone payments expires following the tenth anniversary of the first commercial sale of SY-2101. SY-2101 SY-2101 Business Combinations” SY-2101. SY-2101 SY-2101 SY-2101 SY-2101. License Agreement TMRC Co. Ltd. In September 2015, the Company entered into an exclusive license agreement with TMRC Co. Ltd. (“TMRC”) to develop and commercialize tamibarotene in North America and Europe for the treatment of cancer. This agreement was amended and restated in April 2016, and further amended in January 2021 to expand the territory under which the Company is licensed to include Central and South America, Australia, Israel, and Russia. In exchange for this license, the Company agreed to a non-refundable country-by-country product-by-product know-how The Company also entered into a supply management agreement with TMRC under which the Company agreed to pay TMRC a fee for each kilogram of tamibarotene that is produced. The Company did not incur any fees under this supply management agreement during the three months ended March 31, 2022 and 2021.		10. Commitments and Contingencies Operating Leases On January 8, 2019, the Company entered into a lease (the “2019 Lease”) with respect to approximately 52,859 square feet of space in Cambridge, Massachusetts for a lease term commencing in January 2019 and ending in February 2030. The Company has the option to extend the lease term for one additional ten (10) year period. The 2019 Lease has escalating rent payments and the Company records rent expense on a straight-line basis over the term of the 2019 Lease, including any rent-free periods. The 2019 Lease includes certain lease incentives in the form of tenant allowances. The 2019 Lease also includes an abatement period in which the Company was not required to remit monthly rent payments until March 2020. In connection with the execution of the 2019 Lease, the Company was required to provide the landlord with a letter of credit in the amount of $3.1 million (See Note 6). The Company determined that, for purposes of applying ASC 842, the commencement date of the 2019 Lease occurred on May 1, 2019. The Company recorded a right-of-use The Company elected the practical expedient provided under ASC 842 and therefore has combined all lease and non-lease right-of-use Financing Lease In 2019, the Company entered into equipment lease agreements that have a 48-month right-of-use The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating and financing lease liabilities as of December 31, 2021 (in thousands): Operating Financing Year ending December 31, 2022 $ 3,935 $ 313 Year ending December 31, 2023 4,049 66 Year ending December 31, 2024 4,166 — Year ending December 31, 2025 4,287 — Year ending December 31, 2026 and beyond 19,256 — Total minimum lease payments 35,693 379 Less imputed interest (11,115 ) (23 ) Total lease liability $ 24,578 $ 356 The following table outlines the total lease cost for the Company’s operating and financing leases as well as weighted average information for these leases as of December 31, 2021 (in thousands): Year Ended 2021 Lease cost: Operating lease cost $ 2,958 Financing lease cost: Amortization of right-of-use $ 260 Interest on lease liabilities 48 Total financing lease cost $ 308 Cash paid for amounts included in the measurement of liabilities: Operating cash flows from operating lease $ 3,823 Operating cash flows from financing lease $ 312 Other information: Year Ended 2021 Weighted-average remaining lease term (in years) – operating lease 8.17 Weighted-average discount rate – operating lease 9.30 Weighted-average remaining lease term (in years) – financing lease 1.26 Weighted-average discount rate – financing lease 9.47 Prior to the adoption of ASC 842 effective January 1, 2019, the Company accounted for its leases under the guidance of ASC 840 as either operating with the liability recorded to the balance sheet based on escalating rent payments or capital and recorded to fixed assets and amortized over the term of the lease. Asset Purchase Agreement Orsenix, LLC On December 4, 2020, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Orsenix, LLC (“Orsenix”), pursuant to which the Company acquired all of Orsenix’s assets related to a novel oral form of arsenic trioxide, which the Company refers to as SY-2101. • an upfront fee of $12.0 million, which was paid with cash on hand upon the closing of the transaction; • single-digit million milestone payments related to the development of SY-2101 • $6.0 million following the achievement of a regulatory milestone related to the development of SY-2101 • up to $10.0 million upon the achievement of certain commercial milestones with respect to SY-2101. The Company’s obligation to pay the commercial milestone payments expires following the tenth anniversary of the first commercial sale of SY-2101. SY-2101 such period, and to use commercially reasonable efforts to dose the first patient in a Phase 3 clinical trial of SY-2101 Business Combinations SY-2101. SY-2101 SY-2101 SY-2101 SY-2101. License Agreement TMRC Co. Ltd. In September 2015, the Company entered into an exclusive license agreement with TMRC Co. Ltd. (“TMRC”) to develop and commercialize tamibarotene in North America and Europe for the treatment of cancer. This agreement was amended and restated in April 2016, and further amended in January 2021 to expand the territory under which we are licensed to include Central and South America, Australia, Israel, and Russia. In exchange for this license, the Company agreed to a non-refundable country-by-country product-by-product know-how The Company also entered into a supply management agreement with TMRC under which the Company agreed to pay TMRC a fee for each kilogram of tamibarotene that is produced. The Company incurred fees of $0.6 million and $0.9 million under this supply management agreement during the years ended December 31, 2021 and 2020, respectively. No payments were made under the supply management agreement during the year ended December 31, 2019. Litigation The Company is not party to any litigation and does not have contingency reserves established for any litigation liabilities as of December 31, 2021 or December 31, 2020.
Tyme Technologies, Inc. and Subsidiaries [Member]
Other Commitments [Line Items]
Commitments and Contingencies		Note 9. Commitments and Contingencies. Contract Service Providers In the course of the Company’s normal business operations, it enters into agreements and arrangements with contract service providers to assist in the performance of its research and development and clinical research activities. At March 31, 2022, the Company’s obligations to contract service providers were $0.2 million in the aggregate. On April 1, 2020, the Company amended the Clinical Research Funding and Drug Supply Agreement, dated October 9, 2018, with PanCAN, to enroll individuals diagnosed with pancreatic cancer in a platform style clinical research study. Stage 1 of the study was initiated in the fourth quarter of fiscal year 2020. On January 26, 2022, the Company announced the discontinuation of SM-88 Purchase Commitments The Company has entered into contracts with manufacturers to supply SM-88 non-cancellable Legal Proceedings The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that it believes could have a material adverse effect on the Company, its business, operating results or financial condition. From time to time, the Company may be involved in litigation, claims or other contingencies arising in the ordinary course of business. The Company would accrue a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company would not record a liability, but instead would disclose the nature and the amount of the claim, and an estimate of the loss or range of loss, if such estimate can be made. Legal fees are expensed as incurred.

Stockholders' Equity

Stockholders' Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Stockholders Equity Note Disclosure [Line Items]
Stockholders' Equity	10. Stockholders’ equity Issuance of Securities through an Underwritten Public Offering On January 22, 2021, the Company issued and sold an aggregate of 5,400,000 shares of its common stock in an underwritten public offering at a public offering price of $14.00 per share, resulting in gross proceeds of $75.6 million before deducting underwriting discounts and commissions and other transaction expenses of approximately $5.1 million. Issuance of Securities through a Private Placement On December 8, 2020, the Company issued in a private placement 10,312,500 shares of common stock, and, in lieu of shares of common stock, pre-funded “Pre-Funded Pre-Funded Pre-Funded In the event of certain fundamental transactions involving the Company, the holders of Warrants may require the Company to make a payment based on a Black-Scholes valuation, using specified inputs. The holders of Pre-Funded Pre-Funded Pre-Funded Pre-Funded Convertible Preferred Stock and 2019 Warrants On April 9, 2019, the Company completed two concurrent underwritten public offerings of its equity securities. In the first public offering, the Company sold 8,667,333 shares of its common stock and accompanying Class A warrants (the “2019 Warrants”) to purchase 1,951,844 shares of the Company’s common stock at a combined price to the public of $7.50 per common share and accompanying 2019 Warrant. In the second public offering, the Company sold 666 shares of its Series A convertible preferred stock (the “Series A Preferred Stock”) and accompanying 2019 Warrants to purchase 166,500 shares of the Company’s common stock at a combined public offering price of $7,500 per share and accompanying 2019 Warrant. The offerings resulted in aggregate gross proceeds to the Company of $70.0 million, before underwriting discounts and commissions and offering expenses payable by the Company of approximately $5.0 million. In November 2019, all 666 shares of Series A Preferred Stock were converted by the holder into 666,000 shares of common stock. As of March 31, 2022, there were no shares of Series A Preferred Stock outstanding. Each 2019 Warrant has an exercise price per share of common stock of $8.625, subject to adjustment in certain circumstances, and will expire on October 10, 2022. Each 2019 Warrant is immediately exercisable, provided that the holder is prohibited, subject to certain exceptions, from exercising the 2019 Warrant for shares of the Company’s common stock to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding. This percentage may be changed at the holders’ election to a higher or lower percentage upon 61 days’ notice to the Company. The Company evaluated the Series A Preferred Stock and 2019 Warrants for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity The Series A Preferred Stock was not mandatorily redeemable and did not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series A Preferred Stock would be recorded as permanent equity, not temporary equity, given that the holders of equally and more subordinated equity would be entitled to receive the same form of consideration upon the occurrence of the event that gives rise to the redemption or events of redemption that are within the control of the Company. Additionally, as the effective conversion price of the Series A Preferred Stock of $6.57 was below the fair value of the Company’s common stock on the date of issuance of $7.50, the Company determined that the Series A Preferred Stock included a beneficial conversion feature. The Company calculated the beneficial conversion feature to be approximately $0.6 million, which was recorded as a discount to the Series A Preferred Stock at the time of issuance. The 2019 Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the 2019 Warrants do not provide any guarantee of value or return. The Company valued the 2019 Warrants at issuance using the Black-Scholes option pricing model and determined the fair value of the 2019 Warrants to purchase 2,118,344 shares of the Company’s common stock was $9.0 million. The key inputs to the valuation model included an average volatility of 86.06% and an expected term of 3.5 years. As of March 31, 2022, the 2019 Warrants to purchase 2,117,094 shares of common stock are outstanding and remain unexercised.		11. Stockholders’ equity Issuance of Securities through an Underwritten Public Offering On January 22, 2021, the Company issued and sold an aggregate of 5,400,000 shares of its common stock in an underwritten public offering at a public offering price of $14.00 per share, resulting in gross proceeds of $75.6 million before deducting underwriting discounts and commissions and other transaction expenses of approximately $5.1 million. Issuance of Securities through a Private Placement On December 8, 2020, through a private placement, the Company issued 10,312,500 shares of common stock, and, in lieu of shares of common stock, Pre-Funded Pre-Funded Pre-Funded In the event of certain fundamental transactions involving the Company, the holders of Warrants may require the Company to make a payment based on a Black-Scholes valuation, using specified inputs. The holders of Pre-Funded Pre-Funded Pre-Funded Pre-Funded Convertible Preferred Stock and 2019 Warrants On April 9, 2019, the Company completed two concurrent underwritten public offerings of its equity securities. In the first public offering, the Company sold 8,667,333 shares of its common stock and accompanying 2019 Warrants to purchase 1,951,844 shares of the Company’s common stock, at a combined price to the public of $7.50 per common share and accompanying 2019 Warrant. In the second public offering, the Company sold 666 shares of its Series A Preferred Stock, and accompanying 2019 Warrants to purchase 166,500 shares of the Company’s common stock, at a combined public offering price of $7,500 per share and accompanying 2019 Warrant. The offerings resulted in aggregate gross proceeds to the Company of $70.0 million, before underwriting discounts and commissions and offering expenses payable by the Company of approximately $5.0 million. In November 2019, all 666 shares of Series A Preferred Stock were converted to 666,000 shares of common stock. As of December 31, 2021, there were no shares of our Series A Preferred Stock outstanding. Each 2019 Warrant has an exercise price per share of common stock of $8.625, subject to adjustment in certain circumstances, and will expire on October 10, 2022. Each 2019 Warrant is immediately exercisable, provided that the holder is prohibited, subject to certain exceptions, from exercising the 2019 Warrant for shares of the Company’s common stock to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding. This percentage may be changed at the holders’ election to a higher or lower percentage upon 61 days’ notice to the Company. The Company evaluated the Series A Preferred Stock and 2019 Warrants for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity The Series A Preferred Stock was not mandatorily redeemable and did not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series A Preferred Stock would be recorded as permanent equity, not temporary equity, given that the holders of equally and more subordinated equity would be entitled to receive the same form of consideration upon the occurrence of the event that gives rise to the redemption or events of redemption that are within the control of the Company. Additionally, as the effective conversion price of the Series A Preferred Stock of $6.57 was below the fair value of the Company’s common stock on the date of issuance of $7.50, the Company determined that the Series A Preferred Stock included a beneficial conversion feature. The Company calculated the beneficial conversion feature to be approximately $0.6 million, which was recorded as a discount to the Series A Preferred Stock at the time of issuance. The 2019 Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the 2019 Warrants do not provide any guarantee of value or return. The Company valued the 2019 Warrants at issuance using the Black-Scholes option pricing model and determined the fair value of the 2019 Warrants to purchase 2,118,344 shares of the Company’s common stock at $9.0 million. The key inputs to the valuation model included an average volatility of 86.06% and an expected term of 3.5 years. As of December 31, 2021, 2019 Warrants to purchase 2,117,094 shares of common stock are outstanding and remain unexercised.
Tyme Technologies, Inc. and Subsidiaries [Member]
Stockholders Equity Note Disclosure [Line Items]
Stockholders' Equity		Note 8. Stockholders’ Equity. Preferred Stock The Company is authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $0.0001. Shares of Company preferred stock may be issued from time to time in one or more series and/or classes, each of which will have such distinctive designation or title as shall be determined by the Company’s Board prior to the issuance of any shares of such series or class. The Company preferred stock will have such voting powers, full or limited or no voting powers and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated in such resolution or resolutions providing for the issue of such series or class of Company preferred stock as may be adopted from time to time by the Company’s Board prior to the issuance of any shares thereof. No shares of Company preferred stock are currently issued or outstanding. In connection with the Securities Purchase Agreement, dated January 7, 2020, between the Company and Eagle (the “Eagle SPA”), the Company designated and reserved 10,000 1,000 Common Stock Voting Each holder of Company common stock is entitled to one vote for each share thereof held by such holder at all meetings of stockholders (and written action in lieu of meetings). The number of authorized shares of Company common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of majority of the combined number of issued and outstanding shares of the Company. In connection with the Release Agreement, dated March 24, 2022, the Company and Mr. Hoffman also entered into a Voting Agreement, pursuant to which Mr. Hoffman agreed to vote all shares of TYME common stock beneficially owned by him in accordance with the Board’s recommendation with respect to any matter presented to the stockholders for a period of one year. The Company and Michael Demurjian entered into a Voting Agreement, dated April 18, 2022, pursuant to which Mr. Demurjian agreed to vote all shares of TYME common stock beneficially owned by him in accordance with the board of directors of the Company’s recommendation with respect to any matter presented to the Company’s stockholders for a period of two years from the date of the agreement. Dividends Dividends may be declared and paid on the Company common stock from funds lawfully available therefore, as and when determined by the Board. Liquidation In the event of the liquidation, dissolution, or winding-up Exchange Agreements On May 20, 2020, the Company entered into exchange agreements with holders (the “Holders”) of the warrants issued in April 2019 (the “April 2019 Warrants’). The April 2019 Warrants were offered and issued pursuant to the Company’s previous shelf registration statement on Form S-3 No. 333-211489). Pursuant to exchange agreements (the “Share Exchange Agreements”) with Holders of the April 2019 Warrants to purchase 5,833,333 shares of leak-out Leak-Out The Company also entered into an exchange agreement (the “Warrant Exchange Agreement”) with another Holder of April 2019 Warrants to purchase 2,166,667 shares of Common Stock in the aggregate. Pursuant to the Warrant Exchange Agreement, the Company issued such Holder a new warrant (the “May 2020 Warrant”) to purchase the same number of shares of Common Stock. The May 2020 Warrant has the same expiration date, April 2, 2024, as the April 2019 Warrants, but has an exercise price of $1.80 and does not include the price protection, anti-dilution provisions or other restrictions on Company action from the April 2019 Warrants. Concurrently therewith, such Holder executed and delivered to the Company a leak-out substantially similar to the restrictions on Exchange Shares in the Share Leak-Out leak-out The April 2019 Warrants were remeasured as of May 20, 2020, before the exchange, using the Monte Carlo pricing simulation resulting in a fair value of approximately $7.3 million, and the change in fair value from March 31, 2020 to the fair value before the exchange of approximately $3.7 million expense was recorded as a component of other income (expense) within the consolidated statement of operations for the year ended March 31, 2021. The key assumptions in applying the Monte Carlo simulation model were as follows: $1.70 stock price, 73% volatility, 3.87 years remaining term, 0.28% risk free rate and the probability of fundamental transactions occurring. At May 20, 2020, the fair value of the 2,406,250 shares issued under the Share Exchange Agreements was approximately $3.4 million, which resulted in a gain on exchange of approximately $1.9 million. The exercise price of the May 2020 Warrant is subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company’s Common Stock. The Company determined that the May 2020 Warrant should be recorded as a derivative liability on the consolidated balance sheet due to the May 2020 Warrant’s contractual provisions requiring issuance of registered common shares upon exercise. At May 20, 2020, the May 2020 Warrant was recorded at the fair value of $1.7 million as determined using the Black Scholes model and the change in fair value before and after the exchange of $0.3 million was recorded as a gain on warrant exchange as a component of other income (expense) within the consolidated statement of operations. The key assumptions in applying the Black Scholes model were as follows: $1.64 stock price, 73% volatility, 3.87 years remaining term, 0.27% risk free rate and 7% discount for lack of marketability. The change in fair value of the May 2020 Warrant for the year ended March 31, 2022 of $1.8 million income and for the period from May 20, 2020 through March 31, 2021 of $0.3 million expense was recorded as a component of other income (expense) within the consolidated statement of operations. The following summarizes the common stock warrant activity for the years ended March 31, 2022 and March 31, 2021: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2020 8,937,651 $ 2.31 Granted 2,166,667 1.80 Exchanged (8,000,000 ) 2.00 Outstanding at March 31, 2021 3,104,318 $ 2.77 Granted — — Exchanged — — Outstanding at March 31, 2022 3,104,318 $ 2.77 In May 2020, April 2019 Warrants to purchase 5,833,333 shares of common stock were exchanged on a cashless basis for 2,406,250 shares and April 2019 Warrants to purchase 2,166,667 of common stock were exchanged for a May 2020 Warrant to purchase the same number of shares. At March 31, 2022 and March 31, 2021, 3,074,551 of common stock purchase warrants relating to securities purchase agreements were outstanding and exercisable. Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 May 2020 Liability 2,166,667 $ 1.80 April 2024 At-the-Market On October 18, 2019, the Company entered into the Sale Agreement with Jefferies, pursuant to which the Company may, from time to time, sell shares of Common Stock, having an aggregate offering price of up to $30 million through Jefferies, as the Company’s sales agent. Under the Sale Agreement the minimum share sales price (“Floor Price”) shall not be less than $1.00 without Jefferies prior written consent. As indicated in an amendment, the shares will be offered and sold by the Company pursuant to its currently effective Registration Statement on Form S-3, No. 333-245033). “at-the-market The Company did not sell any shares through the Jefferies ATM during the year ended March 31, 2022. During the year ended March 31, 2021, the Company raised approximately $6.1 million of gross proceeds via sale of 4,453,939 shares of Common Stock under the Jefferies ATM and incurred $0.3 million of related costs which offset the proceeds. At March 31, 2022, there remained approximately $22.2 million of availability to sell shares through the Jefferies ATM subject to the terms of the Sale Agreement. Securities Purchase Agreement On January 7, 2020, the Company and Eagle entered into the Eagle SPA, pursuant to which the Company issued and sold to Eagle 10,000,000 shares of common stock, at a price of $2.00 per share. The Eagle SPA provides that Eagle will, subject to certain conditions, make an additional payment of $20 million upon the occurrence of a milestone event, which is defined as the earlier of (i) achievement of the primary endpoint of overall survival in the TYME-88-Panc SM-88 SM-88 Registered Direct Offering On February 8, 2021, the Company closed on its registered direct offering with several healthcare-focused institutional and other institutional investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers, in a registered direct offering, an aggregate of 40,000,000 shares (the “Shares”) of common stock, $0.0001 par value per share. The Shares were sold at a purchase price of $2.50 per share for aggregate gross proceeds to the Company of $100 million, prior to deducting placement agent’s fees and other offering expenses payable by TYME. The Company incurred $6.2 million of related costs which offset such proceeds. The Shares were offered by the Company pursuant to an effective shelf registration statement on Form S-3, No. 333-245033).

Stock-Based Payments

Stock-Based Payments	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Payments	11. Stock-Based Payments 2016 Stock Incentive Plan The 2016 Stock Incentive Plan (the “2016 Plan”) was adopted by the board of directors on December 15, 2015, approved by the stockholders on June 17, 2016, and became effective on July 6, 2016 upon the closing of the Company’s initial public offering (“IPO”). The 2016 Plan replaced the 2012 Equity Incentive Plan (the “2012 Plan”). Any options or awards outstanding under the 2012 Plan remained outstanding and effective. Under the 2016 Plan, the Company may grant incentive stock options, non-statutory 2016 Employee Stock Purchase Plan The 2016 Employee Stock Purchase Plan (the “2016 ESPP”) was adopted by the board of directors on December 15, 2015, approved by the stockholders on June 17, 2016, and became effective on July 6, 2016 upon the closing of the IPO. The number of shares of the Company’s common stock reserved for issuance under the 2016 ESPP automatically increases on the first day of each calendar year through the 2025 calendar year, in an amount equal to the least of (i) 1,173,333 shares of the Company’s common stock, (ii) 1.0% of the total number of shares of the Company’s common stock outstanding on the first day of the applicable year, and (iii) an amount determined by the Company’s board of directors. For the calendar year beginning January 1, 2022, the number of shares reserved for issuance under the 2016 ESPP was increased by 620,241 shares. At March 31, 2022, 2,857,306 shares remained available for future issuance under the 2016 ESPP. Inducement Grants During the year ended December 31, 2021, the Company granted non-statutory one-year 2022 Inducement Stock Incentive Plan On January 25, 2022, the Company’s board of directors adopted the 2022 Inducement Stock Incentive Plan (the “2022 Plan”), pursuant to which the Company may grant non-statutory 1,000,000 non-employment, Stock Options Terms of stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2016 Plan. Stock option awards granted by the Company generally vest over four years 25 75 three years ten years The Company has granted certain stock options to management for which vesting accelerates upon the achievement of performance-based criteria. Milestone events are specific to the Company’s corporate goals, including but not limited to certain clinical development milestones for the Company’s product candidates and the Company’s ability to execute on its corporate development and financing strategies. Stock-based compensation expense associated with these performance-based stock options is recognized based on the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. Notwithstanding any vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth anniversary of the vesting commencement date. As of December 31, 2020, all performance-based milestones related to these stock options were achieved. The Company did not record any additional stock-based compensation expense related to the achievement of performance-based milestones during the three months ended March 31, 2022 and 2021 The Company has granted options to purchase 75,000 shares of common stock to an advisor that vest solely upon the achievement of performance-based criteria. As of March 31, 2022, none of these performance-based criteria had been achieved. As of March 31, 2022, there was $0.3 million of unrecognized compensation cost related to this option, with a remaining contractual period of 4.5 years. A summary of the status of stock options as of December 31, 2021 and March 31, 2022 and changes during the three months ended March 31, 2022 is presented below: Shares Weighted Remaining Aggregate Outstanding at December 31, 2021 6,657,268 $ 8.27 7.2 $ 494 Granted 951,300 1.59 Exercised (37,700 ) 0.04 Cancelled (43,716 ) 9.93 Outstanding at March 31, 2022 7,527,152 $ 7.45 6.9 $ 26 Exercisable at March 31, 2022 4,081,501 $ 9.01 5.4 $ 26 The intrinsic value of stock options exercised during the three months ended March 31, 2022 and 2021 was $0.1 million and $0.1 million, respectively. As of March 31, 2022, there was $12.1 million of total unrecognized compensation cost related to non-vested Restricted Stock Units From time to time, upon approval by the Company’s board of directors, certain employees have been granted restricted stock units with time-based vesting criteria. The majority of these restricted stock units vest annually over a four-year term with 25% vesting on each anniversary of the grant date. Restricted stock units granted to the Company’s executive officers vest in full three-years from the date of grant. The fair value of restricted stock units is calculated based on the closing sale price of the Company’s common stock on the date of grant. A summary of the status of restricted stock units as of December 31, 2021 and March 31, 2022 and changes during the three months ended March 31, 2022 is presented below: Shares Weighted Outstanding at December 31, 2021 2,687,487 $ 6.52 Granted 2,768,128 1.58 Vested (739,561 ) 7.32 Forfeited (176,325 ) 6.76 Outstanding at March 31, 2022 4,539,729 $ 3.37 As of March 31, 2022, there was $13.9 million of unrecognized stock-based compensation expense related to outstanding restricted stock units, with an expected recognition period of 2.9 years. Stock-based Compensation Expense The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Three Months 2022 2021 Weighted-average risk-free interest rate 1.98 % 0.78 % Expected dividend yield — % — % Expected option term (in years) 6.07 6.08 Volatility 80.70 % 82.10 % The weighted-average grant date fair value per share of options granted in the three months ended March 31, 2022 and 2021 was $1.11 and $7.89, respectively. The following table summarizes the stock-based compensation expense for stock options and restricted stock units granted to employees and non-employees Three Months 2022 2021 Research and development $ 1,395 $ 1,323 General and administrative 1,468 1,607 Total stock-based compensation expense $ 2,863 $ 2,930 Due to an operating loss, the Company does not record tax benefits associated with stock-based	12. Stock-Based Payments 2016 Stock Incentive Plan The 2016 Stock Incentive Plan (the “2016 Plan”) was adopted by the board of directors on December 15, 2015, approved by the stockholders on June 17, 2016, and became effective on July 6, 2016 upon the closing of the Company’s initial public offering (“IPO”). The 2016 Plan replaced the 2012 Equity Incentive Plan (the “2012 Plan”). Any options or awards outstanding under the 2012 Plan remained outstanding and effective. Under the 2016 Plan, the Company may grant incentive stock options, non-statutory as specified by the board of directors. This number is subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. For the calendar year beginning January 1, 2021, the number of shares reserved for issuance under the 2016 Plan was increased by 1,600,000 shares. At December 31, 2021, 2,238,206 shares remained available for future issuance under the 2016 Plan. Under the 2016 Plan, stock options may not be granted at less than fair value on the date of grant. 2016 Employee Stock Purchase Plan The 2016 Employee Stock Purchase Plan (the “2016 ESPP”) was adopted by the board of directors on December 15, 2015, approved by the stockholders on June 17, 2016, and became effective on July 6, 2016 upon the closing of the IPO. The number of shares of the Company’s common stock reserved for issuance under the 2016 ESPP automatically increases on the first day of each calendar year through the 2025 calendar year, in an amount equal to the least of (i) 1,173,333 shares of the Company’s common stock, (ii) 1.0% of the total number of shares of the Company’s common stock outstanding on the first day of the applicable year, and (iii) an amount determined by the Company’s board of directors. For the calendar year beginning January 1, 2021, the number of shares reserved for issuance under the 2016 ESPP was increased by 562,227 shares. At December 31, 2021, 2,237,065 shares remained available for future issuance under the 2016 ESPP. Inducement Grants During the year ended December 31, 2021, the Company granted non-statutory one-year Stock Options Terms of stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2016 Plan. Stock option awards granted by the Company generally vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and 75% vesting ratably, on a monthly basis, over the remaining three years. Such awards have a contractual term of ten years from the grant date. The Company has granted stock options to management for which vesting accelerates upon the achievement of performance-based criteria. Milestone events are specific to the Company’s corporate goals, including but not limited to certain clinical development milestones and the Company’s ability to execute on its corporate development and financing strategies. Stock-based compensation expense associated with these performance-based stock options is recognized based on the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. Notwithstanding any vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth anniversary of the vesting commencement date. During each of the years ended December 31, 2020 and 2019, the Company recorded additional stock-based compensation expense of $0.4 million related to the acceleration of vesting of certain stock options associated with the initiation of the Phase 3 clinical trial of tamibarotene at the end of 2020 and the entry into the GBT Collaboration Agreement in December 2019, respectively. As of December 31, 2020, there was no unrecognized expense related to the performance-based stock options granted to management. The Company did not grant any performance-based stock option to management during the year ended December 31, 2021. The Company has granted options to purchase 75,000 shares of common stock to an advisor that vest solely upon the achievement of performance-based criteria. As of December 31, 2021, none of these performance-based criteria had been achieved. As of December 31, 2021, there was $0.3 million of unrecognized compensation cost related to this option, with a remaining contractual period of 4.7 years. A summary of the status of stock options as of December 31, 2021 and December 31, 2020 and changes during the year ended December 31, 2021 is presented below: Shares Weighted Remaining Aggregate Outstanding at December 31, 2020 5,468,605 $ 8.90 7.2 $ 13,124 Granted 2,417,600 7.69 Exercised (20,134 ) 7.77 Cancelled (1,208,803 ) 10.00 Outstanding at December 31, 2021 6,657,268 $ 8.27 7.2 $ 494 Exercisable at December 31, 2021 3,736,652 $ 8.86 5.8 $ 494 The intrinsic value of stock options exercised during the years ended December 31, 2021, 2020 and 2019 was $0.1 million, $0.8 million and $0.2 million, respectively. As of December 31, 2021, there was $12.8 million of total unrecognized compensation cost related to non-vested Cash received from option exercises during the years ended December 31, 2021, 2020, and 2019 was $0.2 million, $1.1 million, and $0.2 million, respectively. Restricted Stock Units From time to time, upon approval by the Company’s board of directors, certain employees have been granted restricted stock units with time-based vesting criteria. The majority of these restricted stock units vest annually over a four-year term with 25% vesting on each anniversary of the grant date. Restricted stock units granted to the Company’s executive officers vest in full three-years from the date of grant. The fair value of restricted stock units is calculated based on the closing sale price of the Company’s common stock on the date of grant. A summary of the status of restricted stock units as of December 31, 2020 and December 31, 2021 and changes during the year ended December 31, 2021 is presented below: Shares Weighted Outstanding at December 31, 2020 1,734,383 $ 7.40 Granted 1,747,554 6.31 Vested (286,837 ) 7.70 Forfeited (507,613 ) 8.15 Outstanding at December 31, 2021 2,687,487 $ 6.52 As of December 31, 2021, there was $12.0 million of unrecognized stock-based compensation expense related to outstanding restricted stock units, with an expected recognition period of 2.07 years. Stock-based Compensation Expense The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Year Ended December 31, 2021 2020 2019 Weighted-average risk-free interest rate 0.99 % 1.28 % 2.42 % Expected dividend yield — % — % — % Expected option term (in years) 6.03 5.99 6.00 Volatility 81.56 % 78.27 % 91.35 % The weighted-average grant date fair value per share of options granted in the years ended December 31, 2021, 2020 and 2019 was $5.33, $5.30 and $5.05, respectively. The following table summarizes the stock-based compensation expense for stock options, restricted stock units and restricted common stock granted to employees and non-employees Year Ended December 31, 2021 2020 2019 Research and development $ 5,706 $ 4,732 $ 3,472 General and administrative 4,648 6,207 6,367 Total stock-based compensation expense $ 10,354 $ 10,939 $ 9,839 Due to an operating loss, the Company does not record tax benefits associated with stock-based

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Income Taxes		13. Income Taxes The Company accounts for income taxes under FASB Accounting Standards Codification 740 (“ASC 740”). Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The components of the income tax provision for the years ended December 31, 2021, 2020 and 2019 are as follows: Year Ended December 31, 2021 2020 2019 Current $ 1 $ 4 $ 28 Deferred — — — Total $ 1 $ 4 $ 28 A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows for the years ended December 31, 2021, 2020 and 2019: Year ended December 31, 2021 2020 2019 Federal income tax computed at federal statutory tax rate 21.00 % 21.00 % 21.00 % State income tax, net of federal benefit 7.26 6.12 6.56 Permanent items 3.60 (0.68 ) (0.89 ) Federal and state research and development credits 5.79 3.89 4.79 Rate change — — — Other (1.41 ) (0.88 ) (0.77 ) Change in valuation allowance (36.24 ) (29.45 ) (30.73 ) Effective income tax rate — % — % (0.04 )% The principal components of the Company’s deferred tax assets and liabilities consist of the following at December 31, 2021 and 2020 (in thousands): Year ended December 31, 2021 2020 Deferred tax assets: Federal and state net operating loss carryforwards $ 109,166 $ 80,658 Tax credit carryforwards 22,446 17,442 Intangible assets 3,000 3,219 Stock-based compensation 5,700 5,117 Deferred revenue 2,810 6,034 Capital lease 6,812 7,284 Other 2,395 1,725 Total deferred tax assets 152,329 121,479 Less valuation allowance (146,285 ) (114,946 ) Net deferred tax assets 6,044 6,533 Deferred tax liabilities: Right-of-use 3,946 4,215 Fixed assets 2,098 2,318 Total deferred tax liabilities 6,044 6,533 Net deferred taxes $ — $ — ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December 31, 2021 and 2020, respectively because the Company’s management has determined that it is more likely than not that these assets will not be fully realized. The increase in the valuation allowance of $31.3 million in 2021 and $24.7 million in 2020 primarily relates to the net loss incurred by the Company. As of December 31, 2021, the Company had federal net operating loss (“NOL”) carryforwards of approximately $398.9 million and state net operating loss carryforwards of $401.9 million which are available to reduce future taxable income. The Company also had federal tax credits of approximately $19.7 million and state tax credits of $3.5 million which may be used to offset future tax liabilities. Net operating losses generated before 2018 of approximately $135.7 million will expire at various dates through 2037, and net operating loss carryforward of approximately $263.2 million, which were generated after 2017 have an indefinite carryforward period. Federal tax credits will expire at various dates through 2041. State net operating losses will expire at various dates through 2041. State tax credits will expire at various dates through 2036. The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not determined whether an ownership change has occurred and as such, the Company’s NOLs may be limited. The Company’s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. As of December 31, 2021 and 2020 the Company had no unrecognized tax benefits or accrued interest or penalties related to unrecognized tax benefits. The Company’s policy is to recognize both interest and penalties related to unrecognized tax benefits in income tax expense. The Company completed a study to document its qualifying research credits for all years ending before December 31, 2018. For the years ending after December 31, 2017, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an unrecognized tax benefit for the year ended December 31, 2021. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. The federal and state income tax returns are generally subject to examinations for the tax years ended December 31, 2018 through December 31, 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Company files income tax returns in the U.S. federal and Massachusetts jurisdictions. There are currently no federal or state audits in process.
Tyme Technologies, Inc. and Subsidiaries [Member]
Income Taxes [Line Items]
Income Taxes	Note 13. Income Taxes. The Company provides for income taxes under ASC 740. Under ASC 740, the liability method is used in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company has not recorded a current or deferred income tax expense or benefit since its inception. The Company’s loss before income taxes was $23.6 million and $29.0 million for the years ended March 31, 2022 and 2021, respectively, and was generated entirely in the United States. Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following: March 31, 2022 2021 Net operating loss carryforward $ 27,564,077 $ 20,123,621 Research and development credit carryforward 884,130 1,164,895 Orphan Drug Credit 4,157,360 2,002,559 Stock options – NQSOs 4,765,662 5,267,351 Accruals and other temporary differences 662,754 595,418 Gross deferred tax assets 38,033,983 29,153,844 Deferred tax valuation allowance (38,033,983 ) (29,153,844 ) Net deferred taxes $ — $ — Based on the Company’s history of operating losses since inception and consideration of available positive and negative evidence, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of March 31, 2022. The valuation allowance increased by $8.9 million for the year ended March 31, 2022 primarily due to the increase in the net operating loss carryforward and Orphan Drug credit. A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: Year Ended 2022 2021 U.S. statutory income tax rate 21.00 % 21.00 % State taxes, net of federal benefit 11.59 % — Permanent differences — (0.02 )% Tax credit carryforwards 7.93 % 4.70 % Valuation allowance (37.08 )% (20.98 )% Stock compensation (5.05 )% (3.41 )% Warrants 1.61 % (1.29 )% Effective tax rate — % — % As of March 31, 2022, the Company had gross U.S. federal net operating loss carryforwards of approximately $ 119.1 million, which may be available to offset future income tax liabilities and will begin to expire at various dates starting in 2033. As of March 31, 2022, none of the Company’s state net operating losses have value due to the apportionment rule in the states where state income tax returns are currently filed. As permitted under the Protecting Americans Against Tax Hikes Act, which allows the Research and Development tax credit to be applied to Form 941 quarterly payroll tax returns, the Company reduced payroll taxes by $120 thousand and $177 thousand for the years ended March 31, 2022 and March 31, 2021, respectively. As of March 31, 2022, the Company had gross federal research and development tax credit carryforwards of $5.9 million, available to reduce future tax liabilities which will begin to expire at various dates starting in 2030. Under the provisions of the Internal Revenue Code, the NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of a 50% cumulative change in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state tax provisions. This could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financing transactions since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended March 31, 2022 2021 Gross unrecognized tax benefits at beginning of year $ 558,962 $ 318,394 Increases (decreases) for tax positions in prior period — (99,063 ) Increase for tax positions in current period 330,712 339,631 Gross unrecognized tax benefits at end of year $ 889,674 $ 558,962 As of March 31, 2022, the Company had $890,000 of unrecognized tax benefits, which were offset with the net operating loss and valuation allowance on the consolidated balance sheets. None of the gross unrecognized tax benefits would affect the effective tax rate at March 31, 2022, if recognized. In addition, the Company did not record any penalties or interest related to uncertain tax positions for the periods presented in these consolidated financial statements. The Company does not have any positions for which it is reasonably possible that there will be significant increase or decrease in the amounts of unrecognized tax benefits within twelve months of the reporting date. The Company files income tax returns in the United States, and various state jurisdictions. The federal and state income tax returns are generally subject to tax examinations for the period January 1, 2017 through March 31, 2022. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Defined Contribution Plan	14. Defined Contribution Plan The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax or post-tax

Leases

Leases	12 Months Ended
	Mar. 31, 2022
Tyme Technologies, Inc. and Subsidiaries [Member]
Leases [Line Items]
Leases	Note 10. Leases. The Company has a lease for office space in New Jersey, which expires in February 2023. Total Company rent expense, including short term rentals, was approximately $62,000 and $165,000 for the years ended March 31, 2022 and 2021, respectively. Operating lease ROU assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. Payments for additional monthly fees to cover the Company’s share of certain facility expenses are not included in operating lease ROU assets and liabilities. The Company used its estimated incremental borrowing rate of 11.0% to calculate the present value of its lease payments, as the implicit rate in the lease was not readily determinable. As of March 31, 2022, the future minimum lease payments under non-cancellable March 31, Fiscal year 2023 $ 39,240 Total remaining lease payments 39,240 Less: present value adjustment (1,908 ) Total operating lease liabilities 37,332 Less: current portion 37,332 Operating lease liabilities, net of current portion $ —

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2022
Tyme Technologies, Inc. and Subsidiaries [Member]
Related Party Transaction [Line Items]
Related Party Transactions	Note 11. Related Party Transactions. Legal Faegre Drinker Biddle & Reath (“Faegre Drinker”), formerly Drinker Biddle & Reath LLP (“DBR”), has provided legal services to the Company. The Company’s Chief Legal Officer and Corporate Secretary held the consulting role “Senior Counsel” with the Faegre Drinker until December 31, 2021. During the years ended March 31, 2022 and 2021, approximately $0.5 million and $0.6 million ($0.1 million was capitalized into equity in prior year), respectively, have been incurred as legal expenses associated with Faegre Drinker, and the Company had approximately $153,000 and $87,000 in accounts payable and accrued expenses payable to Faegre Drinker at March 31, 2022 and March 31, 2021, respectively.

Equity Incentive Plan

Equity Incentive Plan	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Payments	11. Stock-Based Payments 2016 Stock Incentive Plan The 2016 Stock Incentive Plan (the “2016 Plan”) was adopted by the board of directors on December 15, 2015, approved by the stockholders on June 17, 2016, and became effective on July 6, 2016 upon the closing of the Company’s initial public offering (“IPO”). The 2016 Plan replaced the 2012 Equity Incentive Plan (the “2012 Plan”). Any options or awards outstanding under the 2012 Plan remained outstanding and effective. Under the 2016 Plan, the Company may grant incentive stock options, non-statutory 2016 Employee Stock Purchase Plan The 2016 Employee Stock Purchase Plan (the “2016 ESPP”) was adopted by the board of directors on December 15, 2015, approved by the stockholders on June 17, 2016, and became effective on July 6, 2016 upon the closing of the IPO. The number of shares of the Company’s common stock reserved for issuance under the 2016 ESPP automatically increases on the first day of each calendar year through the 2025 calendar year, in an amount equal to the least of (i) 1,173,333 shares of the Company’s common stock, (ii) 1.0% of the total number of shares of the Company’s common stock outstanding on the first day of the applicable year, and (iii) an amount determined by the Company’s board of directors. For the calendar year beginning January 1, 2022, the number of shares reserved for issuance under the 2016 ESPP was increased by 620,241 shares. At March 31, 2022, 2,857,306 shares remained available for future issuance under the 2016 ESPP. Inducement Grants During the year ended December 31, 2021, the Company granted non-statutory one-year 2022 Inducement Stock Incentive Plan On January 25, 2022, the Company’s board of directors adopted the 2022 Inducement Stock Incentive Plan (the “2022 Plan”), pursuant to which the Company may grant non-statutory 1,000,000 non-employment, Stock Options Terms of stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2016 Plan. Stock option awards granted by the Company generally vest over four years 25 75 three years ten years The Company has granted certain stock options to management for which vesting accelerates upon the achievement of performance-based criteria. Milestone events are specific to the Company’s corporate goals, including but not limited to certain clinical development milestones for the Company’s product candidates and the Company’s ability to execute on its corporate development and financing strategies. Stock-based compensation expense associated with these performance-based stock options is recognized based on the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. Notwithstanding any vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth anniversary of the vesting commencement date. As of December 31, 2020, all performance-based milestones related to these stock options were achieved. The Company did not record any additional stock-based compensation expense related to the achievement of performance-based milestones during the three months ended March 31, 2022 and 2021 The Company has granted options to purchase 75,000 shares of common stock to an advisor that vest solely upon the achievement of performance-based criteria. As of March 31, 2022, none of these performance-based criteria had been achieved. As of March 31, 2022, there was $0.3 million of unrecognized compensation cost related to this option, with a remaining contractual period of 4.5 years. A summary of the status of stock options as of December 31, 2021 and March 31, 2022 and changes during the three months ended March 31, 2022 is presented below: Shares Weighted Remaining Aggregate Outstanding at December 31, 2021 6,657,268 $ 8.27 7.2 $ 494 Granted 951,300 1.59 Exercised (37,700 ) 0.04 Cancelled (43,716 ) 9.93 Outstanding at March 31, 2022 7,527,152 $ 7.45 6.9 $ 26 Exercisable at March 31, 2022 4,081,501 $ 9.01 5.4 $ 26 The intrinsic value of stock options exercised during the three months ended March 31, 2022 and 2021 was $0.1 million and $0.1 million, respectively. As of March 31, 2022, there was $12.1 million of total unrecognized compensation cost related to non-vested Restricted Stock Units From time to time, upon approval by the Company’s board of directors, certain employees have been granted restricted stock units with time-based vesting criteria. The majority of these restricted stock units vest annually over a four-year term with 25% vesting on each anniversary of the grant date. Restricted stock units granted to the Company’s executive officers vest in full three-years from the date of grant. The fair value of restricted stock units is calculated based on the closing sale price of the Company’s common stock on the date of grant. A summary of the status of restricted stock units as of December 31, 2021 and March 31, 2022 and changes during the three months ended March 31, 2022 is presented below: Shares Weighted Outstanding at December 31, 2021 2,687,487 $ 6.52 Granted 2,768,128 1.58 Vested (739,561 ) 7.32 Forfeited (176,325 ) 6.76 Outstanding at March 31, 2022 4,539,729 $ 3.37 As of March 31, 2022, there was $13.9 million of unrecognized stock-based compensation expense related to outstanding restricted stock units, with an expected recognition period of 2.9 years. Stock-based Compensation Expense The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Three Months 2022 2021 Weighted-average risk-free interest rate 1.98 % 0.78 % Expected dividend yield — % — % Expected option term (in years) 6.07 6.08 Volatility 80.70 % 82.10 % The weighted-average grant date fair value per share of options granted in the three months ended March 31, 2022 and 2021 was $1.11 and $7.89, respectively. The following table summarizes the stock-based compensation expense for stock options and restricted stock units granted to employees and non-employees Three Months 2022 2021 Research and development $ 1,395 $ 1,323 General and administrative 1,468 1,607 Total stock-based compensation expense $ 2,863 $ 2,930 Due to an operating loss, the Company does not record tax benefits associated with stock-based		12. Stock-Based Payments 2016 Stock Incentive Plan The 2016 Stock Incentive Plan (the “2016 Plan”) was adopted by the board of directors on December 15, 2015, approved by the stockholders on June 17, 2016, and became effective on July 6, 2016 upon the closing of the Company’s initial public offering (“IPO”). The 2016 Plan replaced the 2012 Equity Incentive Plan (the “2012 Plan”). Any options or awards outstanding under the 2012 Plan remained outstanding and effective. Under the 2016 Plan, the Company may grant incentive stock options, non-statutory as specified by the board of directors. This number is subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. For the calendar year beginning January 1, 2021, the number of shares reserved for issuance under the 2016 Plan was increased by 1,600,000 shares. At December 31, 2021, 2,238,206 shares remained available for future issuance under the 2016 Plan. Under the 2016 Plan, stock options may not be granted at less than fair value on the date of grant. 2016 Employee Stock Purchase Plan The 2016 Employee Stock Purchase Plan (the “2016 ESPP”) was adopted by the board of directors on December 15, 2015, approved by the stockholders on June 17, 2016, and became effective on July 6, 2016 upon the closing of the IPO. The number of shares of the Company’s common stock reserved for issuance under the 2016 ESPP automatically increases on the first day of each calendar year through the 2025 calendar year, in an amount equal to the least of (i) 1,173,333 shares of the Company’s common stock, (ii) 1.0% of the total number of shares of the Company’s common stock outstanding on the first day of the applicable year, and (iii) an amount determined by the Company’s board of directors. For the calendar year beginning January 1, 2021, the number of shares reserved for issuance under the 2016 ESPP was increased by 562,227 shares. At December 31, 2021, 2,237,065 shares remained available for future issuance under the 2016 ESPP. Inducement Grants During the year ended December 31, 2021, the Company granted non-statutory one-year Stock Options Terms of stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2016 Plan. Stock option awards granted by the Company generally vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and 75% vesting ratably, on a monthly basis, over the remaining three years. Such awards have a contractual term of ten years from the grant date. The Company has granted stock options to management for which vesting accelerates upon the achievement of performance-based criteria. Milestone events are specific to the Company’s corporate goals, including but not limited to certain clinical development milestones and the Company’s ability to execute on its corporate development and financing strategies. Stock-based compensation expense associated with these performance-based stock options is recognized based on the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. Notwithstanding any vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth anniversary of the vesting commencement date. During each of the years ended December 31, 2020 and 2019, the Company recorded additional stock-based compensation expense of $0.4 million related to the acceleration of vesting of certain stock options associated with the initiation of the Phase 3 clinical trial of tamibarotene at the end of 2020 and the entry into the GBT Collaboration Agreement in December 2019, respectively. As of December 31, 2020, there was no unrecognized expense related to the performance-based stock options granted to management. The Company did not grant any performance-based stock option to management during the year ended December 31, 2021. The Company has granted options to purchase 75,000 shares of common stock to an advisor that vest solely upon the achievement of performance-based criteria. As of December 31, 2021, none of these performance-based criteria had been achieved. As of December 31, 2021, there was $0.3 million of unrecognized compensation cost related to this option, with a remaining contractual period of 4.7 years. A summary of the status of stock options as of December 31, 2021 and December 31, 2020 and changes during the year ended December 31, 2021 is presented below: Shares Weighted Remaining Aggregate Outstanding at December 31, 2020 5,468,605 $ 8.90 7.2 $ 13,124 Granted 2,417,600 7.69 Exercised (20,134 ) 7.77 Cancelled (1,208,803 ) 10.00 Outstanding at December 31, 2021 6,657,268 $ 8.27 7.2 $ 494 Exercisable at December 31, 2021 3,736,652 $ 8.86 5.8 $ 494 The intrinsic value of stock options exercised during the years ended December 31, 2021, 2020 and 2019 was $0.1 million, $0.8 million and $0.2 million, respectively. As of December 31, 2021, there was $12.8 million of total unrecognized compensation cost related to non-vested Cash received from option exercises during the years ended December 31, 2021, 2020, and 2019 was $0.2 million, $1.1 million, and $0.2 million, respectively. Restricted Stock Units From time to time, upon approval by the Company’s board of directors, certain employees have been granted restricted stock units with time-based vesting criteria. The majority of these restricted stock units vest annually over a four-year term with 25% vesting on each anniversary of the grant date. Restricted stock units granted to the Company’s executive officers vest in full three-years from the date of grant. The fair value of restricted stock units is calculated based on the closing sale price of the Company’s common stock on the date of grant. A summary of the status of restricted stock units as of December 31, 2020 and December 31, 2021 and changes during the year ended December 31, 2021 is presented below: Shares Weighted Outstanding at December 31, 2020 1,734,383 $ 7.40 Granted 1,747,554 6.31 Vested (286,837 ) 7.70 Forfeited (507,613 ) 8.15 Outstanding at December 31, 2021 2,687,487 $ 6.52 As of December 31, 2021, there was $12.0 million of unrecognized stock-based compensation expense related to outstanding restricted stock units, with an expected recognition period of 2.07 years. Stock-based Compensation Expense The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Year Ended December 31, 2021 2020 2019 Weighted-average risk-free interest rate 0.99 % 1.28 % 2.42 % Expected dividend yield — % — % — % Expected option term (in years) 6.03 5.99 6.00 Volatility 81.56 % 78.27 % 91.35 % The weighted-average grant date fair value per share of options granted in the years ended December 31, 2021, 2020 and 2019 was $5.33, $5.30 and $5.05, respectively. The following table summarizes the stock-based compensation expense for stock options, restricted stock units and restricted common stock granted to employees and non-employees Year Ended December 31, 2021 2020 2019 Research and development $ 5,706 $ 4,732 $ 3,472 General and administrative 4,648 6,207 6,367 Total stock-based compensation expense $ 10,354 $ 10,939 $ 9,839 Due to an operating loss, the Company does not record tax benefits associated with stock-based
Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Payments		Note 12. Equity Incentive Plan. On March 5, 2015, the Company’s Board adopted and the Company’s stockholders approved, the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). Awards under the 2015 Plan may include, but need not be limited to, one or more of the following: options, stock appreciation rights, restricted stock, performance grants, stock bonuses, and any other type of award deemed by the administrator to be consistent with the purposes of the 2015 Plan. The exercise price of all options awarded under the 2015 Plan must be no less than 100% of the fair market value of the Company common stock as determined on the date of the grant and have a term of no greater than ten years from the date of grant. In February 2018, the 2015 Plan was amended making available 12.5% of shares of common stock issued and outstanding. As of March 31, 2022, there were 7,223,029 shares available for grant under the 2015 Plan. On August 24, 2021 the stockholders approved the Amended and Restated 2016 Option Plan for Non-Employee one-year Stock Options As of March 31, 2022, and 2021, there was approximately $4.5 million and $3.6 million, respectively, of total unrecognized compensation related to non-vested The Company uses the Black-Scholes option pricing model to determine the fair value of stock options granted. For employees and non-employees, The expected volatility of options granted has been determined using the method described under ASC 718 using a blend of the Company’s expected volatility and those of similar companies. The expected term of options granted to employees, non-employees 2018-7. The assumptions utilized to estimate the fair value of stock options granted are presented in the following table: Year Ended March 31, 2022 2021 Risk free interest rate 0.280% - 2.34% 0.174% - 0.527% Expected volatility 95.39% - 105.37% 88.02% - 101.67% Expected term 2.7 - 6.1 years 2.8 - 6.1 Dividend yield 0.0% 0.0% The following is a summary of the activity of the Company’s stock options under the 2015 Plan and 2016 Director Plan as of March 31, 2022: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2021 12,588,068 $ 2.92 Granted 3,862,388 1.30 Exercised (6,250 ) 0.99 Cancelled/Forfeited (1,939,935 ) 3.83 Outstanding at March 31, 2022 14,504,271 2.36 Options exercisable at March 31, 2022 9,329,798 $ 2.99 Weighted-average grant date fair value of options granted during the years ended March 31, 2022 and 2021 was $1.00 and $0.89, respectively. During the year ended March 31, 2022, holders of options issued under the equity incentive plans exercised their right to acquire an aggregate of 6,250 shares of common stock at a weighted average exercise price of $0.99 resulting in $6,000 total proceeds to the Company. During the year ended March 31, 2021, holders of options issued under the equity incentive plans exercised their rights to acquire an aggregate of 2,028,203 shares of common stock at a weighted average exercise price of $2.64 resulting in $5.4 million total proceeds to the Company. Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at March 31, 2022 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at March 31, 2022 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $0.29 - $8.75 14,504,271 $ 2.36 7 $ 4,610 9,329,798 $ 2.99 6 $ — The intrinsic value calculated as the excess of the market value as of March 31, 2022 over the exercise price of the options is $4,610. The market value as of March 31, 2022 was $0.35 as reported by the NASDAQ Capital Market. The total intrinsic value of options exercised during the year ended March 31, 2022 was $3,500. Options Weighted Average Non-vested 4,355,171 $ 0.91 Granted 3,862,388 1.00 Vested (446,522 ) 0.95 Cancelled/Forfeited (2,596,564 ) 0.99 Non-vested 5,174,473 $ 0.93 The fair value of options vested during the years ended March 31, 2022 and 2021 was $2.6 million and $3.7 million, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events On January 25, 2022, the Board of Directors adopted a 2022 Inducement Stock Incentive Plan (the “2022 Plan”), pursuant to which the Company may grant non-statutory non-employment, On March 7, 2022, the Company entered into a Master Collaboration Agreement and a project schedule (collectively, the “Agreement”), with Qiagen Manchester Limited (“Qiagen”). Pursuant to the Agreement, Qiagen has agreed to develop and commercialize an assay as a companion diagnostic test to determine the expression level of the Company’s proprietary RARA biomarker for use with tamibarotene, a selective retinoic acid receptor alpha, or RARα, agonist, in newly diagnosed higher-risk MDS patients. Subject to the terms of the Agreement and upon achievement of specified technical and development milestones, the Company is obligated to pay Qiagen an amount up to a high single-digit million-dollar payment over the term of the initial project schedule. In addition, the Company will reimburse Qiagen for certain pass-through costs. Qiagen will retain all proceeds from the commercialization of the companion diagnostic test. Syros has no financial obligations to Qiagen under the Agreement on the commercialization of tamibarotene. The initial term of the Agreement expires on the later to occur of (i) the fifth anniversary of the Agreement and (ii) the expiration or termination of all project schedules executed under the Agreement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Summary Of Significant Accounting Policies [Line Items]
Basis of Presentation	Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of March 31, 2022, the results of its operations, statements of cash flows and statements of stockholders’ equity for the three months ended March 31, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three months ended March 31, 2022 are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period.		Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of Syros Pharmaceuticals, Inc. and its wholly owned subsidiaries, Syros Securities Corporation, a Massachusetts corporation formed by the Company in December 2014 to exclusively engage in buying, selling and holding securities on its own behalf, and Syros Pharmaceuticals (Ireland) Limited, an Irish limited liability company formed by the Company in January 2019. All intercompany transactions and balances have been eliminated in consolidation.		Principles of Consolidation The accompanying consolidated financial statements include the accounts of Syros Pharmaceuticals, Inc. and its wholly owned subsidiaries, Syros Securities Corporation, a Massachusetts corporation formed by the Company in December 2014 to exclusively engage in buying, selling and holding securities on its own behalf, and Syros Pharmaceuticals (Ireland) Limited, an Irish limited liability company formed by the Company in January 2019. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, which include, but are not limited to, expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. Management’s estimation process may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, warrant liability, stock-based compensation expense, accrued expenses, income taxes and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results may differ from those estimates or assumptions.		Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, which include, but are not limited to, expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, warrant liability, stock-based compensation expense, accrued expenses, income taxes and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results may differ from those estimates or assumptions.
Segment Information	Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is its chief executive officer. The Company and the chief operating decision maker view the Company’s operations and manage its business in one operating segment. The Company operates only in the United States.		Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business in one operating segment. The Company operates only in the United States.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents, which consist of money market funds that invest in U.S. Treasury obligations, as well as overnight repurchase agreements and corporate debt securities, are stated at fair value. The Company maintains its bank accounts at one major financial institution.		Cash and Cash Equivalents The Company considers all highly liquid instruments that have original maturities of three months or less when acquired to be cash equivalents. Cash equivalents, which consist of money market funds that invest in U.S.
Off-Balance Sheet Risk and Concentrations of Credit Risk	Off-Balance The Company has no financial instruments with off-balance		Off-Balance The Company has no financial instruments with off-balance
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 820, Fair Value Measurement ASC 820 identified fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 established a three-tier fair value hierarchy that distinguishes between the following: Level 1—Quoted market prices (unadjusted) in active markets for identical assets or liabilities. Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3—Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying amounts reflected in the condensed consolidated balance sheets for cash and cash equivalents, prepaid expenses, other current assets, restricted cash, accounts payable, accrued expenses and deferred revenue approximate their respective fair values due to their short-term nature.		Fair Value of Financial Instruments ASC 820, Fair Value Measurement ASC 820 identified fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 established a three-tier Level 1—Quoted market prices (unadjusted) in active markets for identical assets or liabilities. Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3—Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, prepaid expenses, other current assets, restricted cash, accounts payable, accrued expenses, deferred revenue, and financing and operating lease liabilities approximate their respective fair values due to their short-term nature.
Property and Equipment	Property and Equipment Property and equipment consists of laboratory equipment, computer equipment, furniture and fixtures and leasehold improvements, all of which are stated at cost, less accumulated depreciation. Expenditures for maintenance and repairs that do not improve or extend the lives of the respective assets are recorded to expense as incurred. Major betterments are capitalized as additions to property and equipment. Depreciation and amortization are recognized over the estimated useful lives of the assets using the straight-line method. Construction-in-progress construction-in-progress		Property and Equipment Property and equipment consists of laboratory equipment, computer equipment, furniture and fixtures and leasehold improvements, all of which are stated at cost, less accumulated depreciation. Expenditures for maintenance and repairs that do not improve or extend the lives of the respective assets are recorded to expense as incurred. Major betterments are capitalized as additions to property and equipment. Depreciation and amortization are recognized over the estimated useful lives of the assets using the straight-line method. Construction-in-progress construction-in-progress
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses from inception through March 31, 2022.		Impairment of Long-Lived Assets The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book values of the assets exceed their fair value. The Company has not recognized any impairment losses from inception through December 31, 2021.
Other Long-Term Assets	Other Long-Term Assets Other long-term assets primarily consisted of advance payments made to the contract research organizations responsible for conducting the Company’s tamibarotene and SY-5609		Other Long-Term Assets As of December 31, 2021 and 2020, other long-term assets primarily consisted of advance payments made to the contract research organizations responsible for conducting the Company’s tamibarotene and SY-5609
Revenue Recognition	Revenue Recognition To date the Company’s only revenue has consisted of collaboration and license revenue. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers reflects the consideration the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. If the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, the Company records a contract asset, excluding any amounts presented as accounts receivable. The Company includes unbilled accounts receivable as contract assets on its consolidated balance sheets. The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses contract assets and accounts receivable for impairment and, to date, no impairment losses have been recorded. From time to time, the Company may enter into agreements that are within the scope of ASC 606. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements		Revenue Recognition To date the Company’s only revenue has consisted of collaboration and license revenue. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future. For the year ended December 31, 2021, the Company recognized approximately $23.5 million of revenue, $19.4 million of which was related to the Company’s collaboration with Global Blood Therapeutics, Inc. (“GBT”), and $4.1 million of which was related to the Company’s target discovery collaboration with Incyte Corporation (“Incyte”). For the year ended December 31, 2020 the Company recognized $15.1 million of revenue, $11.7 million of which was related to the Company’s collaboration with GBT, and $3.4 million of which was related to the Company’s target discovery collaboration with Incyte. For the year ended December 31, 2019, the Company recognized $2.0 million of revenue, all of which was attributable to the target discovery collaboration with Incyte. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. If a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within such contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. If the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, the Company records a contract asset, excluding any amounts presented as accounts receivable. The Company includes contract assets as unbilled accounts receivable on its consolidated balance sheets. The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses contract assets and accounts receivable for impairment and, to date, no impairment losses have been recorded. From time to time, the Company may enter into agreements that are within the scope of ASC 606. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements
Research and Development	Research and Development Expenditures relating to research and development are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with the development of the Company’s gene control platform and product candidates. Research and development costs include salaries and benefits, materials and supplies, external research, preclinical and clinical development expenses, stock-based compensation expense and facilities costs. Facilities costs primarily include the allocation of rent, utilities, depreciation and amortization. In certain circumstances, the Company is required to make non-refundable non-refundable The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the work being performed, including the phase or completion of the event, invoices received and costs. Significant judgements and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company may in-license in-license up-front		Research and Development Expenditures relating to research and development are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with the development of the Company’s gene control platform and product candidates. Research and development costs include salaries and benefits, materials and supplies, external research, preclinical and clinical development expenses, stock-based compensation expense and facilities costs. Facilities costs primarily include the allocation of rent, utilities, depreciation and amortization. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, even when there is no alternative future use for the research and development, until related goods or services are provided. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the work being performed, including the phase or completion of the event, invoices received and costs. Significant judgements and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company may in-license in-license up-front
Warrants	Warrants The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock 815-40”). 480-10, 480-10, 815-40 ASC 815-40, 815-40, 815-40		Warrants The Company accounts for issued warrants as either liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity 480-10”) 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock 815-40”). 480-10, 480-10, 815-40 815-40, 815-40, 815-40
Stock-Based Compensation Expense	Stock-Based Compensation Expense The Company accounts for its stock-based compensation awards in accordance with ASC 718, Compensation—Stock Compensation non-employees, options. The expected term of stock options to non-employees The Company expenses the fair value of its stock-based awards to employees and non-employees Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period. For stock-based awards that contain performance-based milestones, the Company records stock-based compensation expense in accordance with the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date.		Stock-Based Compensation Expense The Company accounts for its stock-based compensation awards in accordance with ASC 718, Compensation—Stock Compensation non-employees, non-employees non-employees non-employees The Company expenses the fair value of its stock-based awards to employees and non-employees Compensation expense for discounted purchases under the employee stock purchase plan is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the offering period. For stock-based awards that contain performance-based milestones, the Company records stock-based compensation expense in accordance with the accelerated attribution model. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. For certain of the performance-based awards, notwithstanding any vesting in accordance with the achievement of performance-based milestones, such awards vest in full on the sixth anniversary of the vesting commencement date. Compensation expense for such awards is recognized over the six-year
Income Taxes	Income Taxes The Company accounts for uncertain tax positions using a more-likely-than-not		Income Taxes The Company accounts for uncertain tax positions using a more-likely-than-not
Net Loss per Share	Net Loss per Share Basic net earnings per share applicable to common stockholders is calculated by dividing net earnings applicable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net earnings per share applicable to common stockholders is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method and the if-converted As of March 31, 2022, 1,000,000 Pre-Funded The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2022 2021 Stock options 7,527,152 6,504,401 Unvested restricted stock units 4,539,729 2,070,150 Warrants* 4,990,156 4,990,156 Total 17,057,037 13,564,707 * As of March 31, 2022 and 2021, this is comprised of 2,117,094 warrants to purchase common stock issued in connection with the Company’s April 2019 financing (refer to Note 10), 27,548 warrants to purchase common stock issued in connection with the execution of the Company’s loan agreement in February 2020 (refer to Note 7), 17,389 warrants to purchase common stock issued in connection with the second draw on this loan agreement in December 2020 (refer to Note 7), and 2,828,125 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 10).		Net Loss per Share Basic net earnings per share applicable to common stockholders is calculated by dividing net earnings applicable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net earnings per share applicable to common stockholders is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method and the if-converted As of December 31, 2021 and 2020, 1,000,000 Pre-Funded The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of December 31, 2021 2020 2019 Stock options 6,657,268 5,468,605 4,618,421 Unvested restricted stock units 2,687,487 1,734,383 1,116,358 Warrants* 4,990,156 4,990,156 2,118,094 Total 14,334,911 12,193,144 7,852,873 * As of December 31, 2021 and 2020, this is comprised of 2,117,094 2019 Warrants to purchase common stock issued in connection with the Company’s April 2019 financing (refer to Note 11), 27,548 warrants to purchase common stock issued in connection with the execution and first draw of the Loan Agreement in February 2020 (refer to Note 7), 17,389 warrants to purchase common stock issued in connection with the second draw on the Loan Agreement in December 2020 (refer to Note 7), and 2,828,125 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 11). As of December 31, 2019, this was comprised solely of 2,118,094 2019 Warrants to purchase common stock issued in connection with the Company’s April 2019 financing. The weighted average number of common shares used in net loss per share applicable to common stockholders on a basic and diluted basis were 62,534,978, 46,051,617 and 40,222,182 shares for the years ended December 31, 2021, 2020 and 2019, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016-13”), 2016-13 available-for-sale 2016-13 Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): 2020-06”). 2020-06		Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) 815-40): Instruments and Contracts in an Entity’s Own Equity 2020-06”). 2020-06 In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016-13”), 2016-13 available-for-sale 2016-13 early adoption is permitted. The Company is currently evaluating this new standard and does not anticipate that it will have a material impact on its consolidated financial statements and related disclosures. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) 2019-12”), 2019-12
Tyme Technologies, Inc. and Subsidiaries [Member]
Summary Of Significant Accounting Policies [Line Items]
Basis of Presentation		Basis of Presentation The accompanying financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and ASU of the FASB.
Principles of Consolidation		Principles of Consolidation The Company’s consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiary, Tyme, Inc. All intercompany transactions and balances have been eliminated in consolidation.
Reclassifications		Reclassifications Certain prior year amounts, primarily severance expense which was broken out to a separate line item on the Consolidated Statements of Operations and Comprehensive Loss, have been reclassified to conform to the current year presentation. These reclassifications have no effect on the previously reported net loss or cash flows.
Risks and Uncertainties		Risks and Uncertainties The Company is subject to those risks associated with any biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Current Economic Conditions The novel COVID-19 day-to-day COVID-19 COVID-19
Use of Estimates		Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant items subject to such estimation include the calculation of the stock-based compensation and warrant valuation. Actual results could differ from such estimates.
Segment Information		Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. Cash equivalents are stated at fair value. The Company’s cash and cash equivalents consisted of $13.7 million at March 31, 2022 and $107.5 million at March 31, 2021.
Fair Value of Financial Instruments		Fair Value of Financial Instruments The Company records certain financial assets and liabilities at fair value in accordance with the provisions of ASC Topic 820, Fair Value Measurements and Disclosures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value should be based on the assumptions that market participants would use when pricing an asset or liability and is based on a fair value hierarchy that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to the Company’s assumptions (unobservable inputs). Fair value measurements should be disclosed separately by level within the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with established fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. Additionally, from time to time, the Company may be required to record at fair value other assets on a nonrecurring basis, such as assets held for sale and certain other assets. These nonrecurring fair value adjustments typically involve application of lower-of-cost-or-market Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The carrying amounts of the Company’s financial instruments, including cash, accounts payable and other current liabilities approximates fair value given their short-term nature. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. Cash equivalents, marketable securities and the derivative warrant liability are recorded at fair value. See Note 7.
Prepaid Expenses and Other Current Assets		Prepaid Expenses and Other Current Assets Prepaid expenses represent expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time. As of March 31, 2022, prepaid expenses and other current assets includes $1.1 million of prepaid insurance, $0.6 million accrued interest receivable on marketable securities and a $2.1 million deposit with our payroll vendor to satisfy the Chief Science Officer severance payment. As of March 31, 2021, prepaid expenses and other current assets includes $1.0 million of prepaid insurance.
Property and Equipment		Property and Equipment, Net Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives. The Company estimates a life of three years for equipment and furniture and fixtures. Upon sale or
Impairment of Long-Lived Assets		Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets, which include fixed assets and operating lease right of use assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended March 31, 2022 and 2021, the Company determined that there were no triggering events requiring an impairment analysis.
Research and Development		Research and Development Research and development costs are expensed as incurred and are primarily comprised of, but not limited to, external research and development expenses incurred under arrangements with third parties, such as CROs, CMOs and consultants that conduct clinical and preclinical studies, costs associated with preclinical and development activities, costs associated with regulatory operations, depreciation expense for assets used in research and development activities and employee related expenses, including salaries and benefits for research and development personnel. Costs for certain development activities, such as clinical studies, are accrued, over the service period specified in the contract and recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense.
Income Taxes		Income Taxes Income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management’s best estimate of current and future taxes to be paid. The Company is subject to income taxes in the United States, for federal and various state jurisdictions. Significant judgments and estimates are required in the determination of the income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when, after consideration of available positive and negative evidence that it is not more likely than not that the benefit from deferred tax assets will be realizable. In recognition of this risk, we have provided a full valuation allowance against the net deferred tax assets. The assumptions about future taxable income require the use of significant judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various jurisdictions. ASC 740 “Income Taxes” states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. When and if the Company were to recognize interest and penalties related to unrecognized tax benefits, they would be reported in tax expense.
Net Loss per Share		Basic and Diluted Loss Per Share The Company calculates net loss per share in accordance with Earning per Share (Topic 260)
Recent Accounting Pronouncements		Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”), Income Taxes 2019-12 In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016-13”) available-for-sale In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) ’ s Own Equity (Subtopic 815-40) No. 2020-06 No. 2020-06
Concentration of Credit Risk		Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and marketable securities. Cash is deposited with major banks and, at times, such balances with any one financial institution may be in excess of FDIC insurance limits. The Company exceeded the FDIC limit of $250,000 by $10.1 million at March 31, 2022 and $107.3 million at March 31, 2021. Although the Company has exceeded the federally insured limit, it has not incurred losses related to these deposits. Management monitors the Company’s accounts with these institutions to minimize credit risk.
Marketable Securities		Marketable Securities In the first quarter of fiscal year 2022, the Company established an investment policy and invested in a portfolio of highly liquid investments and marketable securities. The primary objectives of the Company’s policy are to preserve capital and diversify risk, while maintaining sufficient liquidity to meet cash flow requirements. All of the Company’s marketable securities are debt securities and are classified as available-for-sale available-for-sale For individual debt securities classified as available-for-sale
Derivative Warrant Liability		Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise and certain price protection provisions. Warrants of this type are subject to re-measurement As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features or requires issuance of registered common shares upon exercise which cause the warrants to be treated as derivatives. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model or the Black-Sholes model and is subsequently re-measured
Stock-based Compensation		Stock-based Compensation The Company follows the authoritative guidance for accounting for stock-based compensation in ASC 718, Compensation-Stock Compensation. The guidance requires that stock-based payment transactions be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over the vesting period as services are being provided. (See Note 12, Equity Incentive Plan.) The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend yield of the common stock. For awards subject to time-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. The Company accounts for forfeitures as they occur. The Company adopted ASU 2018-07 non-employees

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share	The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2022 2021 Stock options 7,527,152 6,504,401 Unvested restricted stock units 4,539,729 2,070,150 Warrants* 4,990,156 4,990,156 Total 17,057,037 13,564,707 * As of March 31, 2022 and 2021, this is comprised of 2,117,094 warrants to purchase common stock issued in connection with the Company’s April 2019 financing (refer to Note 10), 27,548 warrants to purchase common stock issued in connection with the execution of the Company’s loan agreement in February 2020 (refer to Note 7), 17,389 warrants to purchase common stock issued in connection with the second draw on this loan agreement in December 2020 (refer to Note 7), and 2,828,125 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 10).	The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of December 31, 2021 2020 2019 Stock options 6,657,268 5,468,605 4,618,421 Unvested restricted stock units 2,687,487 1,734,383 1,116,358 Warrants* 4,990,156 4,990,156 2,118,094 Total 14,334,911 12,193,144 7,852,873 * As of December 31, 2021 and 2020, this is comprised of 2,117,094 2019 Warrants to purchase common stock issued in connection with the Company’s April 2019 financing (refer to Note 11), 27,548 warrants to purchase common stock issued in connection with the execution and first draw of the Loan Agreement in February 2020 (refer to Note 7), 17,389 warrants to purchase common stock issued in connection with the second draw on the Loan Agreement in December 2020 (refer to Note 7), and 2,828,125 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 11). As of December 31, 2019, this was comprised solely of 2,118,094 2019 Warrants to purchase common stock issued in connection with the Company’s April 2019 financing.

Collaboration and Research Ar_2

Collaboration and Research Arrangements (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Collaborative Arrangement Disclosure [Abstract]
Summary of Changes in Contract Assets and Liabilities	The following table presents the changes in accounts receivable, contract assets and liabilities for the three months ended March 31, 2022 (in thousands): Balance at December 31, Additions Deductions Balance at Accounts receivable and contract assets: Billed receivables from collaboration partners $ — $ 2,857 $ (2,857 ) $ — Unbilled receivables from collaboration partners 2,979 3,181 (2,978 ) 3,182 Total accounts receivable and contract assets $ 2,979 $ 6,038 $ (5,835 ) $ 3,182 Contract liabilities: Deferred revenue—Incyte $ 1,268 $ — $ (421 ) $ 847 Deferred revenue—GBT 8,913 — (1,987 ) 6,926 Total contract liabilities $ 10,181 $ — $ (2,408 ) $ 7,773	The following table presents the changes in contract assets and liabilities for the year ended December 31, 2021 (in thousands): Balance at December 31, 2020 Additions Deductions Balance at 2021 Accounts receivable and contract assets: Billed receivables from collaboration partners $ 7 $ 10,931 $ (10,938 ) $ — Unbilled receivables from collaboration partners 2,324 11,410 (10,755 ) 2,979 Total accounts receivable and contract assets $ 2,331 $ 22,341 $ (21,693 ) $ 2,979 Contract liabilities: Deferred revenue – Incyte $ 5,365 $ — $ (4,097 ) $ 1,268 Deferred revenue – GBT 16,721 174 (7,982 ) 8,913 Total contract liabilities $ 22,086 $ 174 $ (12,079 ) $ 10,181

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Schedule of Anti-dilutive Shares Outstanding	The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2022 2021 Stock options 7,527,152 6,504,401 Unvested restricted stock units 4,539,729 2,070,150 Warrants* 4,990,156 4,990,156 Total 17,057,037 13,564,707 * As of March 31, 2022 and 2021, this is comprised of 2,117,094 warrants to purchase common stock issued in connection with the Company’s April 2019 financing (refer to Note 10), 27,548 warrants to purchase common stock issued in connection with the execution of the Company’s loan agreement in February 2020 (refer to Note 7), 17,389 warrants to purchase common stock issued in connection with the second draw on this loan agreement in December 2020 (refer to Note 7), and 2,828,125 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 10).		The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of December 31, 2021 2020 2019 Stock options 6,657,268 5,468,605 4,618,421 Unvested restricted stock units 2,687,487 1,734,383 1,116,358 Warrants* 4,990,156 4,990,156 2,118,094 Total 14,334,911 12,193,144 7,852,873 * As of December 31, 2021 and 2020, this is comprised of 2,117,094 2019 Warrants to purchase common stock issued in connection with the Company’s April 2019 financing (refer to Note 11), 27,548 warrants to purchase common stock issued in connection with the execution and first draw of the Loan Agreement in February 2020 (refer to Note 7), 17,389 warrants to purchase common stock issued in connection with the second draw on the Loan Agreement in December 2020 (refer to Note 7), and 2,828,125 warrants to purchase common stock issued in connection with the private placement in December 2020 (refer to Note 11). As of December 31, 2019, this was comprised solely of 2,118,094 2019 Warrants to purchase common stock issued in connection with the Company’s April 2019 financing.
Tyme Technologies, Inc. and Subsidiaries [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Schedule of Basic and Diluted Net Loss Per Share		The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Year Ended March 31, 2022 2021 Basic and diluted net loss per common share calculation Net loss $ (23,626,047 ) $ (28,978,763 ) Weighted average common shares outstanding — basic and diluted 172,206,534 134,250,722 Net loss per share of common stock — basic and diluted $ (0.14 ) $ (0.22 )
Schedule of Anti-dilutive Shares Outstanding		The following outstanding securities at March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive: Year Ended March 31, 2022 2021 Stock options 14,504,271 12,588,068 Warrants 3,104,318 3,104,318 Total 17,608,589 15,692,386

Cash, Cash Equivalents and Ma_2

Cash, Cash Equivalents and Marketable Securities (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of Cash, Cash Equivalents and Marketable Securities, Available-for-Sale	Cash, cash equivalents and marketable securities consisted of the following at March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 69,575 $ — $ — $ 69,575 Marketable securities: Corporate debt securities—due in one year or less 28,915 — (111 ) 28,804 US Treasury obligation—due in one year or less 12,000 — (118 ) 11,882 Corporate debt securities—due in more than one year to five years 2,682 — (44 ) 2,638 Total $ 113,172 $ — $ (273 ) $ 112,899 December 31, 2021 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 92,302 $ — $ — $ 92,302 Marketable securities: Corporate debt securities—due in one year or less 30,100 — (12 ) 30,088 US Treasury obligation—due in one year or less 8,000 — (21 ) 7,979 Corporate debt securities—due in more than one year to five years 9,085 — (33 ) 9,052 US Treasury obligation—due in more than one year to five years 3,999 — (13 ) 3,986 Total $ 143,486 $ — $ (79 ) $ 143,407	Cash, cash equivalents and marketable securities, available-for-sale, December 31, 2021 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 92,302 $ — $ — $ 92,302 Marketable securities: Corporate debt securities – due in one year or less 30,100 — (12 ) 30,088 US Treasury obligation – due in one year or less 8,000 — (21 ) 7,979 Corporate debt securities – due in more than one year to five years 9,085 — (33 ) 9,052 US Treasury obligation – due in more than one year to five years 3,999 — (13 ) 3,986 Total $ 143,486 $ — $ (79 ) $ 143,407 December 31, 2020 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 173,984 $ — $ — $ 173,984 Total $ 173,984 $ — $ — $ 173,984

Available-for-Sale-Securities (

Available-for-Sale-Securities (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Schedule of Available-for-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities	Cash, cash equivalents and marketable securities consisted of the following at March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 69,575 $ — $ — $ 69,575 Marketable securities: Corporate debt securities—due in one year or less 28,915 — (111 ) 28,804 US Treasury obligation—due in one year or less 12,000 — (118 ) 11,882 Corporate debt securities—due in more than one year to five years 2,682 — (44 ) 2,638 Total $ 113,172 $ — $ (273 ) $ 112,899 December 31, 2021 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 92,302 $ — $ — $ 92,302 Marketable securities: Corporate debt securities—due in one year or less 30,100 — (12 ) 30,088 US Treasury obligation—due in one year or less 8,000 — (21 ) 7,979 Corporate debt securities—due in more than one year to five years 9,085 — (33 ) 9,052 US Treasury obligation—due in more than one year to five years 3,999 — (13 ) 3,986 Total $ 143,486 $ — $ (79 ) $ 143,407		Cash, cash equivalents and marketable securities, available-for-sale, December 31, 2021 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 92,302 $ — $ — $ 92,302 Marketable securities: Corporate debt securities – due in one year or less 30,100 — (12 ) 30,088 US Treasury obligation – due in one year or less 8,000 — (21 ) 7,979 Corporate debt securities – due in more than one year to five years 9,085 — (33 ) 9,052 US Treasury obligation – due in more than one year to five years 3,999 — (13 ) 3,986 Total $ 143,486 $ — $ (79 ) $ 143,407 December 31, 2020 Amortized Cost Unrealized Unrealized Fair Value Cash and cash equivalents: Cash and money market funds $ 173,984 $ — $ — $ 173,984 Total $ 173,984 $ — $ — $ 173,984
Tyme Technologies, Inc. and Subsidiaries [Member]
Marketable Securities [Line Items]
Schedule of Available-for-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities		The following table summarizes available-for-sale March 31, 2022 Amortized Gross Gross Fair Value Money market funds $ 3,409,178 $ — $ — $ 3,409,178 Corporate debt securities 32,831,174 — (343,134 ) 32,488,040 Municipal debt securities 37,405,722 — (201,130 ) 37,204,592 Total $ 73,646,074 $ $ (544,264 ) $ 73,101,810
Schedule of Classification of Available-for-Sale Securities		The following table summarizes the classification of available-for-sale March 31, March 31, Cash and cash equivalents $ 3,409,178 $ — Marketable securities 69,692,632 — Total $ 73,101,810 $ —
Schedule of Available-for-Sale Securities by Contractual Maturities		The following table summarizes our portfolio of available-for-sale Less than 12 months 12 months or Longer Total Fair Value Net Fair Value Net Fair Value Net Money market funds $ 3,409,178 $ — $ — $ — $ 3,409,178 $ — Corporate debt securities 26,195,025 (227,300 ) 6,293,015 (115,834 ) 32,488,040 (343,134 ) Municipal debt securities 34,416,936 (153,855 ) 2,787,656 (47,275 ) 37,204,592 (201,130 ) Total $ 64,021,139 $ (381,155 ) $ 9,080,671 $ (163,109 ) $ 73,101,810 $ (544,264 )

Accounts Payable and Other Cu_2

Accounts Payable and Other Current Liabilities (Tables)	12 Months Ended
	Mar. 31, 2022
Tyme Technologies, Inc. and Subsidiaries [Member]
Payables and Accruals [Line Items]
Schedule of Accounts Payable and Other Current Liabilities	Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following: March 31, March 31, Legal $ 263,111 $ 454,139 Consultant and professional services 300,051 176,957 Accounting and auditing 14,410 55,349 Research and development 2,776,594 2,657,202 Board of Directors and Scientific Advisory Board Compensation 418,389 435,594 Other 30,872 63,149 $ 3,803,427 $ 3,842,390

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Fair value Disclosure [Line Items]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 were as follows (in thousands): Description March 31, 2022 Active Observable Unobservable Assets: Cash $ 59,769 $ 59,769 — $ — Money market funds 9,806 9,806 — — Corporate debt securities—due in one year or less 28,804 — 28,804 — US Treasury obligation—due in one year or less 11,882 11,882 — — Corporate debt securities—due in more than one year to five years 2,638 — 2,638 — Total $ 112,899 $ 81,457 $ 31,442 $ — Liabilities: Warrant liability $ 581 $ — $ — $ 581 Total $ 581 $ — $ — $ 581 Description December 31, 2021 Active Observable Unobservable Assets: Cash $ 57,213 $ 57,213 $ — $ — Money market funds 35,089 35,089 — — Corporate debt securities—due in one year or less 30,088 — 30,088 — US Treasury obligation—due in one year or less 7,979 7,979 — — US Treasury obligation—due in more than one year to five years 3,986 3,986 — — Corporate debt securities—due in more than one year to five years 9,052 — 9,052 — Total $ 143,407 $ 104,267 $ 39,140 $ — Liabilities: Warrant liability $ 3,029 $ — $ — $ 3,029 Total $ 3,029 $ — $ — $ 3,029		Assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020 were as follows (in thousands): Description December 31, 2021 Active Observable Unobservable Assets: Cash $ 57,213 $ 57,213 $ — $ — Money market funds 35,089 35,089 — — Corporate debt securities – due in one year or less 30,088 — 30,088 — US Treasury obligation – due in one year or less 7,979 7,979 — — US Treasury obligation – due in more than one year to five years 3,986 3,986 — — Corporate debt securities – due in more than one year to five years 9,052 — 9,052 — Total $ 143,407 $ 104,267 $ 39,140 $ — Liabilities: Warrant liability $ 3,029 $ — $ — $ 3,029 Total $ 3,029 $ — $ — $ 3,029 Description December 31, 2020 Active Observable Unobservable Assets: Cash $ 47,579 $ 47,579 $ — $ — Money market funds 126,405 126,405 — — Total $ 173,984 $ 173,984 $ — $ — Liabilities: Warrant liability $ 19,711 $ — $ — $ 19,711 Total $ 19,711 $ — $ — $ 19,711
Summary of Assumptions Used to Record Fair Value of Warrants	A summary of the Black Scholes pricing model assumptions used to record the fair value of the Warrants is as follows: March 31, 2022 December 31, 2021 Stock price $ 1.19 $ 3.26 Risk-free interest rate 2.44 % 1.11 % Dividend yield — — Expected life (in years) 3.69 3.94 Expected volatility 85.49 % 81.14 %		A summary of the Black Scholes pricing model assumptions used to record the fair value of the warrants is as follows: December 31, 2021 December 31, 2020 Stock price $ 3.26 $ 10.85 Risk-free interest rate 1.11 % 0.35 % Dividend yield — — Expected life (in years) 3.94 4.94 Expected volatility 81.14 % 82.66 %
Summary of Changes in Level 3 Warrant Liability Measured at Fair Value on Recurring Basis	The following table reflects the change in the Company’s Level 3 Warrant liability for the three months ended March 31, 2022 and the year ended December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 Fair value of warrant liability as of beginning of the period $ 3,029 $ 19,711 Change in fair value (2,448 ) (16,682 ) Fair value of warrant liability as of end of the period $ 581 $ 3,029		The following table reflects the change in the Company’s Level 3 Warrant liability for the years ended December 31, 2021 and December 31, 2020 (in thousands): December 31, 2021 December 31, 2020 Fair value of warrant liability as of beginning of year $ 19,711 $ 19,336 Change in fair value (16,682 ) 375 Fair value of warrant liability as of end of year $ 3,029 $ 19,711
Tyme Technologies, Inc. and Subsidiaries [Member]
Fair value Disclosure [Line Items]
Summary of Assumptions Used to Record Fair Value of Warrants		The following table details key inputs and assumptions used to estimate the fair value of the May 2020 Warrant as of March 31, 2022 and March 31, 2021 using a Black Scholes model: May 2020 Warrant May 2020 Warrant March 31, 2022 March 31, 2021 Stock price $ 0.35 $ 1.78 Volatility 98 % 78 % Remaining term (years) 2.01 3.01 Expected dividend yield — — Risk-free rate 2.28 % 0.35 %
Summary of Changes in Level 3 Warrant Liability Measured at Fair Value on Recurring Basis		The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: Warrant liability Beginning balance, March 31, 2021 $ 1,931,921 Change in fair value of May 2020 Warrant liability (1,807,441 ) Ending balance, March 31, 2022 $ 124,480
Summary of Financial Instruments Measured at Fair Value on Recurring Basis		The Company’s financial instruments measured at fair value on a recurring basis are as follows: March 31, 2022 Total Quoted prices in active markets Significant other observable inputs Significant unobservable inputs Financial assets Cash equivalents Money market funds $ 3,409,178 $ 3,409,178 $ — $ — Marketable Securities Short-term Corporate debt securities 26,195,025 — 26,195,025 — Municipal debt securities 34,416,936 — 34,416,936 — Long-term Corporate debt securities 6,293,015 — 6,293,015 — Municipal debt securities 2,787,656 — 2,787,656 — $ 73,101,810 $ 3,409,178 $ 69,692,632 $ — Financial liability Warrant liability $ 124,480 $ — $ — $ 124,480 March 31, 2021 Warrant liability $ 1,931,921 — — $ 1,931,921

Restricted Cash (Tables)

Restricted Cash (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Restricted Cash [Abstract]
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the amounts shown in the Company’s condensed consolidated statement of cash flows as of March 31, 2022, and December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 Cash and cash equivalents $ 69,575 $ 92,302 Restricted cash, net of current portion 3,086 3,086 Total cash, cash equivalents and restricted cash $ 72,661 $ 95,388	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the amounts shown in the consolidated statement of cash flows as of December 31, 2021, 2020, 2019 and 2018 (in thousands): December 31, 2021 2020 2019 2018 Cash and cash equivalents $ 92,302 $ 173,984 $ 41,441 $ 49,886 Restricted cash, current portion — — 290 638 Restricted cash, net of current portion 3,086 3,086 3,086 290 Total cash, cash equivalents and restricted cash $ 95,388 $ 177,070 $ 44,817 $ 50,814

Oxford Finance Loan Agreement (

Oxford Finance Loan Agreement (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Minimum Aggregate Future Loan Payments	The Company has the following minimum aggregate future loan payments as of March 31, 2022 (in thousands): Nine months ending December 31, 2022 $ — Year ending December 31, 2023 16,666 Year ending December 31, 2024 20,000 Year ending December 31, 2025 3,334 Total minimum payments $ 40,000 Less unamortized debt discount (410 ) Plus accumulated accretion of final fees 852 Total carrying value of debt 40,442 Less current portion (1,667 ) Long-term debt, net of current portion $ 38,775	The Company has the following minimum aggregate future loan payments as of December 31, 2021 (in thousands): Year ending December 31, 2022 $ — Year ending December 31, 2023 16,666 Year ending December 31, 2024 20,000 Year ending December 31, 2025 3,334 Total minimum payments $ 40,000 Less unamortized debt discount (459 ) Plus accumulated accretion of final fees 716 Less current portion — Long-term debt, net of current portion $ 40,257

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and Equipment consist of the following as of December 31, 2021 and 2020 (in thousands): Estimated useful life December 31, 2021 December 31, 2020 Construction-in-process — $ — $ 6 Laboratory equipment 5 7,989 7,028 Computer equipment 3 1,979 1,841 Furniture and fixtures 4 1,075 897 Leasehold improvements * 11,657 11,657 $ 22,700 $ 21,429 Less: Accumulated depreciation (9,856 ) (7,216 ) Total property and equipment, net $ 12,844 $ 14,213 * Leasehold improvements are depreciated over the shorter of the life of the asset and the term of the lease at 8.2 years and 9.3 years as of December 31, 2021 and 2020, respectively. The Company moved into its corporate headquarters in November 2019 and the 2019 Lease term ends in February 2030.

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 External research and preclinical development 8,521 $ 8,274 Employee compensation and benefits 3,180 6,344 Professional fees 1,495 953 Facilities and other 53 53 Accrued expenses $ 13,249 $ 15,624	Accrued expenses consist of the following as of December 31, 2021 and 2020 (in thousands): December 31, 2021 December 31, 2020 External research and preclinical development $ 8,274 $ 4,702 Employee compensation and benefits 6,344 5,715 Professional fees 953 602 Facilities and other 53 65 Accrued expenses $ 15,624 $ 11,084

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Reconciliation of Maturity Analysis of Annual Undiscounted Cash Flows	The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating and financing lease liabilities as of March 31, 2022 (in thousands): Operating Financing Nine months ending December 31, 2022 $ 2,956 $ 234 Year ending December 31, 2023 4,049 66 Year ending December 31, 2024 4,166 — Year ending December 31, 2025 4,287 — Year ending December 31, 2026 and beyond 19,256 — Total minimum lease payments 34,714 300 Less imputed interest (10,547 ) (14 ) Total lease liability $ 24,167 $ 286	The following is a maturity analysis of the annual undiscounted cash flows reconciled to the carrying value of the operating and financing lease liabilities as of December 31, 2021 (in thousands): Operating Financing Year ending December 31, 2022 $ 3,935 $ 313 Year ending December 31, 2023 4,049 66 Year ending December 31, 2024 4,166 — Year ending December 31, 2025 4,287 — Year ending December 31, 2026 and beyond 19,256 — Total minimum lease payments 35,693 379 Less imputed interest (11,115 ) (23 ) Total lease liability $ 24,578 $ 356
Schedule of Total Lease Cost for Operating and Financing Leases as well as Weighted Average Information for Leases	The following table outlines the total lease cost for the Company’s operating and financing leases as well as weighted average information for these leases as of March 31, 2022 (in thousands): Three Months Ended Lease cost: Operating lease cost $ 772 Financing lease cost: Amortization of right-of-use $ 66 Interest on lease liabilities 7 Total financing lease cost $ 73 Cash paid for amounts included in the measurement of liabilities: Operating cash flows from operating lease $ 979 Operating cash flows from financing lease $ 78 Three Months Ended Other information: Weighted-average remaining lease term (in years)—operating lease 7.92 Weighted-average discount rate—operating lease 9.30 % Weighted-average remaining lease term (in years)—financing lease 1.07 Weighted-average discount rate—financing lease 9.47 %	The following table outlines the total lease cost for the Company’s operating and financing leases as well as weighted average information for these leases as of December 31, 2021 (in thousands): Year Ended 2021 Lease cost: Operating lease cost $ 2,958 Financing lease cost: Amortization of right-of-use $ 260 Interest on lease liabilities 48 Total financing lease cost $ 308 Cash paid for amounts included in the measurement of liabilities: Operating cash flows from operating lease $ 3,823 Operating cash flows from financing lease $ 312 Other information: Year Ended 2021 Weighted-average remaining lease term (in years) – operating lease 8.17 Weighted-average discount rate – operating lease 9.30 Weighted-average remaining lease term (in years) – financing lease 1.26 Weighted-average discount rate – financing lease 9.47

Stock-Based Payments (Tables)

Stock-Based Payments (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of Status of Stock Options	A summary of the status of stock options as of December 31, 2021 and March 31, 2022 and changes during the three months ended March 31, 2022 is presented below: Shares Weighted Remaining Aggregate Outstanding at December 31, 2021 6,657,268 $ 8.27 7.2 $ 494 Granted 951,300 1.59 Exercised (37,700 ) 0.04 Cancelled (43,716 ) 9.93 Outstanding at March 31, 2022 7,527,152 $ 7.45 6.9 $ 26 Exercisable at March 31, 2022 4,081,501 $ 9.01 5.4 $ 26	A summary of the status of stock options as of December 31, 2021 and December 31, 2020 and changes during the year ended December 31, 2021 is presented below: Shares Weighted Remaining Aggregate Outstanding at December 31, 2020 5,468,605 $ 8.90 7.2 $ 13,124 Granted 2,417,600 7.69 Exercised (20,134 ) 7.77 Cancelled (1,208,803 ) 10.00 Outstanding at December 31, 2021 6,657,268 $ 8.27 7.2 $ 494 Exercisable at December 31, 2021 3,736,652 $ 8.86 5.8 $ 494
Summary of Status of Restricted Stock Units	A summary of the status of restricted stock units as of December 31, 2021 and March 31, 2022 and changes during the three months ended March 31, 2022 is presented below: Shares Weighted Outstanding at December 31, 2021 2,687,487 $ 6.52 Granted 2,768,128 1.58 Vested (739,561 ) 7.32 Forfeited (176,325 ) 6.76 Outstanding at March 31, 2022 4,539,729 $ 3.37	A summary of the status of restricted stock units as of December 31, 2020 and December 31, 2021 and changes during the year ended December 31, 2021 is presented below: Shares Weighted Outstanding at December 31, 2020 1,734,383 $ 7.40 Granted 1,747,554 6.31 Vested (286,837 ) 7.70 Forfeited (507,613 ) 8.15 Outstanding at December 31, 2021 2,687,487 $ 6.52
Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model	The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Three Months 2022 2021 Weighted-average risk-free interest rate 1.98 % 0.78 % Expected dividend yield — % — % Expected option term (in years) 6.07 6.08 Volatility 80.70 % 82.10 %	The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Year Ended December 31, 2021 2020 2019 Weighted-average risk-free interest rate 0.99 % 1.28 % 2.42 % Expected dividend yield — % — % — % Expected option term (in years) 6.03 5.99 6.00 Volatility 81.56 % 78.27 % 91.35 %
Summary of Stock-based Compensation Expense for Stock Options and Restricted Stock Units	The following table summarizes the stock-based compensation expense for stock options and restricted stock units granted to employees and non-employees Three Months 2022 2021 Research and development $ 1,395 $ 1,323 General and administrative 1,468 1,607 Total stock-based compensation expense $ 2,863 $ 2,930	The following table summarizes the stock-based compensation expense for stock options, restricted stock units and restricted common stock granted to employees and non-employees Year Ended December 31, 2021 2020 2019 Research and development $ 5,706 $ 4,732 $ 3,472 General and administrative 4,648 6,207 6,367 Total stock-based compensation expense $ 10,354 $ 10,939 $ 9,839

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Components of Income Tax Provision		The components of the income tax provision for the years ended December 31, 2021, 2020 and 2019 are as follows: Year Ended December 31, 2021 2020 2019 Current $ 1 $ 4 $ 28 Deferred — — — Total $ 1 $ 4 $ 28
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate		A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows for the years ended December 31, 2021, 2020 and 2019: Year ended December 31, 2021 2020 2019 Federal income tax computed at federal statutory tax rate 21.00 % 21.00 % 21.00 % State income tax, net of federal benefit 7.26 6.12 6.56 Permanent items 3.60 (0.68 ) (0.89 ) Federal and state research and development credits 5.79 3.89 4.79 Rate change — — — Other (1.41 ) (0.88 ) (0.77 ) Change in valuation allowance (36.24 ) (29.45 ) (30.73 ) Effective income tax rate — % — % (0.04 )%
Schedule of Components of Deferred Tax Assets and Liabilities		The principal components of the Company’s deferred tax assets and liabilities consist of the following at December 31, 2021 and 2020 (in thousands): Year ended December 31, 2021 2020 Deferred tax assets: Federal and state net operating loss carryforwards $ 109,166 $ 80,658 Tax credit carryforwards 22,446 17,442 Intangible assets 3,000 3,219 Stock-based compensation 5,700 5,117 Deferred revenue 2,810 6,034 Capital lease 6,812 7,284 Other 2,395 1,725 Total deferred tax assets 152,329 121,479 Less valuation allowance (146,285 ) (114,946 ) Net deferred tax assets 6,044 6,533 Deferred tax liabilities: Right-of-use 3,946 4,215 Fixed assets 2,098 2,318 Total deferred tax liabilities 6,044 6,533 Net deferred taxes $ — $ —
Tyme Technologies, Inc. and Subsidiaries [Member]
Income Taxes [Line Items]
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate	A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: Year Ended 2022 2021 U.S. statutory income tax rate 21.00 % 21.00 % State taxes, net of federal benefit 11.59 % — Permanent differences — (0.02 )% Tax credit carryforwards 7.93 % 4.70 % Valuation allowance (37.08 )% (20.98 )% Stock compensation (5.05 )% (3.41 )% Warrants 1.61 % (1.29 )% Effective tax rate — % — %
Schedule of Components of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred tax assets are comprised of the following: March 31, 2022 2021 Net operating loss carryforward $ 27,564,077 $ 20,123,621 Research and development credit carryforward 884,130 1,164,895 Orphan Drug Credit 4,157,360 2,002,559 Stock options – NQSOs 4,765,662 5,267,351 Accruals and other temporary differences 662,754 595,418 Gross deferred tax assets 38,033,983 29,153,844 Deferred tax valuation allowance (38,033,983 ) (29,153,844 ) Net deferred taxes $ — $ —
Schedule of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended March 31, 2022 2021 Gross unrecognized tax benefits at beginning of year $ 558,962 $ 318,394 Increases (decreases) for tax positions in prior period — (99,063 ) Increase for tax positions in current period 330,712 339,631 Gross unrecognized tax benefits at end of year $ 889,674 $ 558,962

Stockholders' Equity (Tables)

Stockholders' Equity (Tables) - Tyme Technologies, Inc. and Subsidiaries [Member]	12 Months Ended
	Mar. 31, 2022
Stockholders Equity Note Disclosure [Line Items]
Schedule of Common Stock Warrant Activity	The following summarizes the common stock warrant activity for the years ended March 31, 2022 and March 31, 2021: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2020 8,937,651 $ 2.31 Granted 2,166,667 1.80 Exchanged (8,000,000 ) 2.00 Outstanding at March 31, 2021 3,104,318 $ 2.77 Granted — — Exchanged — — Outstanding at March 31, 2022 3,104,318 $ 2.77
Schedule of Warrants to Purchase Common Stock Outstanding	At March 31, 2022 and March 31, 2021, 3,074,551 of common stock purchase warrants relating to securities purchase agreements were outstanding and exercisable. Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 May 2020 Liability 2,166,667 $ 1.80 April 2024

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted	The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Three Months 2022 2021 Weighted-average risk-free interest rate 1.98 % 0.78 % Expected dividend yield — % — % Expected option term (in years) 6.07 6.08 Volatility 80.70 % 82.10 %		The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions: Year Ended December 31, 2021 2020 2019 Weighted-average risk-free interest rate 0.99 % 1.28 % 2.42 % Expected dividend yield — % — % — % Expected option term (in years) 6.03 5.99 6.00 Volatility 81.56 % 78.27 % 91.35 %
Schedule of Stock Options	A summary of the status of stock options as of December 31, 2021 and March 31, 2022 and changes during the three months ended March 31, 2022 is presented below: Shares Weighted Remaining Aggregate Outstanding at December 31, 2021 6,657,268 $ 8.27 7.2 $ 494 Granted 951,300 1.59 Exercised (37,700 ) 0.04 Cancelled (43,716 ) 9.93 Outstanding at March 31, 2022 7,527,152 $ 7.45 6.9 $ 26 Exercisable at March 31, 2022 4,081,501 $ 9.01 5.4 $ 26		A summary of the status of stock options as of December 31, 2021 and December 31, 2020 and changes during the year ended December 31, 2021 is presented below: Shares Weighted Remaining Aggregate Outstanding at December 31, 2020 5,468,605 $ 8.90 7.2 $ 13,124 Granted 2,417,600 7.69 Exercised (20,134 ) 7.77 Cancelled (1,208,803 ) 10.00 Outstanding at December 31, 2021 6,657,268 $ 8.27 7.2 $ 494 Exercisable at December 31, 2021 3,736,652 $ 8.86 5.8 $ 494
Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted		The assumptions utilized to estimate the fair value of stock options granted are presented in the following table: Year Ended March 31, 2022 2021 Risk free interest rate 0.280% - 2.34% 0.174% - 0.527% Expected volatility 95.39% - 105.37% 88.02% - 101.67% Expected term 2.7 - 6.1 years 2.8 - 6.1 Dividend yield 0.0% 0.0%
Schedule of Stock Options		The following is a summary of the activity of the Company’s stock options under the 2015 Plan and 2016 Director Plan as of March 31, 2022: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2021 12,588,068 $ 2.92 Granted 3,862,388 1.30 Exercised (6,250 ) 0.99 Cancelled/Forfeited (1,939,935 ) 3.83 Outstanding at March 31, 2022 14,504,271 2.36 Options exercisable at March 31, 2022 9,329,798 $ 2.99
Schedule of Stock Option by Exercise Price Range		Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at March 31, 2022 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at March 31, 2022 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $0.29 - $8.75 14,504,271 $ 2.36 7 $ 4,610 9,329,798 $ 2.99 6 $ —
Schedule of Non-vested Options		Options Weighted Average Non-vested 4,355,171 $ 0.91 Granted 3,862,388 1.00 Vested (446,522 ) 0.95 Cancelled/Forfeited (2,596,564 ) 0.99 Non-vested 5,174,473 $ 0.93

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2022
Tyme Technologies, Inc. and Subsidiaries [Member]
Leases [Line Items]
Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements	As of March 31, 2022, the future minimum lease payments under non-cancellable March 31, Fiscal year 2023 $ 39,240 Total remaining lease payments 39,240 Less: present value adjustment (1,908 ) Total operating lease liabilities 37,332 Less: current portion 37,332 Operating lease liabilities, net of current portion $ —

Nature of Business - Additional

Nature of Business - Additional Information (Details)							1 Months Ended		3 Months Ended		12 Months Ended
	Feb. 08, 2021 USD ($) $ / shares shares	Jan. 22, 2021 USD ($) $ / shares shares	Dec. 08, 2020 USD ($) $ / shares shares	Dec. 04, 2020 USD ($)	Jan. 07, 2020 USD ($) $ / shares shares	Apr. 09, 2019 USD ($) Agreement $ / shares shares	Jan. 31, 2021 USD ($) $ / shares shares	Nov. 30, 2019 USD ($) shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) shares	Oct. 18, 2019 USD ($) $ / shares
Stock Offering
Gross proceeds from common stock														$ 11,896,000	$ 824,000
Common stock, par value (in dollars per share) | $ / shares									$ 0.001		$ 0.001	$ 0.001		$ 0.001
Warrants to purchase common stock | shares									2,117,094	2,117,094	2,117,094	2,117,094	2,117,094	2,117,094	2,118,094
Number of underwriting agreements | Agreement						2
Gross proceeds from public offerings						$ 70,000,000
Underwriting discounts and commissions and offering expenses						$ 5,000,000
Net Loss									$ 25,146,000	$ 14,228,000		$ 86,558,000		$ 84,038,000	$ 75,438,000
Accumulated deficit									488,725,000		$ 488,725,000	463,579,000		377,021,000
Cash, cash equivalents and marketable securities, fair value									112,900,000		$ 112,900,000	143,400,000
Net cash used in operating activities									30,017,000	21,990,000		99,540,000		57,364,000	60,253,000
Non-cash equity compensation									2,863,000	2,930,000		10,354,000		10,939,000	9,839,000
Net amortization of premiums and discounts on marketable securities									76,000			224,000		(49,000)	(949,000)
Change in fair value of warrant liability									$ 2,448,000	$ 7,670,000		$ 16,682,000		$ (375,000)	$ 0
Series A Convertible Preferred Stock
Stock Offering
Share price (in dollars per share) | $ / shares									$ 6.57		$ 6.57	$ 6.57
Orsenix, LLC | Asset Purchase Agreement
Stock Offering
Upfront fee payments				$ 12,000,000
Payments made upon achievement of regulatory milestone				6,000,000
Payments made upon achievement of commercial milestone				$ 10,000,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Common stock, par value (in dollars per share) | $ / shares									$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001
Net Loss											$ 23,626,047		$ 28,978,763
Accumulated deficit									$ 160,420,062	$ 136,794,015	160,420,062		136,794,015
Estimated close out trial costs											723,000
Close out trial costs expected to be incurred over next five months									400,000		400,000
Net cash used in operating activities											21,242,745		23,564,478
Non-cash equity compensation											2,451,906		3,456,895
Net amortization of premiums and discounts on marketable securities											1,615,332
Change in fair value of warrant liability											1,807,441		$ (3,915,393)
Working capital									$ 71,500,000		$ 71,500,000
Underwritten Public Offering
Stock Offering
Shares issued | shares		5,400,000					5,400,000
Public offering price per share | $ / shares		$ 14					$ 14
Gross proceeds from common stock		$ 75,600,000					$ 75,600,000
Underwriting discounts and commissions and other transaction expenses		$ 5,100,000					$ 5,100,000
Private Placement
Stock Offering
Warrants to purchase common stock | shares									2,828,125	2,828,125	2,828,125	2,828,125	2,828,125	2,828,125
Gross proceeds of private placement			$ 90,500,000
Transaction costs and Offering expense			$ 400,000
Change in fair value of warrant liability												$ (16,700,000)		$ (400,000)
Private Placement | Common Stock
Stock Offering
Shares issued | shares			10,312,500
Common stock, par value (in dollars per share) | $ / shares			$ 0.001
Private Placement | Pre-Funded Warrant
Stock Offering
Warrants to purchase common stock | shares			1,000,000
Share price (in dollars per share) | $ / shares			$ 8
Private Placement | Warrants
Stock Offering
Share price (in dollars per share) | $ / shares			$ 7.99
Private Placement | Warrants | Maximum
Stock Offering
Warrants to purchase common stock | shares			2,828,125
At Market Sales Facility | Common Stock
Stock Offering
Shares issued | shares								180,787
Aggregate gross proceeds								$ 900,000
Public Offering | Class A Warrants
Stock Offering
Warrants, exercise price | $ / shares						$ 8.625
Warrant expiration date						Oct. 10, 2022
Public Offering | Common Stock Agreement | Class A Warrants
Stock Offering
Warrants to purchase common stock | shares						1,951,844
Share price (in dollars per share) | $ / shares						$ 7.5
Public Offering | Preferred Stock Agreement | Series A Convertible Preferred Stock
Stock Offering
Shares issued | shares						666
Public Offering | Preferred Stock Agreement | Class A Warrants
Stock Offering
Warrants to purchase common stock | shares						166,500
Share price (in dollars per share) | $ / shares						$ 7,500
Public Offering | Common Stock | Common Stock Agreement
Stock Offering
Shares issued | shares						8,667,333
Registered Direct Offering [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Gross proceeds from common stock	$ 100,000,000
Related cost offset the proceeds	$ 6,200,000
Registered Direct Offering [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Common Stock
Stock Offering
Shares issued | shares	40,000,000
Share price (in dollars per share) | $ / shares	$ 2.5
Securities Purchase Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Common Stock
Stock Offering
Shares issued | shares													40,000,000
Securities Purchase Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Common Stock | Eagle Pharmaceuticals, Inc [Member]
Stock Offering
Shares issued | shares					10,000,000
Gross proceeds from common stock					$ 20,000,000
Share price (in dollars per share) | $ / shares					$ 2
Sale Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Shares issued | shares													4,453,939
Gross proceeds from common stock													$ 6,100,000
Related cost offset the proceeds													300,000
Available for offering									$ 22,200,000		$ 22,200,000
Sale Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Jefferies [Member]
Stock Offering
Shares issued | shares											0
Gross proceeds from common stock													6,100,000
Transaction costs and Offering expense													$ 300,000
Available for offering									$ 22,200,000		$ 22,200,000
Sale Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Maximum
Stock Offering
Aggregate offering																$ 30,000,000
Sale Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Maximum | Jefferies [Member]
Stock Offering
Aggregate offering																$ 30,000,000
Sale Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Minimum [Member] | Jefferies [Member]
Stock Offering
Share price (in dollars per share) | $ / shares																$ 1

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022 USD ($) Day shares	Mar. 31, 2021 USD ($) shares	Dec. 31, 2022 shares	Mar. 31, 2022 USD ($) NUMBER shares	Dec. 31, 2021 USD ($) Day shares	Mar. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($) shares	Dec. 31, 2018 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of operating segment | Day	1				1
Number of financial instruments with off-balance sheet risk | Day	0				0
Depreciation and amortization	$ 681,000	$ 666,000			$ 2,758,000		$ 2,774,000	$ 2,521,000
Impairment losses	0				0
Revenue	$ 5,467,000	$ 4,827,000			$ 23,488,000		$ 15,093,000	$ 1,982,000
Warrant issued to purchase common stock | shares	2,117,094	2,117,094		2,117,094	2,117,094	2,117,094	2,117,094	2,118,094
Weighted-average number of common shares used in net loss per share applicable to common stockholders— Basic | shares	63,061,423	61,379,641			62,534,978		46,051,617	40,222,182
Weighted-average number of common shares used in net loss per share applicable to common stockholders— Diluted | shares	63,061,423	61,379,641			62,534,978		46,051,617	40,222,182
Cash and cash equivalents	$ 69,575,000			$ 69,575,000	$ 92,302,000		$ 173,984,000	$ 41,441,000	$ 49,886,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of operating segment | NUMBER				1
Weighted-average number of common shares used in net loss per share applicable to common stockholders— Basic | shares				172,206,534		134,250,722
Weighted-average number of common shares used in net loss per share applicable to common stockholders— Diluted | shares			172,206,534	172,206,534		134,250,722
Cash and cash equivalents	13,738,931	$ 107,516,420		$ 13,738,931		$ 107,516,420
Cash in excess of FDIC insured limit of $250000 amount	10,100,000	107,300,000		10,100,000		107,300,000
Tyme Technologies, Inc. and Subsidiaries [Member] | Prepaid Expenses and Other Current Assets [Member]
Summary Of Significant Accounting Policies [Line Items]
Prepaid insurance	1,100,000	$ 1,000,000		1,100,000		$ 1,000,000
Accrued interest receivable on marketable securities	600,000			600,000
Deposit with payroll vendor	$ 2,100,000			$ 2,100,000
Accounting Standards Update 2019-12 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adoption date					Jan. 01, 2021
Accounting Standards Update 2019-12 [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true			true
Change in accounting principle, accounting standards update, adoption date	Apr. 01, 2021			Apr. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect	true			true
Accounting Standards Update 2020-06 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true			true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022			Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect	true			true
Accounting Standards Update 2020-06 [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true			true
Change in accounting principle, accounting standards update, adoption date	Apr. 01, 2021			Apr. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect	true			true
Accounting Standards Update 2016-13 [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true			true
Change in accounting principle, accounting standards update, adoption date	Apr. 01, 2021			Apr. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect	true			true
Private Placement
Summary Of Significant Accounting Policies [Line Items]
Warrant issued to purchase common stock | shares	2,828,125	2,828,125		2,828,125	2,828,125	2,828,125	2,828,125
Pre-Funded Warrant | Private Placement
Summary Of Significant Accounting Policies [Line Items]
Warrant issued to purchase common stock | shares	1,000,000			1,000,000	1,000,000		1,000,000
Performance-based stock options | Executive Officers
Summary Of Significant Accounting Policies [Line Items]
Compensation expense recognized period					6 years
Global Blood Therapeutics
Summary Of Significant Accounting Policies [Line Items]
Revenue					$ 19,400,000		$ 11,700,000
Incyte
Summary Of Significant Accounting Policies [Line Items]
Revenue	$ 400,000	$ 800,000			4,100,000		$ 3,400,000	$ 2,000,000
Construction in progress
Summary Of Significant Accounting Policies [Line Items]
Depreciation and amortization	$ 0				$ 0
Furniture and Fixtures [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful life					4 years
Furniture and Fixtures [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful life				3 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Anti-dilutive securities
Total shares excluded from diluted net loss per share applicable to common stockholders	17,057,037	13,564,707	14,334,911	12,193,144	7,852,873
Stock options
Anti-dilutive securities
Total shares excluded from diluted net loss per share applicable to common stockholders	7,527,152	6,504,401	6,657,268	5,468,605	4,618,421
Unvested Restricted Stock Units
Anti-dilutive securities
Total shares excluded from diluted net loss per share applicable to common stockholders	4,539,729	2,070,150	2,687,487	1,734,383	1,116,358
Warrants
Anti-dilutive securities
Total shares excluded from diluted net loss per share applicable to common stockholders	4,990,156	4,990,156	4,990,156	4,990,156	2,118,094

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Anti-dilutive securities
Warrant issued to purchase common stock	2,117,094	2,117,094	2,117,094	2,117,094	2,118,094
Private Placement
Anti-dilutive securities
Warrant issued to purchase common stock	2,828,125	2,828,125	2,828,125	2,828,125
First Draw of Loan Agreement
Anti-dilutive securities
Warrant issued to purchase common stock		27,548		27,548
Second Draw on Loan Agreement
Anti-dilutive securities
Warrant issued to purchase common stock	17,389	17,389	17,389	17,389
Loan Agreement
Anti-dilutive securities
Warrant issued to purchase common stock	27,548		27,548

Collaboration and Research Ar_3

Collaboration and Research Arrangements - Additional Information (Details) - USD ($)			1 Months Ended		3 Months Ended		12 Months Ended
	Dec. 17, 2019	Jan. 08, 2018	Nov. 30, 2019	Jan. 31, 2018	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price			$ 12,800,000
Accounts receivable								$ 7,000
Contract asset balances					$ 3,182,000		$ 2,979,000	2,324,000
Revenue recognized					5,467,000	$ 4,827,000	23,488,000	15,093,000	$ 1,982,000
Deferred revenue					7,773,000		10,181,000	22,086,000
Deferred revenue, net of current portion								9,877,000
Global Blood Therapeutics
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized							19,400,000	11,700,000
Deferred revenue					6,926,000		8,913,000	16,721,000
Global Blood Therapeutics | Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial period of research term	3 years
Additional extension period for research term upon mutual agreement	1 year
Upfront payment receivable	$ 20,000,000
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses	$ 40,000,000
Agreement termination, prior written notice if notice delivered during the research term	9 months
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term	90 days
Total transaction price	$ 60,000,000				54,200,000		54,200,000	60,000,000
Upfront non-refundable and non-creditable payment	20,000,000
Reimbursable costs	40,000,000
Accounts receivable							0	0
Contract asset balances							3,000,000	2,300,000
Revenue recognized					5,100,000	4,000,000	19,400,000	11,700,000
Deferred revenue						6,900,000		16,700,000
Deferred revenue, short-term							9,000,000	8,400,000
Deferred revenue, net of current portion								8,300,000
Change in total transaction price					0
Global Blood Therapeutics | Collaboration Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting	$ 315,000,000
Incyte
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized					400,000	800,000	4,100,000	3,400,000	$ 2,000,000
Deferred revenue					847,000	$ 800,000	1,268,000	$ 5,365,000
Deferred revenue, short-term							$ 1,300,000
Incyte | Stock Purchase Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate purchase price				$ 10,000,000
Shares issued				793,021
Share price (in dollars per share)				$ 12.61
Premium to volume-weighted sale price of shares (as a percent)				30%
Incyte | Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price		$ 12,300,000	12,800,000
Upfront non-refundable and non-creditable payment			2,500,000		2,500,000
Up-front consideration				$ 10,000,000
Up-front consideration, cash				2,500,000
Up-front consideration, pre-paid research funding				$ 7,500,000
Share price (in dollars per share)				$ 12.61
Prepaid research amount			7,500,000		7,500,000
Premium paid on equity investment			2,300,000		2,300,000
Collaboration agreement additional consideration incurred			$ 500,000		$ 500,000

Collaboration and Research Ar_4

Collaboration and Research Arrangements - Summary of Changes in Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Accounts receivable and contract assets, Balance at Beginning of Period	$ 2,979	$ 2,331
Accounts receivable and contract assets, Additions	6,038	22,341
Accounts receivable and contract assets, Deductions	(5,835)	(21,693)
Accounts receivable and contract assets, Balance at End of Period	3,182	2,979
Contract liabilities, Balance at Beginning of Period	10,181	22,086
Contract liabilities, Additions		174
Contract liabilities, Deduction	(2,408)	(12,079)
Contract liabilities, Balance at End of Period	7,773	10,181
Incyte
Disaggregation Of Revenue [Line Items]
Contract liabilities, Balance at Beginning of Period	1,268	5,365
Contract liabilities, Deduction	(421)	(4,097)
Contract liabilities, Balance at End of Period	847	1,268
Global Blood Therapeutics
Disaggregation Of Revenue [Line Items]
Contract liabilities, Balance at Beginning of Period	8,913	16,721
Contract liabilities, Additions		174
Contract liabilities, Deduction	(1,987)	(7,982)
Contract liabilities, Balance at End of Period	6,926	8,913
Billed receivables from collaboration partners
Disaggregation Of Revenue [Line Items]
Accounts receivable, Balance at Beginning of Period		7
Accounts receivable, Additions	2,857	10,931
Accounts receivable, Deduction	(2,857)	(10,938)
Unbilled receivables from collaboration partners
Disaggregation Of Revenue [Line Items]
Contract assets, Balance at Beginning of Period	2,979	2,324
Contract assets, Additions	3,181	11,410
Contract assets, Deduction	(2,978)	(10,755)
Contract assets, Balance at End of Period	$ 3,182	$ 2,979

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Basic and diluted net loss per common share calculation
Net loss	$ (25,146,000)	$ (14,228,000)			$ (86,558,000)		$ (84,038,000)	$ (75,438,000)
Weighted average common shares outstanding — Basic	63,061,423	61,379,641			62,534,978		46,051,617	40,222,182
Weighted average common shares outstanding — Diluted	63,061,423	61,379,641			62,534,978		46,051,617	40,222,182
Net loss per share of common stock — Basic	$ (0.4)	$ (0.23)			$ (1.38)		$ (1.82)	$ (1.88)
Net loss per share of common stock — Diluted	$ (0.4)	$ (0.23)			$ (1.38)		$ (1.82)	$ (1.88)
Tyme Technologies, Inc. and Subsidiaries [Member]
Basic and diluted net loss per common share calculation
Net loss				$ (23,626,047)		$ (28,978,763)
Weighted average common shares outstanding — Basic				172,206,534		134,250,722
Weighted average common shares outstanding — Diluted			172,206,534	172,206,534		134,250,722
Net loss per share of common stock — Basic				$ (0.14)		$ (0.22)
Net loss per share of common stock — Diluted				$ (0.14)		$ (0.22)

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Details) - Tyme Technologies, Inc. and Subsidiaries [Member]	12 Months Ended
	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Apr. 30, 2019
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Description of warrants issued	Warrants issued in April 2019, discussed further in Note 8, participated on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors (the “Board”) on the Company’s Common Stock.
Warrants issued for common stock dividends			1
Income allocated to warrants	$ 0	$ 0

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of Anti-dilutive Shares Outstanding (Details) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	17,057,037	13,564,707		14,334,911		12,193,144	7,852,873
Tyme Technologies, Inc. and Subsidiaries [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total			17,608,589		15,692,386
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	7,527,152	6,504,401		6,657,268		5,468,605	4,618,421
Stock options | Tyme Technologies, Inc. and Subsidiaries [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total			14,504,271		12,588,068
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,990,156	4,990,156		4,990,156		4,990,156	2,118,094
Warrants | Tyme Technologies, Inc. and Subsidiaries [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total			3,104,318		3,104,318

Cash, Cash Equivalents and Ma_3

Cash, Cash Equivalents and Marketable Securities - Schedule of Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Equivalents and Marketable Securities
Cash Equivalents, Amortized Cost			$ 173,984
Cash Equivalents, Fair value			173,984
Cash Equivalents and Marketable Securities, Amortized Cost	$ 113,172	$ 143,486
Cash Equivalents and Marketable Securities, Unrealized Losses	(273)	(79)
Cash Equivalents and Marketable Securities, Fair Value	112,899	143,407
Corporate Debt Securities – Due in One Year or Less
Cash Equivalents and Marketable Securities
Marketable Securities, Amortized Cost	28,915	30,100
Marketable Securities, Unrealized Losses	(111)	(12)
Marketable Securities, Fair Value	28,804	30,088
Us Treasury Obligation – Due in One Year or Less
Cash Equivalents and Marketable Securities
Marketable Securities, Amortized Cost	12,000	8,000
Marketable Securities, Unrealized Losses	(118)	(21)
Marketable Securities, Fair Value	11,882	7,979
Corporate Debt Securities – Due in More than One Year to Five Years
Cash Equivalents and Marketable Securities
Marketable Securities, Amortized Cost	2,682	9,085
Marketable Securities, Unrealized Losses	(44)	(33)
Marketable Securities, Fair Value	2,638	9,052
US Treasury Obligation – Due in More Than One Year to Five Years
Cash Equivalents and Marketable Securities
Marketable Securities, Amortized Cost		3,999
Marketable Securities, Unrealized Losses		(13)
Marketable Securities, Fair Value		3,986
Cash and money market funds
Cash Equivalents and Marketable Securities
Cash Equivalents, Amortized Cost	69,575	92,302	173,984
Cash Equivalents, Fair value	$ 69,575	$ 92,302	$ 173,984

Cash, Cash Equivalents and Ma_4

Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022 USD ($) Security item	Mar. 31, 2021 USD ($) item	Dec. 31, 2021 USD ($) Security item	Dec. 31, 2020 USD ($) item	Dec. 31, 2019 USD ($) item
Investments, Debt and Equity Securities [Abstract]
Realized gains (losses)	$ 0	$ 0	$ 0	$ 0	$ 0
Number of investments adjusted for other-than-temporary declines in fair value | item	0	0	0	0	0
Number of securities held unrealized position | Security	10		11
Unrealized loss position for less than twelve months	$ 27,400,000		$ 30,100,000
Unrealized loss position for more than twelve months	0		0
Marketable securities with an other-than temporary impairment	$ 0		$ 0

Available-for-Sale Securities -

Available-for-Sale Securities - Schedule of Available-for-Sale Securities Recorded in Cash and Cash Equivalents or Marketable Securities (Details) - Tyme Technologies, Inc. and Subsidiaries [Member]	Mar. 31, 2022 USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized cost	$ 73,646,074
Gross Unrealized Loss	(544,264)
Fair Value	73,101,810
Municipal Debt Securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	37,405,722
Gross Unrealized Loss	(201,130)
Fair Value	37,204,592
Corporate Debt Securities
Debt Securities, Available-for-sale [Line Items]
Amortized cost	32,831,174
Gross Unrealized Loss	(343,134)
Fair Value	32,488,040
Money Market Funds
Debt Securities, Available-for-sale [Line Items]
Amortized cost	3,409,178
Fair Value	$ 3,409,178

Available-for-Sale Securities_2

Available-for-Sale Securities - Schedule of Classification of Available-for-Sale Securities (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2020
Marketable Securities [Line Items]
Cash and cash equivalents		$ 173,984,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Marketable Securities [Line Items]
Cash and cash equivalents	$ 3,409,178
Marketable securities	69,692,632
Total	$ 73,101,810

Available-for-Sale Securities_3

Available-for-Sale Securities - Summary of Available-for-Sale Securities By Contractual Maturity (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Net Unrealized Losses	$ (27,400,000)	$ (30,100,000)
12 months or Longer, Net Unrealized Losses	0	$ 0
Tyme Technologies, Inc. and Subsidiaries [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	64,021,139
Less than 12 months, Net Unrealized Losses	(381,155)
12 months or Longer, Fair Value	9,080,671
12 months or Longer, Net Unrealized Losses	(163,109)
Total	73,101,810
Total, Net Unrealized Losses	(544,264)
Tyme Technologies, Inc. and Subsidiaries [Member] | Municipal Debt Securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	34,416,936
Less than 12 months, Net Unrealized Losses	(153,855)
12 months or Longer, Fair Value	2,787,656
12 months or Longer, Net Unrealized Losses	(47,275)
Total	37,204,592
Total, Net Unrealized Losses	(201,130)
Tyme Technologies, Inc. and Subsidiaries [Member] | Corporate Debt Securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	26,195,025
Less than 12 months, Net Unrealized Losses	(227,300)
12 months or Longer, Fair Value	6,293,015
12 months or Longer, Net Unrealized Losses	(115,834)
Total	32,488,040
Total, Net Unrealized Losses	(343,134)
Tyme Technologies, Inc. and Subsidiaries [Member] | Money Market Funds
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	3,409,178
Total	$ 3,409,178

Accounts Payable and Other Cu_3

Accounts Payable and Other Current Liabilities - Schedule of Accounts Payable and Other Current Liabilities (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Payables and Accruals [Line Items]
Consultant and professional services	$ 1,495,000	$ 953,000		$ 602,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Payables and Accruals [Line Items]
Legal	263,111		$ 454,139
Consultant and professional services	300,051		176,957
Accounting and auditing	14,410		55,349
Research and development	2,776,594		2,657,202
Board of Directors and Scientific Advisory Board Compensation	418,389		435,594
Other	30,872		63,149
Total	$ 3,803,427		$ 3,842,390

Severance Payable - Additional

Severance Payable - Additional Information (Detail) - Tyme Technologies, Inc. and Subsidiaries [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2022 USD ($) Employee	Mar. 31, 2021 USD ($)	Mar. 31, 2019 USD ($)
Severance Payable [Line Items]
Severance expense		$ 2,437,379	$ 321,825	$ 2,500,000
Number of employees entered into separation and general agreement | Employee		3
Salary continuance term	5 years
Reimbursement of health benefits term	3 years
Discount rate	6%			6%
Stock option modification expense				$ 400,000
Severance liability		$ 3,000,000	$ 1,600,000
Release Agreement, March 15, 2019 | Minimum
Severance Payable [Line Items]
Post-termination exercise period	3 months
Release Agreement, March 15, 2019 | Maximum
Severance Payable [Line Items]
Post-termination exercise period	5 years
Chief Science Officer
Severance Payable [Line Items]
Severance expense		$ 2,100,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Cash equivalents				$ 173,984,000
Marketable securities	$ 40,686,000	$ 38,067,000
Marketable securities	2,638,000	13,038,000
Fair Value, Recurring [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Financial assets	112,899,000	143,407,000		173,984,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Financial assets	81,457,000	104,267,000		173,984,000
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Financial assets	31,442,000	39,140,000
Fair Value, Recurring [Member] | Money Market Funds [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Financial assets	9,806,000	35,089,000		126,405,000
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Financial assets	9,806,000	$ 35,089,000		$ 126,405,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Cash equivalents	3,409,178
Marketable securities	60,611,961
Marketable securities	9,080,671
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Financial assets	73,101,810
Warrant liability	124,480		$ 1,931,921
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Municipal Bonds [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities	34,416,936
Marketable securities	2,787,656
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Corporate Bond Securities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities	26,195,025
Marketable securities	6,293,015
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Financial assets	3,409,178
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Financial assets	69,692,632
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Municipal Bonds [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities	34,416,936
Marketable securities	2,787,656
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Bond Securities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities	26,195,025
Marketable securities	6,293,015
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability	124,480		$ 1,931,921
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Cash equivalents	3,409,178
Tyme Technologies, Inc. and Subsidiaries [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Cash equivalents	$ 3,409,178

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	$ 112,899	$ 143,407	$ 173,984
Total Liabilities	581	3,029	19,711
Cash
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	59,769	57,213	47,579
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	9,806	35,089	126,405
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	81,457	104,267	173,984
Level 1 | Cash
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	59,769	57,213	47,579
Level 1 | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	9,806	35,089	126,405
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	31,442	39,140
Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Liabilities	581	3,029	19,711
Corporate Debt Securities - Due in One Year or Less
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	28,804	30,088
Corporate Debt Securities - Due in One Year or Less | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	28,804	30,088
Us Treasury Obligation - Due in One Year or Less
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	11,882	7,979
Us Treasury Obligation - Due in One Year or Less | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	11,882	7,979
US Treasury Obligation - Due in More Than One Year to Five Years
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets		3,986
US Treasury Obligation - Due in More Than One Year to Five Years | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets		3,986
Corporate Debt Securities - Due in More than One Year to Five Years
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	2,638	9,052
Corporate Debt Securities - Due in More than One Year to Five Years | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Assets	2,638	9,052
Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Liabilities	581	3,029	19,711
Warrants | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Liabilities	$ 581	$ 3,029	$ 19,711

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - shares	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,117,094	2,117,094	2,117,094	2,117,094	2,118,094
Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,828,125	2,828,125	2,828,125	2,828,125

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Assumptions Used to Record Fair Value of Warrants (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2022 $ / shares	Dec. 31, 2021 $ / shares	Dec. 31, 2020 $ / shares	Mar. 31, 2021 $ / shares
Warrant [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 0.35			$ 1.78
Stock Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 1.19	$ 3.26	$ 10.85
Risk-free interest rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants liability measurement input	0.0244	0.0111	0.0035
Risk-free interest rate | Warrant [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	2.28			0.35
Expected life (in years)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected life (in years)	3 years 8 months 8 days	3 years 11 months 8 days	4 years 11 months 8 days
Expected life (in years) | Warrant [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	2 years 3 days			3 years 3 days
Expected volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants liability measurement input	0.8549	0.8114	0.8266
Expected volatility | Warrant [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	98			78

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Changes in Level 3 Warrant Liability Measured at Fair Value on Recurring Basis (Details) - Level 3 - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair value of warrant liability as of beginning of year	$ 3,029		$ 19,711	$ 19,336
Change in fair value	(2,448)		(16,682)	375
Fair value of warrant liability as of end of year	581	$ 581	$ 3,029	$ 19,711
Class Of Warrant Or Right Issued Date Four [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair value of warrant liability as of beginning of year		1,931,921
Change in fair value		(1,807,441)
Fair value of warrant liability as of end of year	$ 124,480	$ 124,480

Restricted Cash - Additional In

Restricted Cash - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Restricted Cash
Long term restricted cash	$ 3,086	$ 3,086		$ 3,086	$ 3,086	$ 290
Operating Lease, January 2019
Restricted Cash
Letter of credit outstanding		$ 3,100	$ 3,100
Letter of credit expiration period		95 days
Operating Lease, October 2023
Restricted Cash
Expected letter of credit amount	2,100	$ 2,100
HQ Lease [Member]
Restricted Cash
Letter of credit outstanding	$ 3,100
Letter of credit expiration period	95 days

Restricted Cash - Schedule of R

Restricted Cash - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 69,575	$ 92,302		$ 173,984	$ 41,441	$ 49,886
Restricted cash, current portion					290	638
Restricted cash, net of current portion	3,086	3,086		3,086	3,086	290
Total cash, cash equivalents and restricted cash	$ 72,661	$ 95,388	$ 225,228	$ 177,070	$ 44,817	$ 50,814

Oxford Finance Loan Agreement -

Oxford Finance Loan Agreement - Additional Information (Details) $ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 23, 2020 USD ($)

Feb. 12, 2020 USD ($)

Mar. 31, 2022 USD ($) shares

Mar. 31, 2021 USD ($) shares

Dec. 31, 2021 USD ($) shares

Dec. 31, 2020 USD ($) shares

Dec. 23, 2020 USD ($)

Dec. 23, 2020 shares

Dec. 23, 2020

Dec. 23, 2020 $ / shares

Dec. 23, 2020 d

Feb. 12, 2020 shares

Feb. 12, 2020

Feb. 12, 2020 $ / shares

Feb. 12, 2020 d

Dec. 31, 2019 shares

Debt Instrument [Line Items]

Term loan

$ 40,000

$ 40,000

Warrants to purchase common stock | shares

2,117,094

2,117,094

2,117,094

2,117,094

2,118,094

Current portion of debt

$ 1,667

Long Term Debt Noncurrent

$ 38,775

$ 40,257

$ 39,551

Advance Prepaid in First 12 Months

Debt Instrument [Line Items]

Term loan, prepayment fee, equal to percentage of the principal amount being prepaid

2%

Loan Agreement

Debt Instrument [Line Items]

Term loan, aggregate principal amount

$ 60,000

Additional term loan advances, description

A first tranche term loan for $20.0 million was funded on February 12, 2020, and a second tranche term loan for $20.0 million was funded on December 23, 2020. The remaining $20.0 million is still available under the Loan Agreement, at the sole discretion of the Lender.

A $20.0 million term loan (first tranche) was funded on February 12, 2020, and another $20.0 million term loan (second tranche) was funded on December 23, 2020. As of December 31, 2021, the final $20.0 million tranche remained available under the Loan Agreement, at the sole discretion of the Lender

Each of available additional term loan advances

$ 20,000

Term loan, interest rate terms

The term loan bears interest at an annual rate equal to the greater of (i) 7.75% and (ii) the sum of 5.98% and the greater of (A) one-month LIBOR or (B) 1.77%.

The term loan bears interest at an annual rate equal to the greater of (i) 7.75% and (ii) the sum of 5.98% and the greater of (A) one-month LIBOR or (B) 1.77%.

Term loan, interest rate

7.75%

Term loan, effective interest rate

5.98%

Term loan, variable interest rate basis spread

1.77%

Term loan, maturity date

Feb. 01, 2025

Term loan, final payment fee percentage

5%

Warrants to purchase common stock | shares

27,548

27,548

Warrant exercisable period from date of issuance

5 years

5 years

Interest expense

$ 1,000

$ 900

$ 3,900

Current portion of debt

1,700

Long Term Debt Noncurrent

$ 38,800

Loan Agreement | Advance Prepaid in First 12 Months

Debt Instrument [Line Items]

Term loan, prepayment fee, equal to percentage of the principal amount being prepaid

2%

Loan Agreement | Advance Prepaid After 12 Months But Prior to 24 Months

Debt Instrument [Line Items]

Term loan, prepayment fee, equal to percentage of the principal amount being prepaid

1%

Loan Agreement | Advance Prepaid After 24 Months But Prior to Maturity Date

Debt Instrument [Line Items]

Term loan, prepayment fee, equal to percentage of the principal amount being prepaid

0.50%

Loan Agreement | First Loan Tranche

Debt Instrument [Line Items]

Term loan

$ 20,000

Term Loan, facilities fee

100

Warrants to purchase common stock | shares

27,548

Warrant exercise price of common stock per share | $ / shares

$ 7.26

Fair value of warrants

100

Loan Agreement | First Loan Tranche | Expected volatility | Weighted Average

Debt Instrument [Line Items]

Fair value of weighted average volatility

75.43

75.43

Loan Agreement | Second Loan Tranche

Debt Instrument [Line Items]

Term loan

20,000

$ 20,000

Term Loan, facilities fee

$ 75,000

Warrants to purchase common stock | shares

17,389

Warrant exercise price of common stock per share | $ / shares

$ 11.5

Fair value of warrants

$ 200

Loan Agreement | Second Loan Tranche | Expected volatility | Weighted Average

Debt Instrument [Line Items]

Fair value of weighted average volatility

82.41

82.41

Loan Agreement | Second Loan Tranche | Expected life (in years) | Weighted Average

Debt Instrument [Line Items]

Fair value of weighted expected term

5 years

Loan Agreement | Final Loan Tranche

Debt Instrument [Line Items]

Each of available additional term loan advances

$ 20,000

Loan Agreement | Third Loan Tranche

Debt Instrument [Line Items]

Term loan, facilities fee

$ 50,000

Oxford Finance Loan Agreement_2

Oxford Finance Loan Agreement - Schedule of Minimum Aggregate Future Loan Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Year ending December 31, 2023	$ 16,666
Year ending December 31, 2024/Year ending December 31, 2023	20,000	$ 16,666
Year ending December 31, 2025/Year ending December 31, 2024	3,334	20,000
Year ending December 31, 2025		3,334
Total minimum payments	40,000	40,000
Less unamortized debt discount	(410)	(459)
Plus accumulated accretion of final fees	852	716
Total carrying value of debt	40,442
Less current portion	(1,667)
Long-term debt, net of current portion	$ 38,775	$ 40,257	$ 39,551

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022
Property, Equipment and Impairment of Long-Lived Assets
Property and equipment	$ 22,700	$ 21,429
Less: Accumulated depreciation	(9,856)	(7,216)
Total property and equipment, net	12,844	14,213	$ 12,554
Construction in progress
Property, Equipment and Impairment of Long-Lived Assets
Property and equipment	0	6
Laboratory equipment
Property, Equipment and Impairment of Long-Lived Assets
Property and equipment	$ 7,989	7,028
Estimated useful life	5 years
Computer equipment
Property, Equipment and Impairment of Long-Lived Assets
Property and equipment	$ 1,979	1,841
Estimated useful life	3 years
Furniture and fixtures
Property, Equipment and Impairment of Long-Lived Assets
Property and equipment	$ 1,075	897
Estimated useful life	4 years
Leasehold improvements
Property, Equipment and Impairment of Long-Lived Assets
Property and equipment	$ 11,657	$ 11,657
Estimated useful life	8 years 2 months 12 days	9 years 3 months 18 days

Property and Equipment - Sche_2

Property and Equipment - Schedule of Property and Equipment (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leasehold improvements
Property, Equipment and Impairment of Long-Lived Assets
Estimated useful life	8 years 2 months 12 days	9 years 3 months 18 days

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 681	$ 666	$ 2,758	$ 2,774	$ 2,521

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities, Current [Abstract]
External research and preclinical development	$ 8,521	$ 8,274	$ 4,702
Employee compensation and benefits	3,180	6,344	5,715
Professional fees	1,495	953	602
Facilities and other	53	53	65
Accrued expenses	$ 13,249	$ 15,624	$ 11,084

Commitments and Contingencies -

Commitments and Contingencies - Operating Leases - Additional Information (Details) $ in Thousands		3 Months Ended	12 Months Ended
	Jan. 08, 2019 ft²	Mar. 31, 2022 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Lessee Lease Description [Line Items]
Operating lease, right-of-use asset		$ 13,900		$ 14,104		$ 14,831
Operating lease liability, long-term		22,378		22,858		24,578
Operating lease liability, short term		1,789		$ 1,720		1,463
Accounting Standards Update 2016-02
Lessee Lease Description [Line Items]
Operating lease, right-of-use asset		15,800	$ 15,800
Operating lease liability, long-term		15,800	15,800
Net of tenant allowances expected to be received		$ 9,300	$ 9,300
Lease operating, discounted borrowing rate		9.30%	9.30%
Operating Lease, January 2019
Lessee Lease Description [Line Items]
Area of office and laboratory space leased | ft²	52,859
Term of option to extend the lease				10 years
Letter of credit outstanding				$ 3,100	$ 3,100
Operating Lease, January 2019 | Accounting Standards Update 2016-02
Lessee Lease Description [Line Items]
Operating lease liability, long-term				22,900		24,600
Operating lease liability, short term				$ 1,700		$ 1,400
HQ Lease
Lessee Lease Description [Line Items]
Area of office and laboratory space leased | ft²	52,859
Term of option to extend the lease		10 years
Letter of credit outstanding		$ 3,100
HQ Lease | Accounting Standards Update 2016-02
Lessee Lease Description [Line Items]
Operating lease liability, long-term		22,400
Operating lease liability, short term		$ 1,800

Commitments and Contingencies_2

Commitments and Contingencies - Finance Lease - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Mar. 31, 2019
Leases, Operating [Abstract]
Equipment lease term			48 months	48 months
Financing lease liabilities	$ 286	$ 356	$ 1,000	$ 1,000

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Reconciliation of Maturity Analysis of Annual Undiscounted Cash Flows (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Nine months ending December 31, 2022	$ 2,956
Year ending December 31, 2023 and December 31, 2022	4,049	$ 3,935
Year ending December 31, 2024 and December 31, 2023	4,166	4,049
Year ending December 31, 2025 and December 31, 2024	4,287	4,166
Year ending December 31, 2025		4,287
Year ending December 31, 2026 and beyond	19,256	19,256
Total remaining lease payments	34,714	35,693
Operating Lease, Less imputed interest	(10,547)	(11,115)
Operating Lease, Liability	24,167	24,578
Nine months ending December 31, 2022	234
Year ending December 31, 2023 and December 31, 2022	66	313
Year ending December 31, 2023		66
Finance Lease, Total minimum lease payments	300	379
Finance Lease, Less imputed interest	(14)	(23)
Financing lease liability	$ 286	$ 356	$ 1,000	$ 1,000

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Total Lease Cost for Operating and Financing Leases as well as Weighted Average Information for Leases (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Lease cost:
Operating lease cost	$ 772		$ 2,958
Financing lease cost:
Amortization of right-of-use asset	66	$ 65	260	$ 261	$ 201
Interest on lease liabilities	7		48
Total financing lease cost	73		308
Cash paid for amounts included in the measurement of liabilities:
Operating cash flows from operating lease	979		3,823
Operating cash flows from financing lease	$ 78		$ 312
Other information:
Weighted-average remaining lease term (in years) - operating lease	7 years 11 months 1 day		8 years 2 months 1 day
Weighted-average discount rate - operating lease	9.30%		9.30%
Weighted-average remaining lease term (in years) - financing lease	1 year 25 days		1 year 3 months 3 days
Weighted-average discount rate - financing lease	9.47%		9.47%

Commitments and Contingencies_5

Commitments and Contingencies - Asset Purchase Agreement (Details) - Orsenix, LLC - Asset Purchase Agreement $ in Millions	Dec. 04, 2020 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fee payments	$ 12
Payments made upon achievement of regulatory milestone	6
Payments made upon achievement of commercial milestone	$ 10

Commitments and Contingencies_6

Commitments and Contingencies - License Agreements - Additional Information (Details) - TMRC - USD ($) $ in Millions	1 Months Ended						12 Months Ended
	Sep. 30, 2021	May 31, 2021	Jan. 31, 2021	Sep. 30, 2016	May 31, 2016	Sep. 30, 2015	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Up-front license fee						$ 1
Payment of up-front license fee					$ 0.5	0.5
Payments per indication due upon the successful achievement of clinical and regulatory milestones						$ 13
Payments made upon achievement of development milestone	$ 1	$ 2	$ 2	$ 1						$ 1
Fees incurred under supply management agreement							$ 0.6	$ 0.9
Payments made under the supply management agreement									$ 0

Commitments and Contingencies_7

Commitments and Contingencies - Additional Information (Details) - Tyme Technologies, Inc. and Subsidiaries [Member] $ in Millions	Mar. 31, 2022 USD ($)
Commitment And Contingencies [Line Items]
Contractual Obligation	$ 0.2
Ongoing Clinical Trials [Member]
Commitment And Contingencies [Line Items]
Contractual Obligation	0.9
Clinical Registration Activity [Member]
Commitment And Contingencies [Line Items]
Contractual Obligation	$ 2.5

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)								1 Months Ended	3 Months Ended		10 Months Ended	12 Months Ended
	Feb. 08, 2021 USD ($) $ / shares shares	Jan. 22, 2021 USD ($) $ / shares shares	Dec. 08, 2020 USD ($) $ / shares shares	May 20, 2020 USD ($) $ / shares shares	Jan. 07, 2020 USD ($) $ / shares shares	Oct. 18, 2019 USD ($) $ / shares	Apr. 09, 2019 USD ($) Agreement $ / shares shares	Jan. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) TradingDay $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) shares	Mar. 31, 2020 shares	Nov. 30, 2019 shares
Stock Offering
Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs | $															$ 11,896,000	$ 824,000
Warrants to purchase common stock									2,117,094	2,117,094	2,117,094	2,117,094	2,117,094	2,117,094	2,117,094	2,118,094
Remeasured fair value of warrants | $									$ 581,000			$ 581,000	$ 3,029,000		$ 19,711,000
Change in fair value of warrant liability | $									$ (2,448,000)	$ (7,670,000)			$ (16,682,000)		$ 375,000	$ 0
Number of underwriting agreements | Agreement							2
Aggregate gross proceeds from public offerings | $							$ 70,000,000
Underwriting discounts and commissions and estimated offering expenses payable | $							$ 5,000,000
Preferred stock, shares outstanding									0			0	0		0			666
Conversion of series A stock into common stock																		666,000
Common stock, par value (in dollars per share) | $ / shares									$ 0.001			$ 0.001	$ 0.001		$ 0.001
Preferred stock, shares authorized									10,000,000			10,000,000	10,000,000		10,000,000
Preferred stock, par value (in dollars per share) | $ / shares									$ 0.001			$ 0.001	$ 0.001		$ 0.001
Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Remeasured fair value of warrants | $									$ 124,480	$ 1,931,921	$ 1,931,921	$ 124,480		$ 1,931,921
Change in fair value of warrant liability | $												$ (1,807,441)		$ 3,915,393
Preferred stock, shares outstanding									0	0	0	0		0
Warrants outstanding and remain unexercised									3,104,318	3,104,318	3,104,318	3,104,318		3,104,318			8,937,651
Fair value of warrants | $				$ 3,400,000					$ 1,800,000			$ 1,800,000
Gain on warrant exchange | $														$ 2,228,697
Common stock, par value (in dollars per share) | $ / shares									$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares authorized									10,000,000	10,000,000	10,000,000	10,000,000		10,000,000
Preferred stock, par value (in dollars per share) | $ / shares									$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001
2016 Plan
Stock Offering
Preferred stock, shares outstanding									0			0
Series A Convertible Preferred Stock
Stock Offering
Share price (in dollars per share) | $ / shares									$ 6.57			$ 6.57	$ 6.57
Preferred stock, shares outstanding													0					666
Convertible preferred stock beneficial conversion feature | $									$ 600,000				$ 600,000
2019 Warrants
Stock Offering
Warrants to purchase common stock																2,118,344
Warrant exercise price of common stock per share | $ / shares									$ 8.625			$ 8.625	$ 8.625
Warrants expiration date									Oct. 10, 2022				Oct. 10, 2022
Maximum ownership percentage to total number stock issued and outstanding holder is prohibited from conversion									4.99%				4.99%
Notice period for change in owning percentage									61 days				61 days
Warrants outstanding and remain unexercised													2,117,094
Fair value of warrants | $									$ 9,000,000				$ 9,000,000
Class A Warrants
Stock Offering
Warrants outstanding and remain unexercised									2,117,094			2,117,094
Share Exchange Agreements [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Warrants to purchase common stock				5,833,333
Share Leak Out Agreement Trading Restrictions On Exchange Shares Description												trading restrictions with respect to the Exchange Shares, which (i) for the first 90 days, prohibit any sales of Exchange Shares, (ii) for the subsequent 90 days, limit sales of Exchange Shares on any day to 2.5% of that day’s trading volume of Common Stock, and (iii) prohibit new short positions or short sales on Common Stock for the combined 180 day period.
Gain on warrant exchange | $				$ 1,900,000
Warrant Exchange Agreements [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Warrants to purchase common stock				2,166,667
Warrant exercise price of common stock per share | $ / shares				$ 1.8
Warrants expiration date				Apr. 02, 2024
Number of common stock shares applicable for leak-out restrictions under leak-out agreement				893,750
Fair value of warrants | $				$ 7,300,000
Warrant Exchange Agreements [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Nonoperating Income (Expense) [Member]
Stock Offering
Change in fair value of warrant liability | $											$ 300,000			$ 3,700,000
Gain on warrant exchange | $				$ 300,000
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Expected volatility | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				73
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Measurement Input, Share Price [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				1.7
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Measurement Input, Expected Term [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				3 years 10 months 13 days
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Measurement Input, Risk Free Interest Rate [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				0.28
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Five [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Fair value of warrants | $				$ 1,700,000
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Five [Member] | Expected volatility | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				73
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Five [Member] | Measurement Input, Share Price [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				1.64
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Five [Member] | Measurement Input, Expected Term [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				3 years 10 months 13 days
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Five [Member] | Measurement Input, Risk Free Interest Rate [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				0.27
Warrant Exchange Agreements [Member] | Class Of Warrant Or Right Issued Date Five [Member] | Measurement Input, Discount for Lack of Marketability [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Fair value assumptions				7
Securities Purchase Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Share price (in dollars per share) | $ / shares					$ 2
Milestone payments upon occurrence of milestone event payable | $					$ 20,000,000
Milestone payments upon occurrence of milestone event payable in cash | $					10,000,000
Milestone payments upon occurrence of milestone event payable in shares | $					$ 10,000,000
Milestone payments upon occurrence of milestone event payable in shares, Percentage of premium over share price					15%
Restricted Period For Sale Of Shares Description					shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement.
Securities Purchase Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member] | Warrant [Member]
Stock Offering
Common stock purchase warrants outstanding and exercisable									3,074,551	3,074,551	3,074,551	3,074,551		3,074,551
Securities Purchase Agreement [Member] | Series A Preferred Stock [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Shares designated and reserved for future issuance									10,000			10,000
Stock conversion ratio equal to quotient of $1,000												1.15
Threshold Trading Days For Computation Of Weighted Average Price On Conversion Of Stock | TradingDay												7
Registered Direct Offering [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs | $	$ 100,000,000
Related cost offset the proceeds | $	$ 6,200,000
Weighted Average | 2019 Warrants | Expected volatility
Stock Offering
Fair value of weighted average volatility							86.06%		86.06%
Weighted Average | 2019 Warrants | Dividend yield
Stock Offering
Fair value of weighted expected term							3 years 6 months		3 years 6 months
Common Stock | Series A Convertible Preferred Stock
Stock Offering
Conversion of series A stock into common stock																		666,000
Common Stock | Class Of Warrant Or Right Issued Date Four [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Warrant exercise price of common stock per share | $ / shares									$ 1.8			$ 1.8
Warrants outstanding and remain unexercised									2,166,667			2,166,667
Common Stock | Share Exchange Agreements [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Shares issued				2,406,250
Common Stock | Securities Purchase Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Shares issued					10,000,000
Common Stock | Registered Direct Offering [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Shares issued	40,000,000
Share price (in dollars per share) | $ / shares	$ 2.5
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Warrant [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Share price (in dollars per share) | $ / shares									$ 0.35	$ 1.78	$ 1.78	$ 0.35		$ 1.78
Warrant [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Expected volatility | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Fair value assumptions									98	78	78	98		78
Warrant [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Measurement Input, Expected Term [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Fair value assumptions									2 years 3 days	3 years 3 days	3 years 3 days	2 years 3 days		3 years 3 days
Warrant [Member] | Class Of Warrant Or Right Issued Date Four [Member] | Measurement Input, Risk Free Interest Rate [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Fair value assumptions									2.28	0.35	0.35	2.28		0.35
Underwritten Public Offering
Stock Offering
Shares issued		5,400,000						5,400,000
Public offering price per share | $ / shares		$ 14						$ 14
Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs | $		$ 75,600,000						$ 75,600,000
Underwriting discounts and commissions and other transaction expenses | $		$ 5,100,000						$ 5,100,000
Private Placement
Stock Offering
Warrants to purchase common stock									2,828,125	2,828,125	2,828,125	2,828,125	2,828,125	2,828,125	2,828,125
Gross proceeds of private placement | $			$ 90,500,000
Transaction costs | $			400,000
Initial fair value of warrants at issuance | $			$ 19,300,000
Remeasured fair value of warrants | $									$ 600,000			$ 600,000	$ 3,000,000		$ 19,700,000
Change in fair value of warrant liability | $													$ 16,700,000		$ 400,000
Private Placement | Common Stock
Stock Offering
Shares issued			10,312,500
Common stock, par value (in dollars per share) | $ / shares			$ 0.001
Private Placement | Pre-Funded Warrant
Stock Offering
Warrants to purchase common stock			1,000,000
Share price (in dollars per share) | $ / shares			$ 8
Private Placement | Warrant [Member]
Stock Offering
Share price (in dollars per share) | $ / shares			$ 7.99
Private Placement | Warrant [Member] | Maximum
Stock Offering
Warrants to purchase common stock			2,828,125
Public Offering | Class A Warrants
Stock Offering
Warrant exercise price of common stock per share | $ / shares							$ 8.625
Warrants expiration date							Oct. 10, 2022
Public Offering | Common Stock Agreement | 2019 Warrants
Stock Offering
Warrants to purchase common stock							1,951,844
Share price (in dollars per share) | $ / shares							$ 7.5		$ 7.5			$ 7.5	$ 7.5
Public Offering | Common Stock Agreement | Class A Warrants
Stock Offering
Warrants to purchase common stock							1,951,844
Share price (in dollars per share) | $ / shares							$ 7.5
Public Offering | Preferred Stock Agreement | Series A Convertible Preferred Stock
Stock Offering
Shares issued							666
Public Offering | Preferred Stock Agreement | 2019 Warrants
Stock Offering
Warrants to purchase common stock							166,500
Share price (in dollars per share) | $ / shares							$ 7,500
Public Offering | Preferred Stock Agreement | Class A Warrants
Stock Offering
Warrants to purchase common stock							166,500
Share price (in dollars per share) | $ / shares							$ 7,500
Public Offering | Common Stock | Common Stock Agreement
Stock Offering
Shares issued							8,667,333
Open Market Sale Agreement [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Shares issued														4,453,939
Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs | $														$ 6,100,000
Payment of commission rate from gross proceeds						3%
Related cost offset the proceeds | $														$ 300,000
Available for offering | $									$ 22,200,000			$ 22,200,000
Open Market Sale Agreement [Member] | Maximum | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Offering
Aggregate offering | $						$ 30,000,000
Open Market Sale Agreement [Member] | Maximum | Tyme Technologies, Inc. and Subsidiaries [Member] | Interest Rate Floor [Member]
Stock Offering
Share price (in dollars per share) | $ / shares						$ 1

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock Warrant Activity (Detail) - Tyme Technologies, Inc. and Subsidiaries [Member] - $ / shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stockholders Equity Note Disclosure [Line Items]
Warrant Shares of Common Stock, Outstanding at Beginning	3,104,318	8,937,651
Class of Warrant or Right Number of Securities Called By Warrants or Rights Granted	0	2,166,667
Class of Warrant or Right Number of Securities Called by Warrants or Rights Exchanged	0	(8,000,000)
Warrant Shares of Common Stock, Outstanding at Ending	3,104,318	3,104,318
Weighted Average Exercise Price, Outstanding at Beginning	2.77	2.31
Weighted Average Exercise Price, Granted	0	1.8
Weighted Average Exercise Price, Exchanged	$ 0	$ 2
Weighted Average Exercise Price, Outstanding at Ending	2.77	2.77

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Detail) - Tyme Technologies, Inc. and Subsidiaries [Member] - $ / shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Class of Warrant or Right [Line Items]
Warrants Outstanding	3,104,318	3,104,318	8,937,651
December 2015 | Common Stock [Member]
Class of Warrant or Right [Line Items]
Issued	2015-12
Classification	Equity
Warrants Outstanding	446,500
Exercise Price	$ 5
Expiration	2025-12
February 2016 | Common Stock [Member]
Class of Warrant or Right [Line Items]
Issued	2016-02
Classification	Equity
Warrants Outstanding	461,384
Exercise Price	$ 5
Expiration	2026-02
July 2016 | Common Stock [Member]
Class of Warrant or Right [Line Items]
Issued	2016-07
Classification	Equity
Warrants Outstanding	29,767
Exercise Price	$ 5
Expiration	2026-06
May 2020 | Common Stock [Member]
Class of Warrant or Right [Line Items]
Issued	2020-05
Classification	Liability
Warrants Outstanding	2,166,667
Exercise Price	$ 1.8
Expiration	2024-04

Stock-Based Payments - 2016 Sto

Stock-Based Payments - 2016 Stock Incentive Plan (Details) - 2016 Plan - shares			3 Months Ended	12 Months Ended
	Jan. 01, 2022	Jan. 01, 2021	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in number of shares of common stock reserved for issuance of awards on the first day of each calendar year (in shares)			1,600,000	1,600,000
Increase in number of shares of common stock reserved for issuance of awards on the first day of each calendar year, as a percentage of outstanding shares			4%	4%
Increase in number of shares of common stock reserved for issuance (in shares)	1,600,000	1,600,000
Number of shares available for grants			428,219	2,238,206

Stock-Based Payments - 2016 Emp

Stock-Based Payments - 2016 Employee Stock Purchase Plan (Details) - 2016 ESPP - shares	Jan. 01, 2022	Jan. 01, 2021	Jul. 06, 2016	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in number of shares of common stock reserved for issuance of awards on the first day of each calendar year (in shares)			1,173,333
Increase in number of shares of common stock reserved for issuance of awards on the first day of each calendar year, as a percentage of outstanding shares			1%
Increase in number of shares of common stock reserved for issuance (in shares)	620,241	562,227
Number of shares available for grants				2,857,306	2,237,065

Stock-Based Payments - Induceme

Stock-Based Payments - Inducement Grants (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted	951,300	2,417,600
Inducement Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non statutory stock options to purchase an aggregate shares of common stock		1,110,000
Vesting period		4 years
Award expiration period		3 years
Vesting on one year anniversary of vesting commencement date | Inducement Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting (as a percent)		25%
Vesting ratably on a monthly basis | Inducement Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting (as a percent)		75%
Non Statutory Stock Option [Member] | Inducement Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Award expiration period	3 years
Granted	1,110,000
Non Statutory Stock Option [Member] | Vesting on one year anniversary of vesting commencement date | Inducement Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting (as a percent)	25%
Non Statutory Stock Option [Member] | Vesting ratably on a monthly basis | Inducement Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting (as a percent)	75%

Stock-Based Payments - 2022 Ind

Stock-Based Payments - 2022 Inducement Stock Incentive Plan (Details)	Jan. 25, 2022 shares
2022 Inducement Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock shares grant	1,000,000

Stock-Based Payments - Stock Op

Stock-Based Payments - Stock Options (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation costs	$ 12,100,000		$ 12,800,000
Granted and outstanding (in shares)	951,300		2,417,600
Period in which compensation costs will be recognized	3 years 1 month 6 days		2 years 11 months 19 days
Intrinsic value of the exercised option	$ 100,000	$ 100,000	$ 100,000	$ 800,000	$ 200,000
Proceeds from exercise of stock options	1,000		$ 200,000	1,100,000	200,000
Performance-based stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional stock-based compensation expense recorded related to achievement of certain performance-based milestones				400,000	$ 400,000
Unrecognized compensation costs				$ 0
Granted and outstanding (in shares)			0
Performance-based stock options | Advisor
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation costs	$ 300,000		$ 300,000
Granted and outstanding (in shares)	75,000		75,000
Period in which compensation costs will be recognized	4 years 6 months		4 years 8 months 12 days
Stock Option | 2016 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years		4 years
Award expiration period	3 years		3 years
Stock Option | 2016 Plan | Cliff Vesting
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting (as a percent)	25%		25%
Stock Option | 2016 Plan | Graded Vesting
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	10 years		10 years
Vesting (as a percent)	75%		75%
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation costs	$ 13,900,000		$ 12,000,000
Period in which compensation costs will be recognized	2 years 10 months 24 days		2 years 25 days
Vesting period	4 years		4 years
Vesting (as a percent)	25%		25%

Stock-Based Payments - Summary

Stock-Based Payments - Summary of Status of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Outstanding at beginning of year (in shares)	6,657,268	5,468,605
Granted	951,300	2,417,600
Exercised (in shares)	(37,700)	(20,134)
Cancelled (in shares)	(43,716)	(1,208,803)
Outstanding at end of period (in shares)	7,527,152	6,657,268	5,468,605
Options exercisable	4,081,501	3,736,652
Outstanding at beginning of year (in dollars per share)	$ 8.27	$ 8.9
Granted	1.59	7.69
Options exercised, weighted average exercise price	0.04	7.77
Cancelled (in dollars per share)	9.93	10
Outstanding at end of period (in dollars per share)	7.45	8.27	$ 8.9
Options exercisable	$ 9.01	$ 8.86
Remaining Contractual Life, Outstanding	6 years 10 months 24 days	7 years 2 months 12 days	7 years 2 months 12 days
Remaining Contractual Life, Exercisable	5 years 4 months 24 days	5 years 9 months 18 days
Aggregate Intrinsic Value	$ 26	$ 494	$ 13,124
Aggregate Intrinsic Value, Options Exercisable	$ 26	$ 494

Stock-Based Payments - Restrict

Stock-Based Payments - Restricted Stock Units Stock (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation costs	$ 12.1	$ 12.8
Period in which compensation costs will be recognized	3 years 1 month 6 days	2 years 11 months 19 days
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years	4 years
Vesting (as a percent)	25%	25%
Unrecognized compensation costs	$ 13.9	$ 12
Period in which compensation costs will be recognized	2 years 10 months 24 days	2 years 25 days
Restricted Stock Units | Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years	3 years

Stock-Based Payments - Summar_2

Stock-Based Payments - Summary of Status of Restricted Stock Units (Details) - Restricted Stock Units - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of year (in shares)	2,687,487	1,734,383
Granted (in shares)	2,768,128	1,747,554
Vested (in shares)	(739,561)	(286,837)
Forfeited (in shares)	(176,325)	(507,613)
Outstanding at end of period (in shares)	4,539,729	2,687,487
Weighted Average Grant Date Fair Value, Outstanding at beginning of year (in dollars per share)	$ 6.52	$ 7.4
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	1.58	6.31
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	7.32	7.7
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	6.76	8.15
Weighted Average Grant Date Fair Value, Outstanding at end of period (in dollars per share)	$ 3.37	$ 6.52

Stock-Based Payments - Schedule

Stock-Based Payments - Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model (Details) - Stock Option	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average risk-free interest rate	1.98%	0.78%	0.99%	1.28%	2.42%
Expected option term	6 years 25 days	6 years 29 days	6 years 10 days	5 years 11 months 26 days	6 years
Volatility	80.70%	82.10%	81.56%	78.27%	91.35%

Stock-Based Payments - Weighted

Stock-Based Payments - Weighted-Average Assumptions to Estimate Fair Value of Stock Options (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value of options granted	$ 1.11	$ 7.89	$ 5.33	$ 5.3	$ 5.05

Stock-Based Payments - Summar_3

Stock-Based Payments - Summary of Stock-based Compensation Expense for Stock Options and Restricted Stock Units (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 2,863	$ 2,930	$ 10,354	$ 10,939	$ 9,839
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,395	1,323	5,706	4,732	3,472
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,468	$ 1,607	$ 4,648	$ 6,207	$ 6,367

Income Taxes - Components of In

Income Taxes - Components of Income Tax Provision - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Current	$ 1	$ 4	$ 28
Total	$ 1	$ 4	$ 28

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate - (Details)	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate [Line Items]
Federal income tax computed at federal statutory tax rate		21%		21%	21%
State income tax, net of federal benefit		7.26%		6.12%	6.56%
Permanent items		3.60%		(0.68%)	(0.89%)
Federal and state research and development credits		5.79%		3.89%	4.79%
Other		(1.41%)		(0.88%)	(0.77%)
Change in valuation allowance		(36.24%)		(29.45%)	(30.73%)
Effective income tax rate					(0.04%)
Tyme Technologies, Inc. and Subsidiaries [Member]
Schedule of Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate [Line Items]
Federal income tax computed at federal statutory tax rate	21%		21%
State income tax, net of federal benefit	11.59%		0%
Permanent differences	0%		(0.02%)
Federal and state research and development credits	7.93%		4.70%
Stock compensation	(5.05%)		(3.41%)
Warrants	1.61%		(1.29%)
Change in valuation allowance	(37.08%)		(20.98%)
Effective income tax rate	0%		0%

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Federal and state net operating loss carryforwards		$ 109,166,000		$ 80,658,000
Tax credit carryforwards		22,446,000		17,442,000
Intangible assets		3,000,000		3,219,000
Stock-based compensation		5,700,000		5,117,000
Deferred revenue		2,810,000		6,034,000
Capital lease		6,812,000		7,284,000
Other		2,395,000		1,725,000
Total deferred tax assets		152,329,000		121,479,000
Less valuation allowance		(146,285,000)		(114,946,000)
Net deferred tax assets		6,044,000		6,533,000
Deferred tax liabilities:
Right-of-use asset		3,946,000		4,215,000
Fixed assets		2,098,000		2,318,000
Total deferred tax liabilities		$ 6,044,000		$ 6,533,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Deferred tax assets:
Federal and state net operating loss carryforwards	$ 27,564,077		$ 20,123,621
Research and development credit carryforward	884,130		1,164,895
Orphan drug credit	4,157,360		2,002,559
Stock options - NQSOs	4,765,662		5,267,351
Accruals and other temporary differences	662,754		595,418
Total deferred tax assets	38,033,983		29,153,844
Less valuation allowance	(38,033,983)		(29,153,844)
Net deferred tax assets	$ 0		$ 0

Income Taxes - Valuation Allowa

Income Taxes - Valuation Allowance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Increase in valuation allowance	$ 31.3	$ 24.7

Income Taxes - NOL carryforward

Income Taxes - NOL carryforwards (Details) $ in Millions	Dec. 31, 2021 USD ($)
Indefinite Carryforward Period
Operating Loss Carryforwards [Line Items]
NOL carryforwards	$ 263.2
Expire at Various Dates Through 2037
Operating Loss Carryforwards [Line Items]
NOL carryforwards	135.7
Federal
Operating Loss Carryforwards [Line Items]
NOL carryforwards	398.9
Tax credits	19.7
State
Operating Loss Carryforwards [Line Items]
NOL carryforwards	401.9
Tax credits	$ 3.5

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - Tyme Technologies, Inc. and Subsidiaries [Member] - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of Unrecognized Tax Benefits [Line Items]
Gross unrecognized tax benefits at beginning of year	$ 558,962	$ 318,394
Increases (decreases) for tax positions in prior period		(99,063)
Increase for tax positions in current period	330,712	339,631
Gross unrecognized tax benefits at end of year	$ 889,674	$ 558,962

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Income Taxes [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ 31,300,000		$ 24,700,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Income Taxes [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ 23,626,047		$ 28,978,763
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	8,900,000
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	119,100,000
Reduction Of Payroll Taxes	120,000		$ 177,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	5,900,000
Amount of unrecognized tax benefits.	$ 890,000,000

Defined Contribution Plan - (De

Defined Contribution Plan - (Details) - USD ($) $ in Millions		12 Months Ended
	Sep. 01, 2017	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan Disclosure [Line Items]
Employer match (as a percent)	100%	100%
Plan Compensation (as a percent) for 100%	1%	2%
Employer match (as a percent)	50%	50%
Contribution made by the company		$ 0.8	$ 0.5	$ 0.5
Minimum
Defined Contribution Plan Disclosure [Line Items]
Plan Compensation (as a percent) for 50%	1%	2%
Maximum
Defined Contribution Plan Disclosure [Line Items]
Plan Compensation (as a percent) for 50%	6%	6%

Leases - Additional Information

Leases - Additional Information (Detail) - Tyme Technologies, Inc. and Subsidiaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee, Lease, Description [Line Items]
Rent expense	$ 62,000	$ 165,000
Estimated incremental borrowing rate to calculate present value of lease payments	11%
New Jersey | Office Space
Lessee, Lease, Description [Line Items]
Operating lease, expiration term	2023-02

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Leases [Line Items]
Fiscal year 2023	$ 4,049,000	$ 3,935,000
Total remaining lease payments	34,714,000	35,693,000
Less: present value adjustment	10,547,000	11,115,000
Total operating lease liabilities	24,167,000	24,578,000
Less: current portion	1,789,000	1,720,000		$ 1,463,000
Operating lease liabilities, net of current portion	22,378,000	$ 22,858,000		$ 24,578,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Leases [Line Items]
Fiscal year 2023	39,240
Total remaining lease payments	39,240
Less: present value adjustment	1,908
Total operating lease liabilities	37,332
Less: current portion	37,332		$ 34,658
Operating lease liabilities, net of current portion			$ 41,256

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Tyme Technologies, Inc. and Subsidiaries [Member] - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Related Party Transaction [Line Items]
Accounts payable and accrued expenses payable	$ 153,000	$ 87,000
Faegre Drinker Biddle And Reath
Related Party Transaction [Line Items]
Legal expenses	500,000	600,000
Capitalized legal expenses		100,000
Accounts payable and accrued expenses payable	$ 153,000	$ 87,000

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Details) - USD ($)			3 Months Ended		12 Months Ended
	Aug. 24, 2021	Mar. 05, 2015	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense recognition period			3 years 1 month 6 days			2 years 11 months 19 days
Allocated compensation expense			$ 2,863,000	$ 2,930,000		$ 10,354,000		$ 10,939,000	$ 9,839,000
Options exercised			37,700			20,134
Options exercised, weighted average exercise price			$ 0.04			$ 7.77
Total proceeds from option exercises			$ 1,000			$ 200,000		1,100,000	200,000
Aggregate intrinsic value, options			26,000		$ 26,000	494,000		13,124,000
Intrinsic value of the exercised option			100,000	100,000		100,000		800,000	200,000
Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense			4,500,000	3,600,000	$ 4,500,000		$ 3,600,000
Unrecognized compensation expense recognition period					2 years 9 months 18 days
Allocated compensation expense					$ 2,500,000		$ 3,500,000
Grant date fair value of options granted					$ 1		$ 0.89
Options exercised					6,250		2,028,203
Options exercised, weighted average exercise price					$ 0.99		$ 2.64
Total proceeds from option exercises					$ 6,188		$ 5,351,323
Fair value of options vested					2,600,000		3,700,000
General and Administrative Expense [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated compensation expense					1,900,000		2,100,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated compensation expense			$ 1,395,000	$ 1,323,000		$ 5,706,000		$ 4,732,000	$ 3,472,000
Research and development expense [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated compensation expense					$ 600,000		$ 1,400,000
2015 Equity Incentive Plan [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value on date of grant		100%
Award expiration period		10 years
Equity incentive plan, available percentage of common stock share issued and outstanding		12.50%
Number of shares available for grants			7,223,029		7,223,029
Total proceeds from option exercises					$ 6,000
2016 Director Plan [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grants	3,411,279
Increase in total number of common shares authorized	3,000,000
Number of common shares authorized	5,750,000
Number of shares available for initial grants	176,000
Annual grants stock option granted in future	88,000
Initial grants term	10 years
Annual grants term	10 years
Initial grants vesting period	3 years
Annual grants vesting period	1 year
Term of stock option awards					(i) “Initial Grants” upon a director’s initial appointment to the Board consisting of an immediate stock option grant of 176,000 shares at fair market value and the shares will vest in equal quarterly increments over a three-year period from the date of grant; and (ii) “Annual Grants” for members who continue in service as members of the Board subsequent to each annual meeting of stockholders occurring subsequent to an Initial Grant, an annual stock option grant of 88,000 shares at fair market value and the shares will vest in equal quarterly increments over a one-year period from the date of grant. The Initial Grants and Annual Grants have a ten year term, subject to applicable termination or forfeiture provisions. As of March 31, 2022, there were 3,411,279 shares available for grant under the 2016 Director Plan.
Equity Incentive Plan 2015 and 2016 [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, options			$ 4,610		$ 4,610
Stock price			$ 0.35		$ 0.35
Intrinsic value of the exercised option					$ 3,500

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted (Details) - Tyme Technologies, Inc. and Subsidiaries [Member]	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Summary Of Stock Option Activities [Line Items]
Dividend yield	0%	0%
Minimum [Member]
Summary Of Stock Option Activities [Line Items]
Risk-free interest rate	0.28%	0.174%
Expected volatility	95.39%	88.02%
Expected term	2 years 8 months 12 days	2 years 9 months 18 days
Maximum [Member]
Summary Of Stock Option Activities [Line Items]
Risk-free interest rate	2.34%	0.527%
Expected volatility	105.37%	101.67%
Expected term	6 years 1 month 6 days	6 years 1 month 6 days

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of Stock Options (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of year (in shares)	6,657,268	5,468,605		5,468,605
Granted	951,300			2,417,600
Exercised	(37,700)			(20,134)
Outstanding at end of period (in shares)	7,527,152		7,527,152	6,657,268
Options exercisable	4,081,501		4,081,501	3,736,652
Outstanding at beginning of year (in dollars per share)	$ 8.27	$ 8.9		$ 8.9
Granted	1.59			7.69
Options exercised, weighted average exercise price	0.04			7.77
Outstanding at end of period (in dollars per share)	7.45		$ 7.45	8.27
Options exercisable	$ 9.01		$ 9.01	$ 8.86
Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of year (in shares)			12,588,068
Granted			3,862,388
Exercised			(6,250)		(2,028,203)
Cancelled/Forfeited			(1,939,935)
Outstanding at end of period (in shares)	14,504,271	12,588,068	14,504,271		12,588,068
Options exercisable	9,329,798		9,329,798
Outstanding at beginning of year (in dollars per share)			$ 2.92
Granted			1.3
Options exercised, weighted average exercise price			0.99		$ 2.64
Cancelled/Forfeited			3.83
Outstanding at end of period (in dollars per share)	$ 2.36	$ 2.92	2.36		$ 2.92
Options exercisable	$ 2.99		$ 2.99

Equity Incentive Plan - Sched_3

Equity Incentive Plan - Schedule of Stock Option by Exercise Price Range (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock Options Outstanding
Aggregate Intrinsic Value	$ 26	$ 494	$ 13,124
Exercise Price $0.29 - $8.75 [Member] | Tyme Technologies, Inc. and Subsidiaries [Member]
Stock Options Outstanding
Number Outstanding	14,504,271
Weighted Average Exercise Price	$ 2.36
Weighted Average Remaining Life (Years)	7 years
Aggregate Intrinsic Value	$ 4,610
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Number Vested	9,329,798
Weighted Average Exercise Price	$ 2.99
Weighted Average Remaining Life (Years)	6 years

Equity Incentive Plan - Sched_4

Equity Incentive Plan - Schedule of Non-vested Options (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Granted	951,300		2,417,600
Tyme Technologies, Inc. and Subsidiaries [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Non-vested options at beginning		4,355,171
Granted		3,862,388
Vested		(446,522)
Cancelled/Forfeited		(2,596,564)
Non-vested options at ending	5,174,473	5,174,473		4,355,171
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested options at beginning		$ 0.91
Granted		1		$ 0.89
Vested		0.95
Cancelled/Forfeited		0.99
Non-vested options at ending	$ 0.93	$ 0.93		$ 0.91

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - 2022 Plan	Jan. 25, 2022 shares
Subsequent Event [Line Items]
Number of common stock shares grant	1,000,000
Subsequent Events
Subsequent Event [Line Items]
Number of common stock shares grant	1,000,000